
<html lang="en"     class="pb-page"  data-request-id="aa13f65e-468a-4d34-8aaa-8b4bb56fe8b1"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2015.58.issue-5;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm501940y"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluation of Novel Matrix Metalloproteinase Inhibitors As Potent Antihemorrhagic Agents: From Hit Identification to an Optimized Lead" /></meta><meta name="dc.Creator" content="Josune  Orbe" /></meta><meta name="dc.Creator" content="Juan A.  Sánchez-Arias" /></meta><meta name="dc.Creator" content="Obdulia  Rabal" /></meta><meta name="dc.Creator" content="José A.  Rodríguez" /></meta><meta name="dc.Creator" content="Agustina  Salicio" /></meta><meta name="dc.Creator" content="Ana  Ugarte" /></meta><meta name="dc.Creator" content="Miriam  Belzunce" /></meta><meta name="dc.Creator" content="Musheng  Xu" /></meta><meta name="dc.Creator" content="Wei  Wu" /></meta><meta name="dc.Creator" content="Haizhong  Tan" /></meta><meta name="dc.Creator" content="Hongyu  Ma" /></meta><meta name="dc.Creator" content="José A.  Páramo" /></meta><meta name="dc.Creator" content="Julen  Oyarzabal" /></meta><meta name="dc.Description" content="Growing evidence suggests that matrix metalloproteinases (MMP) are involved in thrombus dissolution; then, considering that new therapeutic strategies are required for controlling hemorrhage, we hy..." /></meta><meta name="Description" content="Growing evidence suggests that matrix metalloproteinases (MMP) are involved in thrombus dissolution; then, considering that new therapeutic strategies are required for controlling hemorrhage, we hy..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 25, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm501940y" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm501940y" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm501940y" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm501940y" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluation of Novel Matrix Metalloproteinase Inhibitors As Potent Antihemorrhagic Agents: From Hit Identification to an Optimized Lead | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm501940y" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluation of Novel Matrix Metalloproteinase Inhibitors As Potent Antihemorrhagic Agents: From Hit Identification to an Optimized Lead" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0019.jpeg" /></meta><meta property="og:description" content="Growing evidence suggests that matrix metalloproteinases (MMP) are involved in thrombus dissolution; then, considering that new therapeutic strategies are required for controlling hemorrhage, we hypothesized that MMP inhibition may reduce bleeding by delaying fibrinolysis. Thus, we designed and synthesized a novel series of MMP inhibitors to identify potential candidates for acute treatment of bleeding. Structure-based and knowledge-based strategies were utilized to design this novel chemical series, α-spiropiperidine hydroxamates, of potent and soluble (&gt;75 μg/mL) pan-MMP inhibitors. The initial hit, 12, was progressed to an optimal lead 19d. Racemic 19d showed a remarkable in vitro phenotypic response and outstanding in vivo efficacy; in fact, the mouse bleeding time at 1 mg/kg was 0.85 min compared to 29.28 min using saline. In addition, 19d displayed an optimal ADME and safety profile (e.g., no thrombus formation). Its corresponding enantiomers were separated, leading to the preclinical candidate 5 (described in Drug Annotations series, J. Med. Chem. 2015, 10.1021/jm501939z)." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm501940y"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm501940y">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm501940y&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm501940y&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm501940y&amp;href=/doi/10.1021/jm501940y" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2465-2488</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm5019302" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm501997q" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluation of Novel Matrix Metalloproteinase Inhibitors As Potent Antihemorrhagic Agents: From Hit Identification to an Optimized Lead</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Josune++Orbe">Josune Orbe</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Juan+A.++S%C3%A1nchez-Arias">Juan A. Sánchez-Arias</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Obdulia++Rabal">Obdulia Rabal</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jos%C3%A9+A.++Rodr%C3%ADguez">José A. Rodríguez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Agustina++Salicio">Agustina Salicio</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ana++Ugarte">Ana Ugarte</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Miriam++Belzunce">Miriam Belzunce</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Musheng++Xu">Musheng Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Wu">Wei Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Haizhong++Tan">Haizhong Tan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hongyu++Ma">Hongyu Ma</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jos%C3%A9+A.++P%C3%A1ramo">José A. Páramo</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julen++Oyarzabal">Julen Oyarzabal</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Atherosclerosis Research Laboratory, <sup>‡</sup>Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, 4th Avenue, Tianjin 300456, PR China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">∥</span> <span class="aff-text">Hematology Service, Clínica Universidad de Navarra, University of Navarra. Avenida Pio XII 36, E-31008 Pamplona, Spain</span></div><div class="corresp-info"><strong>*</strong>For J.A.P.: phone, +34 948 194700 ext 3015; E-mail, <a href="/cdn-cgi/l/email-protection#d0bab1a0b1a2b1bdbf90a5beb1a6feb5a3"><span class="__cf_email__" data-cfemail="f8929988998a999597b88d96998ed69d8b">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For J.O.: phone, +34 948 194700 ext 2044; E-mail, <a href="/cdn-cgi/l/email-protection#4c263920292223352d3e362d2e2d200c39222d3a62293f"><span class="__cf_email__" data-cfemail="0c667960696263756d7e766d6e6d604c79626d7a22697f">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm501940y&amp;href=/doi/10.1021%2Fjm501940y" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2465–2488</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 16, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 December 2014</li><li><span class="item_label"><b>Published</b> online</span>25 February 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 March 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm501940y" title="DOI URL">https://doi.org/10.1021/jm501940y</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2465%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJosune%2BOrbe%252C%2BJuan%2BA.%2BS%25C3%25A1nchez-Arias%252C%2BObdulia%2BRabal%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D5%26contentID%3Djm501940y%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BNovel%2BMatrix%2BMetalloproteinase%2BInhibitors%2BAs%2BPotent%2BAntihemorrhagic%2BAgents%253A%2BFrom%2BHit%2BIdentification%2Bto%2Ban%2BOptimized%2BLead%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2488%26publicationDate%3DMarch%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm501940y"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1433</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">17</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm501940y" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluation of Novel Matrix Metalloproteinase Inhibitors As Potent Antihemorrhagic Agents: From Hit Identification to an Optimized Lead&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Josune&quot;,&quot;last_name&quot;:&quot;Orbe&quot;},{&quot;first_name&quot;:&quot;Juan&quot;,&quot;last_name&quot;:&quot;A. Sánchez-Arias&quot;},{&quot;first_name&quot;:&quot;Obdulia&quot;,&quot;last_name&quot;:&quot;Rabal&quot;},{&quot;first_name&quot;:&quot;José&quot;,&quot;last_name&quot;:&quot;A. Rodríguez&quot;},{&quot;first_name&quot;:&quot;Agustina&quot;,&quot;last_name&quot;:&quot;Salicio&quot;},{&quot;first_name&quot;:&quot;Ana&quot;,&quot;last_name&quot;:&quot;Ugarte&quot;},{&quot;first_name&quot;:&quot;Miriam&quot;,&quot;last_name&quot;:&quot;Belzunce&quot;},{&quot;first_name&quot;:&quot;Musheng&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Haizhong&quot;,&quot;last_name&quot;:&quot;Tan&quot;},{&quot;first_name&quot;:&quot;Hongyu&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;José&quot;,&quot;last_name&quot;:&quot;A. Páramo&quot;},{&quot;first_name&quot;:&quot;Julen&quot;,&quot;last_name&quot;:&quot;Oyarzabal&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;2465-2488&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm501940y&quot;},&quot;abstract&quot;:&quot;Growing evidence suggests that matrix metalloproteinases (MMP) are involved in thrombus dissolution; then, considering that new therapeutic strategies are required for controlling hemorrhage, we hypothesized that MMP inhibition may reduce bleeding by delaying fibrinolysis. Thus, we designed and synthesized a novel series of MMP inhibitors to identify potential candidates for acute treatment of bleeding. Structure-based and knowledge-based strategies were utilized to design this novel chemical series, α-spiropiperidine hydroxamates, of potent and soluble (&gt;75 μg/mL) pan-MMP inhibitors. The initial hit, 12, was progressed to an optimal lead 19d. Racemic 19d showed a remarkable in vitro phenotypic response and outstanding in vivo efficacy; in fact, the mouse bleeding time at 1 mg/kg was 0.85 min compared to 29.28 min using saline. In addition, 19d displayed an optimal ADME and safety profile (e.g., no thrombus formation). Its corresponding enantiomers were separated, leading to the preclinical candidate 5 (descr&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501940y&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501940y" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501940y&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501940y" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501940y&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501940y" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm501940y&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501940y&amp;href=/doi/10.1021/jm501940y" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm501940y" /></input><a href="/doi/pdf/10.1021/jm501940y" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm501940y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm501940y%26sid%3Dliteratum%253Aachs%26pmid%3D25686153%26genre%3Darticle%26aulast%3DOrbe%26date%3D2015%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BNovel%2BMatrix%2BMetalloproteinase%2BInhibitors%2BAs%2BPotent%2BAntihemorrhagic%2BAgents%253A%2BFrom%2BHit%2BIdentification%2Bto%2Ban%2BOptimized%2BLead%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D5%26spage%3D2465%26epage%3D2488%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jmcmar.2015.58.issue-5/20150312/jmcmar.2015.58.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Growing evidence suggests that matrix metalloproteinases (MMP) are involved in thrombus dissolution; then, considering that new therapeutic strategies are required for controlling hemorrhage, we hypothesized that MMP inhibition may reduce bleeding by delaying fibrinolysis. Thus, we designed and synthesized a novel series of MMP inhibitors to identify potential candidates for acute treatment of bleeding. Structure-based and knowledge-based strategies were utilized to design this novel chemical series, α-spiropiperidine hydroxamates, of potent and soluble (>75 μg/mL) pan-MMP inhibitors. The initial hit, <b>12</b>, was progressed to an optimal lead <b>19d</b>. Racemic <b>19d</b> showed a remarkable in vitro phenotypic response and outstanding in vivo efficacy; in fact, the mouse bleeding time at 1 mg/kg was 0.85 min compared to 29.28 min using saline. In addition, <b>19d</b> displayed an optimal ADME and safety profile (e.g., no thrombus formation). Its corresponding enantiomers were separated, leading to the preclinical candidate <b>5</b> (described in Drug Annotations series,  <cite>J. Med. Chem.</cite> <span class="NLM_year">2015</span>, <pub-id pub-id-type="doi">10.1021/jm501939z</pub-id>).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45274" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45274" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bleeding represents a dangerous complication that can result in the need for blood transfusion and is associated with substantial morbidity and mortality. Hemorrhage is responsible for almost 50% of deaths occurring within the first 24 h of traumatic injury and for up to 80% of intraoperative trauma mortality.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Physiologically, coagulation occurs to prevent excesive blood loss after injury and fibrinolysis is required to remove the blood clots after wound repair. Pathological alterations of this delicate balance can lead to thrombosis or hemorrhage. Plasmin, the key protein in fibrinolysis, results from plasminogen activation, and dysregulation of this system can lead to hyperfibrinolysis, which plays an important role in major bleeding events.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Thus, antifibrinolytic agents are widely used in major surgeries and trauma episodes to reduce blood loss and transfusion and in the treatment of heavy menstrual bleeding.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Two synthetic lysine analogues, ε-aminocaproic acid (EACA, <b>1</b>) and tranexamic acid (TXA, <b>2</b>), are the only antifibrinolytics commercially available to control bleeding (chemical structures described in Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>); in fact, they are the current standard of care (SoC). Recently, AZD6564 (<b>3</b>, Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>), a piperidyl-isoxazolone with improved potency over compound <b>2</b>, was reported as a preclinical candidate for further development.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Antifibrinolytics elicit their effects by competitively reducing the binding of plasminogen to fibrin, thus inhibiting the activation of plasminogen to plasmin, an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Molecule <b>2</b> has been associated with adverse side effects and requires a high oral dose,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and <b>1</b> is less effective.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Moreover, there are some concerns with these compounds due to the potential risk of thrombotic complications.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> Although aprotinin, a polypeptidic, bovine-derived protease inhibitor, was an effective agent used to reduce bleeding during complex surgery, safety issues led to its temporary withdrawal from the market in 2008.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, very recently, the European Medicines Agency (EMA) has recommended that the suspension be lifted for a restricted range of indications.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Thus, in this scenario, new therapeutic strategies are required for the prevention of major bleeding events.</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Known Antifibrinolytics (<b>1</b>, <b>2</b> and <b>3</b>), MMP Inhibitors (<b>4</b>, <b>6</b>, <b>7</b>, <b>8</b>, <b>9</b>, and <b>10</b>), and Structure of a Novel Antihemorrhagic Agent CM-352 (<b>5</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The fibrinolytic and matrix metalloproteinase (MMP) systems cooperate in thrombus dissolution.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> MMPs can act either through direct fibrin/ogen targeting or by enhancing tissue plasminogen activator (tPA)-induced fibrinolysis.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> This provides a new pharmacological target for fibrinolysis control (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), as demonstrated by the markedly reduced fibrinolytic activity and bleeding time found in MMP-10 null mice, that can be reversed by administration of active recombinant human MMP-10.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Moreover, MMP-3, another fibrinolytic MMP 82% homologous to MMP-10,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> has also been associated with intracranial hemorrhage.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Thus, the inhibition of MMP-10, MMP-3, and/or other MMPs may provide a new opportunity for controlling bleeding. In spite of limited clinical success of hydroxamate-based MMP inhibitors in human cancer trials, mainly due to lack of efficacy and to reports of side effects (i.e., musculoskeletal pain and inflammation) which occurred after 2–3 months of treatment<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> and subsided within 1–3 weeks of discontinuation,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> there is still hope for MMP inhibition as a therapeutic approach.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In fact, the doses of MMP inhibitors required for acute use in antihemorrhagic treatment are much lower than those for reducing metastasis;<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> and, in addition, this indication only requires short-term MMP inhibition. Thus, these conditions lead to a new therapeutic opportunity for MMP inhibitors, as antihemorrhagic agents. In this regard, we have recently demonstrated this hypothesis with GM6001 (Ilomastat, <b>4</b>), a synthetic broad-spectrum MMP inhibitor, and a novel, preclinical antihemorrhagic candidate, CM-352 (<b>5</b>, Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> This novel compound (<b>5</b>) showed remarkable efficacy and safety; thus, <b>5</b> became a preclinical candidate for the acute treatment of hemorrhage. Herein we present a detailed account of the discovery of this series from hit identification to an optimized lead.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0003.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Simplified scheme for the proposed cooperation between fibrinolytic and MMP systems in thrombus dissolution.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38765" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38765" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Validation of a Novel α-Spiropiperidine Hydroxamate Chemical Series as MMP Inhibitors</h3><div class="NLM_p">MMP inhibitors (MMPi) have been explored as anticancer, anti-inflammatory, and antiviral agents, and different structures have been designed to target the zinc catalytic center of these enzymes, with the majority of them containing a hydroxamic acid group acting as a chelating zinc binding group (ZBG).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Particularly, α-sulfonyl-4-tetrahydropyranyl (THP) and α-sulfonyl-α-piperidinyl hydroxamates have been explored as potent MMP-2, -9, and -13 inhibitors, including the development candidate <b>6</b> (SC-78080/SD-2590) and the α-THP <b>7</b> (SC-77774) by Pfizer (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> These compounds spare MMP-1. The α-sulfone α-THP series possesses better ADME and PK properties than the closely related β-sulfone α-THP core of the Roche clinical candidate RS-130830 (<b>8</b>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Wyeth’s initial work on the α-sulfone α-piperidinyl series described compound <b>9</b> as a potent, selective, and orally active MMP inhibitor in the clinically relevant advanced rabbit osteoarthritis model.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Recent work on this chemical series by Wyeth has evolved toward selective TNF-α converting enzyme (TACE/ADAM17) inhibitors over MMPs by incorporating a butynyloxyphenyl P1′ moiety.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0004.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural information for MMP-13 and MMP-3 isoforms, in complex with ligands, guided the design of novel chemical series <b>5</b>′. (A) Complex of SC-78080 <b>6</b> with MMP-13 (PDB accession code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRY">3KRY</a>). (B) Complex of <b>10</b> with MMP-3 (PDB accession code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1D8F">1D8F</a>). The molecular surface is drawn to demonstrate the narrowness of the S1′ pocket. (C) Markush formula of novel α-spiropiperidine hydroxamates <b>5</b>′.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">According to the X-ray structure of <b>6</b> with MMP-13,<a onclick="showRef(event, 'cit21b'); return false;" href="javascript:void(0);" class="ref cit21b">(21b)</a> PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRY">3KRY</a>, and the X-ray structure of MMP-3 complexed with the 1-sulfonyl-4-benzyloxycarbonyl-piperazine <b>10</b>, PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1D8F">1D8F</a>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> the piperidine N-substituent is directed toward the solvent region (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A,B). In fact, structural modifications in this region, the solvent accessible area, generally have a minor effect on potency and can provide a handle for modulating solubility and pharmacokinetic parameters. From this structural information, we focused our efforts on replacing the piperidine ring with a conformationally constrained ring system. Conformationally constrained ring systems are considered privileged structures.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Among them, the azaspirocyclic system and, in particular, spiropiperidines, have emerged as valuable fragments in drug discovery programs.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Potentially, the reduced molecular flexibility of these fragments and their spatial conformation may have a favorable impact on the molecular properties as well as their off-target profile (i.e., hERG and P450s). Thus, we designed a new series of MMP inhibitors incorporating a spiropiperidine unit (<b>5</b>′, Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>C) while maintaining the hydroxamic acid moiety as a zinc binding group (ZBG). The presence of an ionizable basic nitrogen in our molecules has a positive impact on the water solubility of these compounds, an issue of the THP chemical series.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> In addition, proposed molecules bearing this chemotype ensure an intellectual property position for this novel chemical series of α-spiropiperidine hydroxamates (<b>5</b>′).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_p">To validate our hypothesis, compounds <b>11</b>–<b>18</b>, bearing different S1′ fragments selected according to structure-based and knowledge-based approaches, together with their synthetic accessibility, were synthesized and evaluated for their inhibition against MMP-3 and MMP-10 (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The simple 4-methoxyphenyl derivative <b>12</b> exhibited nanomolar potency, with IC<sub>50</sub> values of <100 nM against MMP-3 and -10. Replacement of the methyl group in the ether with a 4-methoxyphenyl moiety (<b>13</b>) resulted in 10-fold higher IC<sub>50</sub> values against both isoforms (IC<sub>50</sub> = 9 and 12 nM against MMP-3 and MMP-10, respectively). The corresponding 4-methoxyphenyl ethers at the <i>meta</i>- (<b>14</b>) and <i>ortho</i>- (<b>15</b>) positions of the first aryl ring reduced the potency (<b>14</b>) or even led to an inactive compound (<b>15</b>), most likely due to steric factors given the narrowness of the S1′ pocket. Thus, we exclusively concentrated on substitutions at the 4-position of the first phenyl ring. Replacement of the 4-methoxy group of compound <b>13</b> with 4-OCF<sub>3</sub> (compound <b>16</b>) improved the activity, lowering the IC<sub>50</sub> values to 4 nM against both isoforms; the homologation of the distal phenyl by replacement with a benzyl ring slightly attenuated the potency (compound <b>17</b>), with IC<sub>50</sub> values of 20 nM (MMP-3) and 32 nM (MMP-10). Replacement of the ether linker with an amino linker (compound <b>18</b>) decreased the activity against MMPs. Thus, a pairwise comparison between <b>17</b> and <b>18</b> reveals that the NH-linked compound is more than 1.5 and 0.80 log units less potent as an MMP-3 and MMP-10 inhibitor, respectively, than the corresponding oxygen-linked derivative <b>17</b>. Consequently, the phenotypic functional assay clearly shows lower efficacy in the corresponding antifibrinolytic activity.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial Set of α-Spiropiperidine Hydroxamates</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0015.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Human whole blood.</p></div></div><div></div></div><div class="NLM_p">The similar trend in structure–activity relationships (SAR) against MMP3 and MMP10 can be explained by the high sequence similarity between both isoforms, with 86% of identical residues in the catalytic domain. A superposition of the MMP3 and MMP10 crystal structures (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1D8F">1D8F</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q3A">1Q3A</a>,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> respectively) revealed minor differences between both proteins (rms superposition of main chain atoms of 0.80 Å); the main difference is the replacement of His724 (MMP3) for Asn240 (MMP10), which have their side chains oriented outside the S1′ pocket.</div><div class="NLM_p last">Following our screening funnel, compounds with inhibition activities in the low nM range (IC<sub>50</sub> <100 nM) were tested as antifibrinolytic agents in a phenotypic functional assay using thromboelastometry of whole blood in the presence of tPA. The effective concentration of a compound to delay clot lysis time (CLT) by 50% (EC<sub>50</sub>) was considered to represent antifibrinolytic activity (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The EC<sub>50</sub> determined for compound <b>2</b> was 3 μM;<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> therefore, our initial aim was the identification of compounds with improved functional efficacy (EC<sub>50</sub>) compared to reference molecule <b>2</b>. In a first assessment, the lowest concentration tested by thromboelastometry was 400 nM. Compounds <b>12</b>, <b>13</b>, <b>16</b>, and <b>17</b> in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> had EC<sub>50</sub> values below this threshold value, showing excellent antifibrinolytic activity compared to <b>2</b>. Hence, modifications of the ether linker moiety was our initial favorite strategy for exploring different substituents on the distal ring, with the most potent compounds, <b>13</b>, <b>16</b>, and <b>17</b> being our initial reference points.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Exploration of Phenoxyphenyl and Benzyloxyphenyl Sulfone Moieties in Α-Spiropiperidine Hydroxamates</h3><div class="NLM_p">Diverse substituents on the distal aryl moiety, entering deep into the hydrophobic selectivity S1′ pocket,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> were selected by following our recently reported strategy for navigating the biologically relevant chemical space (BRCS).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> This approach relies on the concept of sampling R-groups according to the different potential interactions they may establish with the protein (ligand–receptor interactions, LRI) depending on their nature: alkyl, aryl, heteroaryl, primary/secondary amine (with hydrogen bond donor), tertiary amine, amide (with hydrogen bond acceptor and donor), ether, and keto (with hydrogen bond acceptor) and up to 14 classes of different substitution patterns. Representative analogues of the substituted aryloxyphenyl α-spiropiperidine hydroxamates are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. A wide variety of substituents at the 4- position, such as alkyl (<b>19a</b>, <b>19b</b>), alkoxy (<b>13</b>), and fluorinated alkoxy groups (<b>16</b>, <b>19c</b>) as well as mono- (<b>19d</b>) and disubstituted amides (<b>19e</b>), are well tolerated; in fact, these molecules exhibit IC<sub>50</sub> values in the low nanomolar range. According to the proposed binding site (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B), <b>19f</b> should fit and lead to a potent molecule; however, surprisingly, this compound, bearing an ionizable tertiary amine at the <i>para</i> position that might interact with Phe732 (cation−π), was inactive. Replacement of the phenyl ring with a 3-pyrido ring (<b>19g</b>) selectively attenuated the potency against MMP-10 (IC<sub>50</sub> = 62 nM) compared to compound <b>13</b>, which was 5-fold more potent, without significantly altering the potency against MMP-3. Hence, the potent compounds <b>19a</b>–<b>19e</b> and <b>19g</b> performed excellently in the functional antifibrinolytic assay, with EC<sub>50</sub>s ≤400 nM. <i>Meta</i> substitution on the distal phenyl ring led to compounds with equivalent (compound <b>19h</b> compared to <b>13</b>) or slightly reduced potency (compound <b>19j</b> compared to <b>19d</b>) for MMP inhibition. However, surprisingly, both <i>meta</i> derivatives showed poor efficacy in the functional assay, with EC<sub>50</sub>s of 3.7 μM (<b>19h</b>) and 7.5 μM (<b>19j</b>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Exploration of Phenoxyphenyl and Benzyloxyphenyl Sulfone Moieties in α-Spiropiperidine Hydroxamates</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0016.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Human whole blood.</p></div></div><div></div></div><div class="NLM_p last">The introduction of substitution at the <i>ortho</i> position of the distal phenyl ring resulted in a significant drop in MMP inhibitory activity (compound <b>19i</b> in the low micromolar range) or in its total abolishment (compound <b>19k</b>). Similarly, the incorporation of a chlorine at the 3-position of the first phenyl ring in the derivative of <b>16</b> (compound <b>19p</b>) abolished its MMP inhibitory activity. These substitutions induced nonplanarity in the R<sub>1</sub> substructure; thus, this loss of primary activity can be explained by the spatial conformations of these fragments placed in the S1′ pocket and the narrowness of S1′ (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B). This negative impact on the primary activity was confirmed in their corresponding phenotypic functional assay data. The introduction of a methoxy group, at the <i>meta</i> position, in the derivative <b>19d</b> led to compound <b>19l</b>. This new molecule had a decreased potency against the two MMP isoforms (-3 and -10) by more than 1 log unit. In addition, the functional response of <b>19l</b>, with an EC<sub>50</sub> value of 900 nM, confirmed the detrimental impact of <i>meta</i> substituents on the phenotypic response (as illustrated above for <b>19h</b> and <b>19j</b>). However, as we previously described for compound <b>17</b>, the replacement of the terminal phenyl ring with a benzyl ring resulted in minor differences in inhibitory activity. These results perfectly fit the structural description of the S1′ pocket (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B), narrow and long; thus, the methylene bridge is accommodated within S1′, for example, <b>19d</b> compared with <b>19n</b> (21 vs 39 nM, respectively, against MMP-3; and 21 vs 68 nM, respectively, against MMP-10). Finally, replacement of the aryl moiety with nonaromatic and polar large fragments (<b>19o</b>) appears to be detrimental to biochemical activity, leading to IC<sub>50</sub> values greater than 400 nM, most likely due to the hydrophobic nature of the S1′ pocket.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Exploration of N-Substituted Aryloxyphenyl α-Spiropiperidine Hydroxamates</h3><div class="NLM_p">The next stage involved an exploration around the basic nitrogen of the spiropiperidine in our chemical series, <b>5</b>′. As anticipated and according to the proposed binding mode (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B), the impact on primary activity due to growing the vector (R′) from the nitrogen facing the solvent-accessible area was minimal. Thus, the corresponding secondary amine of the spiro ring in compound <b>13</b> was converted into a tertiary amine (e.g., R<sub>1</sub> = Me, <b>20a</b>), a fluorinated alkyl-containing tertiary amine (<b>20b</b>), and an amide (<b>20c</b>), and their corresponding IC<sub>50</sub> values against MMPs, as well as their antifibrinolytic activities, were essentially unchanged (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). These compounds were initially designed to explore a variety of p<i>K</i><sub>a</sub> values and to evaluate their impact on ADME properties, mainly focused on solubility and hERG binding. Therefore, considering that the primary and functional activities are maintained, these molecules, covering a diversity in physicochemical properties, may provide alternative profiles from an ADME perspective. In fact, on the basis of the estimated p<i>K</i><sub>a</sub>s (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), compounds <b>13</b>, <b>20a</b>, and <b>20b</b> will be ionized to different extents at physiological pH, but molecule <b>20c</b>, bearing a tertiary amide considered as “nonbasic” and “nonacidic” under physiologic conditions, will not be protonated. However, because the synthesized molecules bearing a secondary amine did not show any hERG-related issues and optimal solubility was achieved as described below, no further exploration around this position has been performed.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Exploration of N-Substituted α-Spiropiperidine Hydroxamates</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0017.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Human whole blood.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">In silico estimation performed using the algorithm implemented in Pipeline Pilot v 8.5.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Exploration of Acyl Linker Aryl Moieties</h3><div class="NLM_p">Therapeutic scenarios where the stoppage of bleeding is required (surgery, trauma, and first aid, etc.) involve an acute treatment; therefore, we also designed molecules that have very short half-lives, i.e., immediate elimination after achieving their goal, allowing for subsequent wound healing. Thus, taking into account the structural description of the S1′ pocket (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B), we explored ester-linked analogues (<b>21</b>), and those corresponding to compounds <b>13</b> and <b>19d</b> (<b>21a</b> and <b>21b</b>) were synthesized (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Compound <b>21a</b> exhibited potency and functional activity similar to compound <b>13</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Exploration of Ester-Linked Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0018.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Human whole blood.</p></div></div><div></div></div><div class="NLM_p">Some of synthesized compounds (<b>13</b>, <b>16</b>, <b>19d</b>, <b>19p</b>, and <b>20a</b>) were screened against other MMP isoforms (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). In general, no selectivity was observed against any isoform at 10 μM, with inhibitory activities greater than 90% for most of the screened isoforms (MMP-1, -2, -8, -9, -12, -13, -14, and -20), except for MMP-1 and MMP-7 vs compound <b>19p</b>, whose inhibition were 9% and 26%. Nonplanarity induced by chlorine atom at the <i>meta</i> position led to this selective MMP inhibitor, <b>19p</b>, inactive against MMP-1, -3, -7, and -10; its R<sub>1</sub> substructure did not accommodate within S1′ pocket. Unfortunately, this molecule did not interact with the MMPs of interest (MMP-3 and MM-10) and, consequently, its functional antifibrinolytic response was really poor (EC<sub>50</sub> > 15 μM).</div><div class="NLM_p">In vitro ADME data (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>) guided us during the lead optimization process to prioritize which compounds were to progress to the in vivo assay. Our compounds showed low permeability (PAMPA Pe < 1 nm/s), which is a desirable feature; in fact, to be efficacious as antifibrinolytics, the compounds must be maintained in the bloodstream, minimizing tissue distribution and avoiding undesirable side effects. Additionally, all of these compounds showed low inhibition of the five major cytochrome P450 isoforms (1A2, 2C9, 2C19, 2D6, and 3A4); in fact, the percentage inhibition values, at 10 μM, were less than 50% for all tested compounds. The metabolic stability of this set of compounds was evaluated in human, mouse, and rat liver microsomes after 20 min of incubation at a concentration of 1 μM. All compounds, except for compound <b>21a</b> with the metabolically labile ester functionality, showed good microsomal stability in human and mouse species (>70% remaining). Replacement of the −OCF<sub>3</sub> group with the methylaminocarbonyl group tended to increase the stability, especially in the case of the pair <b>17</b> and <b>19n</b> (68.9% vs 97.6%, 71.1% vs 90.2%, and 68.7% vs 91.4%, for human, mouse, and rat, respectively). In addition, there was minimal interaction with the hERG channel according to the binding assay; in fact, all assayed molecules showed hERG IC<sub>50</sub> values >30 μM, and some of them, compounds <b>16</b>, <b>19d</b>, <b>19e</b>, and <b>19n</b>, even had IC<sub>50</sub> values ≥100 μM.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. ADME Profile<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">PAMPA Pe (nm/s)</th><th class="colsep0 rowsep0" align="center" char=".">1A2 (%)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">2C9 (%)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">2C19 (%)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">2D6 (%)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">3A4 (%)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">HLM (%)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">MLM (%)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">RLM (%)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">hERG IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="center">0.009</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">19.4</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">87.7</td><td class="colsep0 rowsep0" align="char" char=".">83.8</td><td class="colsep0 rowsep0" align="char" char=".">52.3</td><td class="colsep0 rowsep0" align="char" char=".">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="center">0.007</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td><td class="colsep0 rowsep0" align="char" char=".">10.6</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">92.1</td><td class="colsep0 rowsep0" align="char" char=".">87.2</td><td class="colsep0 rowsep0" align="char" char=".">95.6</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="center">N/D</td><td class="colsep0 rowsep0" align="char" char=".">13.6</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="char" char=".">30.5</td><td class="colsep0 rowsep0" align="char" char=".">19.9</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">68.9</td><td class="colsep0 rowsep0" align="char" char=".">71.1</td><td class="colsep0 rowsep0" align="char" char=".">68.7</td><td class="colsep0 rowsep0" align="char" char=".">50.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19d</b></td><td class="colsep0 rowsep0" align="center">0.010</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">91.1</td><td class="colsep0 rowsep0" align="char" char=".">97.5</td><td class="colsep0 rowsep0" align="char" char=".">99.8</td><td class="colsep0 rowsep0" align="char" char=".">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19e</b></td><td class="colsep0 rowsep0" align="center">N/D</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">18.9</td><td class="colsep0 rowsep0" align="char" char=".">28.8</td><td class="colsep0 rowsep0" align="char" char=".">8.3</td><td class="colsep0 rowsep0" align="char" char=".">90.2</td><td class="colsep0 rowsep0" align="char" char=".">90.6</td><td class="colsep0 rowsep0" align="char" char=".">92.6</td><td class="colsep0 rowsep0" align="char" char=".">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19n</b></td><td class="colsep0 rowsep0" align="center">N/D</td><td class="colsep0 rowsep0" align="char" char=".">25.6</td><td class="colsep0 rowsep0" align="char" char=".">12.3</td><td class="colsep0 rowsep0" align="char" char=".">40.2</td><td class="colsep0 rowsep0" align="char" char=".">37.2</td><td class="colsep0 rowsep0" align="char" char=".">11.6</td><td class="colsep0 rowsep0" align="char" char=".">97.6</td><td class="colsep0 rowsep0" align="char" char=".">90.2</td><td class="colsep0 rowsep0" align="char" char=".">91.4</td><td class="colsep0 rowsep0" align="char" char=".">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21a</b></td><td class="colsep0 rowsep0" align="center">0.002</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">11.1</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">63.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">N/D: not determined.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">% inhibition at 10 μM.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">% compound remaining after a 20 min incubation in human, mouse or rat liver microsomes (HLM, MLM, and RLM, respectively).</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> In Vivo Efficacy in Murine Bleeding Models</h3><div class="NLM_p">The most active compounds in the functional antifibrinolytic assay (EC<sub>50</sub> <1 μM) with the appropriate ADME profiles, the molecules described in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, were advanced into a mouse model known as the hyperfibrinolytic tail bleeding test. In this in vivo efficacy model, after administration of 0.5 mg/kg tissue plasminogen activator (tPA) alone, bleeding time (defined as the interval between the initial transection and the visual cessation of hemorrhaging) was significantly prolonged (29.28 ± 0.4 min), with 189 ± 26 μL of blood loss observed (i.e., 10% of the total volume). It could be demonstrated that compounds in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>, infused at 1 mg/kg/h, significantly reduced bleeding time relative to vehicle-treated controls and <b>2</b> (300 mg/kg/h), the current SoC. To assess toxicity and the absence of thrombus formation, an anatomopathological analysis focused on the brain, liver, lungs, and kidneys was carried out following treatment at 10 mg/kg/h, a 10-fold higher dose than the efficacious dose, to consider a wide safety window. Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a> reports whether signs of toxicity or thrombosis were observed (0) or not (1). Compounds <b>16</b> and <b>19d</b> were among the most efficient analogues at shortening bleeding time, with mean times of 0.99 ± 0.35 and 0.85 ± 0.45 min, respectively. However, mice treated with compound <b>16</b> presented signs of thrombosis in the lungs (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>); therefore, this safety issue prohibited any further investigation with compound <b>16</b>. However, as expected, compound <b>21a</b> exhibited poor metabolic stability (<5% for all three species, Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>) and led to poor in vivo efficacy, which precluded its further development. However, its reduction of bleeding time was still comparable to the current SoC (<b>2</b>) at a 300-fold lower dose. Unfortunately, <b>21a</b> also led to thrombus formation. Further studies are required to decipher the cause of thrombus formation; for example, comparison of exhaustive off-target selectivity profilings, biodistribution, pharmacokinetic parameters, etc.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vivo Efficacy in a Mouse tPA-Induced Tail Bleeding Model<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">bleeding time (min) at 1 mg/kg</th><th class="colsep0 rowsep0" align="center" char=".">SEM</th><th class="colsep0 rowsep0" align="center" char="."><i>P</i> value vs saline-treated control</th><th class="colsep0 rowsep0" align="center" char="."><i>P</i> value vs <b>2</b>-treated control</th><th class="colsep0 rowsep0" align="center">anatomopathological analysis, at 10 mg/kg</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">saline</td><td class="colsep0 rowsep0" align="char" char=".">29.28</td><td class="colsep0 rowsep0" align="char" char=".">±0.4</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">14.2</td><td class="colsep0 rowsep0" align="char" char=".">±3.1</td><td class="colsep0 rowsep0" align="char" char="."><0.0001</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center">1<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aprotinin<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">12.43</td><td class="colsep0 rowsep0" align="char" char=".">±4.3</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.393</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">16.37</td><td class="colsep0 rowsep0" align="char" char=".">±3.88</td><td class="colsep0 rowsep0" align="char" char=".">0.0090</td><td class="colsep0 rowsep0" align="char" char=".">0.91</td><td class="colsep0 rowsep0" align="center">N/D<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char=".">0.99</td><td class="colsep0 rowsep0" align="char" char=".">±0.12</td><td class="colsep0 rowsep0" align="char" char="."><0.0001</td><td class="colsep0 rowsep0" align="char" char="."><0.0001</td><td class="colsep0 rowsep0" align="center">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="char" char=".">2.09</td><td class="colsep0 rowsep0" align="char" char=".">±0.70</td><td class="colsep0 rowsep0" align="char" char="."><0.0001</td><td class="colsep0 rowsep0" align="char" char="."><0.0001</td><td class="colsep0 rowsep0" align="center">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19d</b></td><td class="colsep0 rowsep0" align="char" char=".">0.85</td><td class="colsep0 rowsep0" align="char" char=".">±0.15</td><td class="colsep0 rowsep0" align="char" char="."><0.0001</td><td class="colsep0 rowsep0" align="char" char="."><0.0001</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19e</b></td><td class="colsep0 rowsep0" align="char" char=".">8.21</td><td class="colsep0 rowsep0" align="char" char=".">±3.66</td><td class="colsep0 rowsep0" align="char" char="."><0.0001</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19m</b></td><td class="colsep0 rowsep0" align="char" char=".">18.45</td><td class="colsep0 rowsep0" align="char" char=".">±3.72</td><td class="colsep0 rowsep0" align="char" char=".">0.01</td><td class="colsep0 rowsep0" align="char" char=".">0.44</td><td class="colsep0 rowsep0" align="center">N/D<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19n</b></td><td class="colsep0 rowsep0" align="char" char=".">2.67</td><td class="colsep0 rowsep0" align="char" char=".">±1.27</td><td class="colsep0 rowsep0" align="char" char="."><0.0001</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="center">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21a</b></td><td class="colsep0 rowsep0" align="char" char=".">13.43</td><td class="colsep0 rowsep0" align="char" char=".">±4.53</td><td class="colsep0 rowsep0" align="char" char=".">0.01</td><td class="colsep0 rowsep0" align="char" char=".">0.44</td><td class="colsep0 rowsep0" align="center">0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last"><i>n</i> ≥ 10 mice/group.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Compound <b>2</b> was tested at 300 mg/kg, and its corresponding anatomopathological analysis was also performed at this dose.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Aprotinin was tested at 10 mg/kg.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">N/D: not determined. Data were evaluated using the Mann–Whitney U test, where bleeding time is reported as the mean value and SEM (standard error of the mean).</p></div></div></div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0005.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Anatomopathological images of mice treated with compounds <b>16</b> and <b>19d</b>. (A,B) Anatomopathological images of mice treated with <b>16</b> (10 mg/kg). (A) Hematoxylin and eosin staining of lung tissue vessels (magnification 400×) showing a microthrombus (arrows), (B) kidney with slight hypercellularity and small spheres of protein in the Bowman’s capsule (arrows) (magnification 600×). (C,D) Anatomopathological images of mice treated with <b>19d</b> (10 mg/kg). Hematoxylin and eosin staining of lung tissue vessels (magnification 100×) and kidney glomeruli and tubules (magnification 400×) with normal appearance and no thrombus formation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>19d</b> was a promising therapeutic agent in terms of in vitro ADME profile as well as in vivo efficacy and safety; therefore, both enantiomers, <i>R</i>-(<b>5</b>) and <i>S</i>-(<b>22</b>), were resolved by supercritical fluid chromatography (SFC). The absolute stereochemistry of these compounds was confirmed by X-ray diffraction analysis of derivatives <b>23a</b> and <b>23b</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). The synthesis of <b>23a</b> has been previously described by our group,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and we followed the same protocol for compound <b>23b</b> (details in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0006.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of compounds <b>23a</b> and <b>23b</b> obtained by X-ray crystallographic analysis. (A) <b>23a</b>, as previously reported;<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (B) <b>23b</b> together with its corresponding color-coded stick representation. Details for the X-ray crystallographic data of compound <b>23b</b> and its corresponding coordinates are reported in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>5</b> had IC<sub>50</sub>s of 15 and 12 nM against MMP-3 and MMP-10, respectively. The corresponding IC<sub>50</sub>s for compound <b>22</b> were 18 nM (MMP-3) and 17 nM (MMP-10). For these advanced compounds, the exact EC<sub>50</sub> was determined (by testing a broad range of concentrations below 400 nM) as 0.7 nM (<b>5</b>) and 17.6 nM (<b>22</b>). As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>, both enantiomers exhibited preliminary ADME properties comparable to the racemic compound <b>19d</b>, except for P450 inhibition. In this case, we performed a Caco-2 permeability assay instead of a PAMPA assay, where only passive diffusion is assessed; although low permeability was confirmed for both molecules, the data suggests that <b>5</b> likely acts as an efflux pump substrate (efflux ratio >2.5). Thus, this fact might favor the exposure of <b>5</b> to the bloodstream and enhance its efficacy compared to that of <b>22</b>. The solubility of these two enantiomers, <b>5</b> and <b>22</b>, was very similar at 103.25 and 97.96 μg/mL, respectively, at pH = 7.4; for both compounds, a patch clamp electrophysiology assay gave IC<sub>50</sub> values >30 μM. Therefore, regarding cardiovascular safety, these data suggest that there is a good correlation with the hERG binding values (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>), as expected, and the assayed compounds do not raise any alerts from a cardiovascular safety perspective. Notably, as reported below in Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>, the in vivo efficacy of the <i>R</i> enantiomer <b>5</b> outperformed that of the <i>S</i> enantiomer <b>22</b> (mean bleeding time of 1.82 ± 0.42 vs 10.36 ± 4.31 min, respectively) as well as that of the current standards of care, <b>2</b>, and aprotinin. It is noteworthy that pharmacokinetic study revealed a short half-life (1.4 h) for <b>5</b>;<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> thus, leading to the desirable profile in acute treatment of bleeding: stable enough to achieve the goal and fast elimination.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. ADME Profile for the Enantiomers of <b>19d</b>: <b>5</b> (<i>R</i>) and <b>22</b> (<i>S</i>)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">Caco-2 <i>P</i><sub>app</sub> (nm/s)</th><th class="colsep0 rowsep0" align="center" char=".">Caco-2 efflux ratio</th><th class="colsep0 rowsep0" align="center" char=".">1A2 (%)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">2C9 (%)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">2C19 (%)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">2D6 (%)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">3A4 (%)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">HLM (%)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">MLM (%)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">RLM (%)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">hERG IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b><a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></td><td class="colsep0 rowsep0" align="char" char=".">0.0016</td><td class="colsep0 rowsep0" align="char" char=".">2.60</td><td class="colsep0 rowsep0" align="char" char=".">28.7</td><td class="colsep0 rowsep0" align="char" char=".">9.4</td><td class="colsep0 rowsep0" align="char" char=".">28.6</td><td class="colsep0 rowsep0" align="char" char=".">43.7</td><td class="colsep0 rowsep0" align="char" char=".">17.6</td><td class="colsep0 rowsep0" align="char" char=".">93.5</td><td class="colsep0 rowsep0" align="char" char=".">98.0</td><td class="colsep0 rowsep0" align="char" char=".">98.1</td><td class="colsep0 rowsep0" align="char" char=".">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char=".">0.0059</td><td class="colsep0 rowsep0" align="char" char=".">1.12</td><td class="colsep0 rowsep0" align="char" char=".">28.7</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td><td class="colsep0 rowsep0" align="char" char=".">22.2</td><td class="colsep0 rowsep0" align="char" char=".">45.6</td><td class="colsep0 rowsep0" align="char" char=".">15.9</td><td class="colsep0 rowsep0" align="char" char=".">97.0</td><td class="colsep0 rowsep0" align="char" char=".">89.6</td><td class="colsep0 rowsep0" align="char" char=".">97.4</td><td class="colsep0 rowsep0" align="char" char=".">>100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">% inhibition at 10 μM.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">% compound remaining after a 20 min incubation in human, mouse or rat liver microsomes (HLM, MLM, and RLM, respectively).</p></div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. In Vivo Efficacy in a Mouse tPA-Induced Tail Bleeding Model<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">bleeding time (min) at 1 mg/kg</th><th class="colsep0 rowsep0" align="center" char=".">SEM</th><th class="colsep0 rowsep0" align="center" char="."><i>P</i> value vs saline-treated control</th><th class="colsep0 rowsep0" align="center" char="."><i>P</i> value vs <b>2</b>-treated control</th><th class="colsep0 rowsep0" align="center" char="."><i>P</i> value vs aprotinin-treated control</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b><a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></td><td class="colsep0 rowsep0" align="char" char=".">1.82</td><td class="colsep0 rowsep0" align="char" char=".">±0.42</td><td class="colsep0 rowsep0" align="char" char="."><0.0001</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.079</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char=".">10.36</td><td class="colsep0 rowsep0" align="char" char=".">±4.31</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">0.529</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last"><i>n</i> ≥ 10 mice/group. Data were evaluated using the Mann–Whitney U test, where bleeding time is reported as the mean value and SEM (standard error of the mean).</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry</h3><div class="NLM_p">As a general strategy, all of the analogues in this series were first prepared as racemic mixtures. For selected compounds, the racemic mixture was resolved by chiral HPLC to give both enantiomers. The preparation of α-spiropiperidine hydroxamates with different linkers is summarized in the following schemes. Racemic α-spiropiperidine hydroxamate compounds <b>11</b>–<b>13</b>, <b>16</b>, <b>19a</b>–<b>c</b>, and <b>19f</b>–<b>i</b> were synthesized as depicted in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. The methodology is closely related to that previously reported.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Commercially available 8-<i>tert</i>-butyl-2-methyl-8-azaspiro[4.5]decane-2,8-dicarboxylate <b>24</b> was deprotonated with LDA and sulfonylated with 4-fluorobenzenesulfonyl fluoride. Then, saponification of methyl ester <b>25</b> gave carboxylic acid <b>26</b>, which was converted into the THP-protected hydroxamic acid <b>27</b> by reaction with <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine using EDC/HOBt as the coupling system. Subsequent acidic deprotection of the hydroxamate and BOC moieties of compound <b>27</b> afforded the 4-fluorophenyl intermediate <b>11</b>. Alternatively, reaction of <b>27</b> with aqueous NaOMe gave the protected precursor of methoxy compound <b>12</b>, obtained after removal of the BOC and THP groups. Nucleophilic aromatic substitution of the aryl fluoride <b>27</b> with the appropriate aryl alcohols in the presence of cesium carbonate afforded the corresponding aryl ethers <b>29a</b>–<b>i</b>. Acidic removal of both BOC and THP groups with HCl afforded the target compounds <b>13</b>, <b>16</b>, <b>19a</b>–<b>c</b>, and <b>19f</b>–<b>i</b>.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>11</b>–<b>13</b>, <b>16</b>, <b>19a</b>–<b>c</b>, and <b>19f</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) LDA, THF, −78 °C, 1 h, then 4-fluorobenzenesulfonyl fluoride, −78 °C, 1 h to RT overnight; (b) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (3:3:2), RT, 4 h; (c) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, RT, overnight; (d) NaOMe, overnight; (e) HCl/dioxane (2N), RT, 1 h; (f) corresponding aryl alcohol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80–90 °C, MW or conventional heating.</p></p></figure><div class="NLM_p">Aryl fluoride <b>27</b> was also coupled with other alcohols in the presence of NaH to yield intermediates <b>30a</b>–<b>b</b> and <b>31</b>, which, after acidic deprotection, afforded compounds <b>17</b>, <b>19m</b>, and <b>19o</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).</div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of compounds <b>17</b>, <b>19m</b>, and <b>19o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) corresponding alcohol, NaH, RT, 30 min, then <b>27</b>, 80–90 °C, overnight; (b) HCl/dioxane (2N), RT, 1 h.</p></p></figure><div class="NLM_p">Similar chemistry could be used to arrive at amides <b>19d</b>, <b>19e</b>, <b>19j</b>, and <b>19l</b> through the corresponding ester-substituted aryl ether precursors <b>32a</b>–<b>c</b> (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>), which could be converted into carboxylic acids <b>33a</b>–<b>c</b> with LiOH. These intermediates were coupled with the appropriate amines. Finally, the protected amide analogues <b>34a</b>–<b>d</b> were deprotected to obtain the desired hydroxamic acids <b>19d</b>, <b>19e</b>, <b>19j</b>, and <b>19l</b>.</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>19d</b>, <b>19e</b>, <b>19j</b>, and <b>19l</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) corresponding alcohol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80–90 °C, overnight or DMA, 120 °C, MW, 2 h; (b) LiOH·H<sub>2</sub>O, THF/H<sub>2</sub>O (3:1 or 3:2) or THF/MeOH/H<sub>2</sub>O (3:3:2), RT, 4 h; (1c) EDC·HCl, HOBt, CH<sub>3</sub>NH·HCl or pyrrolidine, NMM, DMF, RT, overnight; (2c) Et<sub>3</sub>N, HATU, CH<sub>3</sub>NH·HCl, CH<sub>3</sub>CN, RT, overnight; (d) HCl/dioxane (2N), RT, 1–2 h.</p></p></figure><div class="NLM_p">Preparation of compounds <b>14</b>, <b>15</b>, and <b>19p</b> is shown in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. In this case, compound <b>24</b> was coupled with the appropriate benzenesulfonyl fluoride in each case to afford intermediates <b>35a</b>–<b>c</b>. Then, reaction with an aryl alcohol led to the corresponding esters, which were hydrolyzed to carboxylic acids <b>37a</b>–<b>c</b>. These products were converted into hydroxamic acids <b>14</b>, <b>15</b>, and <b>19p</b>, as previously described.</div><figure id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of compounds <b>14</b>, <b>15</b>, and <b>19p</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) LDA, THF, −78 °C, 1 h, then corresponding sulfonyl fluoride, −78 °C, 1 h and RT overnight; (1b) corresponding alcohol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80–100 °C, overnight; (2b) corresponding alcohol, Cs<sub>2</sub>CO<sub>3</sub>, CuI, <i>N</i>,<i>N</i>′-dimethylglycine, dioxane, reflux, overnight; (c) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (3:3:2), RT, 4 h; (d) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, RT, overnight; (e) HCl/dioxane (2N), RT, 2–3 h.</p></p></figure><div class="NLM_p">In the case of methyl amides <b>19k</b> and <b>19n</b>, phenol <b>40</b> was first prepared from intermediate <b>27</b> (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>). Subsequent reaction with the corresponding benzoate afforded <b>41a</b>–<b>b</b>. Ester hydrolysis gave the corresponding carboxylic acids <b>42a</b>–<b>b</b>, which were then converted to the corresponding amides <b>43a</b>–<b>b</b>. Final deprotection under acidic conditions led to the desired products <b>19k</b> and <b>19n</b>.</div><figure id="sch5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>19k</b> and <b>19n</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, benzyl alcohol, THF, RT, 30 min, then <b>27</b>, 80 °C, overnight; (b) Pd/C, H<sub>2</sub> (1 atm), MeOH, RT, 1 h; (1c) ethyl 2-fluorobenzoate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, overnight; (2c) methyl 4-(bromomethyl)benzoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 0 °C to RT, overnight; (d) LiOH·H<sub>2</sub>O, THF/H<sub>2</sub>O (3:1), RT, overnight; (e) EDC·HCl, HOBt, CH<sub>3</sub>NH·HCl, NMM, DMF, RT, overnight; (f) HCl/dioxane (2N), RT, 1 h.</p></p></figure><div class="NLM_p">The synthetic route for the preparation of compound <b>18</b> with an amino linker is outlined in Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>. Starting from intermediate <b>27</b>, [4-(trifluoromethoxy)phenyl]methanamine was used for the nucleophilic aromatic substitution to obtain precursor <b>44</b>, which was finally deprotected in acidic media.</div><figure id="sch6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0012.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compound <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) [4-(trifluoromethoxy)phenyl]methanamine, 110 °C, overnight; (b) HCl/dioxane (2N), RT, 2 h.</p></p></figure><div class="NLM_p">The N-substituted α-spiropiperidine analogue <b>20a</b> was prepared as summarized in Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>A. Reaction of the aryl fluoride <b>25</b> with 4-methoxyphenol followed by BOC deprotection gave the key N-unsubstituted intermediate <b>46</b>, which was then methylated to give the N-substituted derivative <b>47</b>. Ester hydrolysis gave the corresponding carboxylic acid <b>48</b>, which was then converted to the hydroxamate <b>20a</b> via the THP-protected intermediate <b>49</b>. Other N-substituted products, <b>20b</b> and <b>20c</b>, were also prepared by direct alkylation or acylation of compound <b>13</b> (Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>B).</div><figure id="sch7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0013.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>20a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4-methoxyphenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C, 2 h; (b) HCl/dioxane (4N), RT, 3 h; (c) MeI, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, RT, 30 min; (d) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (3:3:2), reflux, overnight; (e) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, RT, overnight; (f) HCl/dioxane (4N), RT, 3 h; (g) 3-bromo-1,1,1-trifluoropropane, K<sub>2</sub>CO<sub>3</sub>, DMF, RT, overnight; (h) pyridine, acetyl chloride, DMF, 0 °C, 5 min.</p></p></figure><div class="NLM_p">Finally, ester-linked compounds <b>21a</b> and <b>21b</b> were prepared from intermediate <b>40</b> (Scheme <a class="ref internalNav" href="#sch8" aria-label="8">8</a>). Acylation of this phenol with the corresponding acyl chlorides lead to esters <b>50a</b> and <b>50b</b>. Then, the desired product, <b>21a</b>, was obtained by acidic deprotection. However, precursor <b>50b</b> was converted into <b>21b</b> by hydrogenation, reaction with CH<sub>3</sub>NH<sub>2</sub>·HCl, and removal of the BOC and THP protecting groups.</div><figure id="sch8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0014.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>21a</b>–<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) corresponding acyl chloride, Et<sub>3</sub>N, DCM, RT, overnight; (b) HCl/dioxane (2N), RT, 1 h; (c) Pd/C, H<sub>2</sub> (1 atm), MeOH, RT, 1 h; (d) CH<sub>3</sub>NH·HCl, Et<sub>3</sub>N, HATU, CH<sub>3</sub>CN, RT, overnight.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18468" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18468" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">On the basis of structural information as well as the available structure–activity relationship data for MMP inhibitors, we designed a novel chemical series, α-spiropiperidine hydroxamates. Synthesized compounds exploring this chemical series were found to be potent pan-MMP inhibitors (low nanomolar) that overcome identified drawbacks of previously known MMP inhibitors chemical series, e.g., solubility.</div><div class="NLM_p last">Exploration around the two main growing vectors borne by our chemical series <b>5</b>′, R and R′ (facing the S1′ pocket and the solvent accessible area, respectively), led us to evolve from the initial hit compound <b>12</b> and achieve an optimal lead molecule <b>19d</b>. The racemic compound <b>19d</b> showed a remarkable in vitro phenotypic response, delaying clot lysis time by 50% in human whole blood at a concentration lower than 400 nM and exhibiting outstanding in vivo efficacy; in fact, the bleeding time in mice at 1 mg/kg was 0.85 min versus 29.28 min using saline. ADME profiling for compound <b>19d</b> was also adequate: P450 inhibition at 10 μM for the five major isoforms was less than 50%, and its IC<sub>50</sub> value for hERG potassium channel inhibition was greater than 100 μM. Finally, an anatomopathological analysis was performed on mice treated with 10 times the effective dose of <b>19d</b>, and no thrombus formation was identified. Thus, its corresponding enantiomers were separated, which provided the preclinical candidate <b>5</b>.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In summary, we have described the discovery of a novel chemical series of potent and safe antifibrinolytic agents, acting via MMP inhibition, for the acute treatment of bleeding.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53764" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53764" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Chemistry. General Procedure</h3><div class="NLM_p">Unless otherwise noted, all reagents and solvents were of the highest commercial quality and used without further purification. All experiments involving moisture sensitive compounds were conducted under nitrogen. The reactions were monitored by thin layer chromatography (TLC) on silica gel-coated plates (Merck 60 F254) using reagent grade solvents. Flash column chromatography was performed on silica gel, particle size 60 Å, mesh = 230–400 (Merck) using standard techniques. Automated flash column chromatography was performed, using ready-to-connect cartridges from Varian with irregular silica gel, particle size 15–40 μm (normal phase disposable flash columns), on a Biotage SPX flash purification system. Supercritical fluid chromatography was conducted on a Thar analytical SFC apparatus (for analytical separation) and an Mg II preparative SFC apparatus (for preparative separation); details are provided in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. Microwave-assisted reactions were performed in a Biotage Smith Synthesis microwave reactor. The NMR spectroscopic data were recorded on a Bruker AV400 or VARIAN 400MR spectrometer with standard pulse sequences operating at 400 MHz. Chemical shifts (δ) are reported in parts per million (ppm) downfield from tetramethylsilane (TMS), which was used as an internal standard. The abbreviations used to describe multiplicities are s = singlet, d = doublet, t = triplet, m = multiplet. Coupling constants (<i>J</i>) are in hertz. HPLC analysis was performed using a Shimadzu LC-20AB or LC-20AD chromatograph with a Luna-C18(2), 5 μm, 2.0 mm × 50 mm column at 40 °C with UV detection. Flow from the column was split to a MS spectrometer. The MS detector (Agilent 1200, 6110MS, or Agilent 1200, 6120MS quadrupole) was configured with an electrospray or API/APCI source. Nitrogen was used as the nebulizer gas. The source temperature was maintained at 50 °C. Data acquisition was accomplished with ChemStation LC/MSD quad software. All tested compounds possessed a purity of at least 95% established by HPLC. Reported yields were not optimized, with the emphasis being on purity of product rather than quantity.</div><div id="sec4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> O8-<i>tert</i>-Butyl O3-Methyl 3-(4-Fluorophenyl)sulfonyl-8-azaspiro[4.5]decane-3,8-dicarboxylate (<b>25</b>)</h4><div class="NLM_p last">To a solution of commercially available 8-<i>tert</i>-butyl-2-methyl-8-azaspiro[4.5]decane-2,8-dicarboxylate <b>24</b> (18.38 g, 0.062 mol) in THF (200 mL) was added LDA (102 mL, 1.25 M) at −78 °C. After stirring at −78 °C for 1 h, 4-fluoro-benzenesulfonyl fluoride (22.23 g, 2 equiv) was added to the solution, the reaction was stirred at −78 °C for 1 h, and the mixture was stirred at RT overnight. After TLC (petroleum ether/EtOAc, 5:1) showed that the starting material had been consumed, the mixture was quenched with aqueous NH<sub>4</sub>Cl and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product, which was purified by column chromatography to give pure compound <b>25</b> (18.94 g, 67%) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.86–7.82 (m, 2H), 7.28–7.22 (m, 2H), 3.70 (s, 3H), 3.44–3.30 (m, 4H), 2.57–2.42 (m, 3H), 2.34–2.31 (d, 1H), 1.81–1.74 (m, 1H), 1.63–1.50 (m, 3H), 1.46 (s, 9H), 1.34–1.33 (m, 2H). MS <i>m</i>/<i>z</i> 456 [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>30</sub>FNO<sub>6</sub>S.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 8-<i>tert</i>-Butoxycarbonyl-3-(4-fluorophenyl)sulfonyl-8-azaspiro[4.5]decane-3-carboxylic Acid (<b>26</b>)</h4><div class="NLM_p last">To a solution of compound <b>25</b> (10 g, 0.022 mol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 80 mL) was added LiOH·H<sub>2</sub>O (9.23 g, 10 equiv). The resulting mixture was stirred at RT for 4 h, after which TLC (petroleum ether/EtOAc, 5:1) showed that the starting materials had been consumed completely. Then, the mixture was diluted with water and adjusted pH to 2–3 with 1 N HCl, and the mixture was extracted with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product <b>26</b> (9.60 g, 99%) as a pale-yellow oil, which was used in the next step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.92–7.88 (m, 2H), 7.24–7.19 (m, 2H), 3.45–3.27 (m, 4H), 2.58–2.44 (m, 3H), 2.27–2.07 (m, 1H), 1.75–1.71 (m, 2H), 1.62–1.51 (m, 2H), 1.47 (s, 9H), 1.31–1.27 (m, 2H). MS <i>m</i>/<i>z</i> 442 [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>28</sub>FNO<sub>6</sub>S.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>tert</i>-Butyl 3-(4-Fluorophenyl)sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>27</b>)</h4><div class="NLM_p last">To a solution of compound <b>26</b> (9.60 g, 0.022 mol) in DMF (100 mL) was added EDC·HCl (8.40 g, 2 equiv), HOBt (5.85 g, 2 equiv), THPONH<sub>2</sub> (3.86 g, 1.5 equiv), and NMM (6.67 g, 3 equiv) at RT, then the mixture was stirred at RT overnight. The mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product, which was purified by column chromatography to give pure compound <b>27</b> (9.0 g, 76%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.93–7.89 (m, 2H), 7.24–7.18 (m, 2H), 4.95–4.91(m, 1H), 4.00–3.95 (m, 1H), 3.69–3.67 (m, 1H), 3.46–3.21 (m, 4H), 2.58–2.15 (m, 4H), 1.85–1.50 (m, 10H), 1.42 (s, 9H), 1.38–1.37 (m, 2H). MS <i>m</i>/<i>z</i> 541 [M + H]<sup>+</sup> calcd for C<sub>26</sub>H<sub>37</sub>FN<sub>2</sub>O<sub>7</sub>S.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-(4-Fluorophenyl)sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>11</b>)</h4><div class="NLM_p last">A solution of compound <b>27</b> (30 mg, 0.056 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>11</b> (17.0 mg, 85%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.95–7.91 (m, 2H), 7.39–7.35 (m, 2H), 3.22–3.13 (m, 4H), 2.58–2.26 (m, 4H), 1.88–1.62 (m, 6H). MS <i>m</i>/<i>z</i> 357 [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>21</sub>FN<sub>2</sub>O<sub>4</sub>S.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>tert</i>-Butyl 3-(4-Methoxyphenyl)sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>28</b>)</h4><div class="NLM_p last">A solution of compound <b>27</b> (60 mg, 0.111 mmol) in 33% aqueous NaOMe (5 mL) was stirred overnight after TLC (PE/AE 2:1) showed the starting material was consumed. Then the mixture was concentrated, extracted with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>28</b> (45 mg, 74%) as a pale-yellow oil. MS <i>m</i>/<i>z</i> 553 [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>40</sub>N<sub>2</sub>O<sub>8</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-(4-Methoxyphenyl)sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>12</b>)</h4><div class="NLM_p last">A solution of compound <b>28</b> (45 mg, 0.082 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>12</b> (25.0 mg, 83%) as a red solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.80–7.78 (d, <i>J</i> = 8.8 Hz, 2H), 7.13–7.11 (d, <i>J</i> = 8.8 Hz, 2H), 3.92 (s, 3H), 3.19–3.13 (m, 4H), 2.56–2.24 (m, 4H), 1.83–1.80 (m, 3H), 1.69–1.62 (m, 3H). MS <i>m</i>/<i>z</i> 369 [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>S.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>tert</i>-Butyl 3-[4-(4-Methoxyphenoxy)phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>29a</b>)</h4><div class="NLM_p last">To a solution of compound <b>27</b> (200 mg, 0.37 mmol) in DMF (5 mL) was added 4-methoxyphenol (69 mg, 1.5 equiv) and Cs<sub>2</sub>CO<sub>3</sub> (241 mg, 2 equiv), then the reaction mixture was stirred at 90 °C overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>29a</b> (150 mg, 63%) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.83–7.80 (m, 2H), 7.05–6.95 (m, 6H), 4.98–4.97 (m, 1H), 4.03–3.98 (m, 1H), 3.85 (s, 3H), 3.72–3.69 (m, 1H), 3.49–3.25 (m, 4H), 2.45–2.06 (m, 4H), 1.89–1.61 (m, 10H), 1.58 (s, 9H), 1.56–1.55 (m, 2H). MS <i>m</i>/<i>z</i> 645 [M + H]<sup>+</sup> calcd for C<sub>33</sub>H<sub>44</sub>N<sub>2</sub>O<sub>9</sub>S.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 3-[4-(4-Methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid Hydrochloride (<b>13</b>)</h4><div class="NLM_p last">A solution of compound <b>29a</b> (150 mg, 0.233 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>13</b> (50 mg, 47%) as a red solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.76–7.74 (m, 2H), 7.04–6.97 (m, 6H), 3.79 (s, 3H), 3.16–3.10 (m, 4H), 2.55–2.48 (m, 2H), 2.41–2.34 (m, 1H), 2.24–2.20 (m, 1H), 1.83–1.76 (m, 3H), 1.68–1.58 (m, 3H). MS <i>m</i>/<i>z</i> 460 [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>28</sub>N<sub>2</sub>O<sub>6</sub>S.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>tert</i>-Butyl 3-(Tetrahydropyran-2-yloxycarbamoyl)-3-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-8-carboxylate (<b>29b</b>)</h4><div class="NLM_p last">To a solution of compound <b>27</b> (60 mg, 0.111 mmol) in DMF (3 mL) was added 4-(trifluoromethoxy)phenol (60 mg, 3 equiv) and Cs<sub>2</sub>CO<sub>3</sub> (109 mg, 3 equiv), then the reaction mixture was stirred at 80 °C overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>29b</b> (65 mg, 84%) as a white solid. MS <i>m</i>/<i>z</i> 699 [M + H]<sup>+</sup> calcd for C<sub>33</sub>H<sub>41</sub>F<sub>3</sub>N<sub>2</sub>O<sub>9</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 3-[4-[4-(Trifluoromethoxy)phenoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>16</b>)</h4><div class="NLM_p last">A solution of compound <b>29b</b> (65 mg, 0.093 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>16</b> (18.2 mg, 37.5%) as a red solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.84–7.82 (d, <i>J</i> = 9.2 Hz, 2H), 7.38–7.36 (d, <i>J</i> = 8.8 Hz, 2H), 7.24–7.21 (m, 2H), 7.14–7.12 (d, <i>J</i> = 8.8 Hz, 2H), 3.18–3.10 (m, 4H), 2.55–2.24 (m, 4H), 1.85–1.79 (m, 3H), 1.63–1.60 (m, 3H). MS <i>m</i>/<i>z</i> 515 [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>25</sub>F<sub>3</sub>N<sub>2</sub>O<sub>6</sub>S.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>tert</i>-Butyl 3-[4-(4-Methylphenoxy)phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>29c</b>)</h4><div class="NLM_p last">To a solution of compound <b>27</b> (100 mg, 0.185 mmol) in DMF (3 mL) was added <i>p</i>-methylphenol (60 mg, 3 equiv) and Cs<sub>2</sub>CO<sub>3</sub> (181 mg, 3 equiv), then the reaction mixture was stirred at 100 °C for 90 min with microwave. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>29c</b> (75 mg, 65%) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.83–7.81 (d, <i>J</i> = 7.6 Hz, 2H), 7.24–7.22 (d, <i>J</i> = 8 Hz, 2H), 7.03–6.98 (m, 4H), 4.98 (s, 1H), 4.03–3.98 (m, 1H), 3.71–3.69 (m, 1H), 3.49–3.25 (m, 4H), 2.61–2.42 (m, 3H), 2.39 (s, 3H), 2.30–2.19 (m, 1H), 1.88–1.53 (m, 10H), 1.46 (s, 9H), 1.43–1.42 (m, 2H). MS <i>m</i>/<i>z</i> 629 [M + H]<sup>+</sup> calcd for C<sub>33</sub>H<sub>44</sub>N<sub>2</sub>O<sub>8</sub>S.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 3-[4-(4-Methylphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>19a</b>)</h4><div class="NLM_p last">A solution of compound <b>29c</b> (75 mg, 0.119 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19a</b> (51.4 mg, 97%) as a red solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.79–7.76 (m, 2H), 7.27–7.25 (m, 2H), 7.06–7.00 (m, 2H), 6.99–6.98 (m, 2H), 3.19–3.10 (m, 4H), 2.58–2.51 (m, 2H), 2.42–2.37 (m, 1H), 2.36 (s, 3H), 2.26–2.22 (m, 1H), 1.93–1.78 (m, 3H), 1.70–1.60 (m, 3H). MS <i>m</i>/<i>z</i> 445 [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub>S.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>tert</i>-Butyl 3-[4-(4-<i>tert</i>-Butylphenoxy)phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>29d</b>)</h4><div class="NLM_p last">To a solution of compound <b>27</b> (261 mg, 0.498 mmol) in DMF (5 mL) was added 4-<i>tert</i>-butyl phenol (112 mg, 1.5 equiv) and Cs<sub>2</sub>CO<sub>3</sub> (324 mg, 2 equiv), then the reaction mixture was stirred at 90 °C overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE = 2:1) to give pure compound <b>29d</b> (204 mg, 61%) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.79–7.77 (m, 2H), 7.41–7.37 (m, 2H), 7.01–6.95 (m, 4H), 4.87 (s, 1H), 3.68 (s, 1H), 3.51–3.25 (m, 5H), 2.53–2.38 (m, 3H), 2.15–2.08 (m, 1H), 1.81–1.57 (m, 10H), 1.53 (s, 9H), 1.49–1.40 (m, 2H), 1.32 (s, 9H). MS <i>m</i>/<i>z</i> 671 [M + H]<sup>+</sup>calcd for C<sub>36</sub>H<sub>50</sub>N<sub>2</sub>O<sub>8</sub>S.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 3-[4-(4-<i>tert</i>-Butylphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>19b</b>)</h4><div class="NLM_p last">A solution of compound <b>29d</b> (180 mg, 0.277 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19b</b> (26.9 mg, 19%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.77–7.75 (d, <i>J</i> = 8.8 Hz, 2H), 7.48–7.46 (d, <i>J</i> = 8.8 Hz, 2H), 7.05–7.01 (m, 4H), 3.18–3.08 (m, 4H), 2.57–2.49 (m, 2H), 2.41–2.34 (m, 1H), 2.24–2.21 (d, <i>J</i> = 14.4 Hz, 1H), 1.84–1.77 (m, 3H), 1.68–1.58 (m, 3H), 1.33 (s, 9H). MS <i>m</i>/<i>z</i> 487 [M + H]<sup>+</sup> calcd for C<sub>26</sub>H<sub>34</sub>N<sub>2</sub>O<sub>5</sub>S.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>tert</i>-Butyl 3-[4-[4-(Difluoromethoxy)phenoxy]phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>29e</b>)</h4><div class="NLM_p last">The compound <b>27</b> (50 mg, 0.093 mmol), 4-(difluoromethoxy)phenol (30 mg, 0.186 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (91 mg, 0.279 mmol) were dissolved in DMF (5 mL). The solution was stirred at 110 °C overnight. The mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by preparative TLC to give the compound <b>29e</b> (40 mg, 66%) as a pale-yellow solid. MS <i>m</i>/<i>z</i> 541 [M-139] calcd for C<sub>33</sub>H<sub>42</sub>F<sub>2</sub>N<sub>2</sub>O<sub>9</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 3-[4-[4-(Difluoromethoxy)phenoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>19c</b>)</h4><div class="NLM_p last">A solution of compound <b>29e</b> (40 mg, 0.059 mmol) in HCl/dioxane (2 N, 10 mL) was stirred at RT for 2 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19c</b> (19.9 mg, 68%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.82–7.80 (d, <i>J</i> = 8 Hz, 2H), 7.26–7.24 (d, <i>J</i> = 8 Hz, 2H), 7.18–7.16 (d, <i>J</i> = 8 Hz, 2H), 7.11–7.09 (d, <i>J</i> = 8 Hz, 2H), 7.01–6.66 (m, 1H), 3.25–3.05 (m, 4H), 2.60–2.50 (m, 2H), 2.45–2.35 (m, 1H), 2.30–2.25 (m, 1H), 1.90–1.72 (m, 3H), 1.72–1.55 (m, 3H). MS <i>m</i>/<i>z</i> 497 [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>26</sub>F<sub>2</sub>N<sub>2</sub>O<sub>6</sub>S.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>tert</i>-Butyl 3-[4-[4-[(Dimethylamino)methyl]phenoxy]phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>29f</b>)</h4><div class="NLM_p last">To a solution of compound <b>27</b> (200 mg, 0.37 mmol) in DMF (5 mL) was added 4-((dimethylamino)methyl)phenol (168 mg, 3 equiv) and Cs<sub>2</sub>CO<sub>3</sub> (361 mg, 3 equiv), then the reaction mixture was stirred at 100 °C for 90 min with microwave. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified to give pure compound <b>29f</b> (30 mg, 12%) as a pale-yellow oil. MS <i>m</i>/<i>z</i> 672 [M + H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>49</sub>N<sub>3</sub>O<sub>8</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 3-[4-[4-[(Dimethylamino)methyl]phenoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>19f</b>)</h4><div class="NLM_p last">A solution of compound <b>29f</b> (30 mg, 0.045 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19f</b> (3.5 mg, 16%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.74–7.72 (d, <i>J</i> = 8.0 Hz, 2H), 7.48–7.47 (d, <i>J</i> = 7.2 Hz, 1H), 7.37–7.34 (m, 1H), 7.25–7.20 (m, 1H), 7.02–7.00 (d, <i>J</i> = 9.2 Hz, 3H), 3.66 (s, 2H), 3.07–3.03 (m, 4H), 2.45–2.15 (m, 10H), 1.72–1.52 (m, 6H). MS <i>m</i>/<i>z</i> 488 [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>33</sub>N<sub>3</sub>O<sub>5</sub>S.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>tert</i>-Butyl 3-[4-[(6-Methoxy-3-pyridyl)oxy]phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>29g</b>)</h4><div class="NLM_p last">To a solution of compound <b>27</b> (200 mg, 0.37 mmol) in DMF (5 mL) was added 6-methoxypyridin-3-ol (93 mg, 2 equiv) and Cs<sub>2</sub>CO<sub>3</sub> (241 mg, 2 equiv), then the reaction mixture was stirred at 90 °C overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>29g</b> (215 mg, 90%) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.01–8.00 (d, <i>J</i> = 2.8 Hz, 1H), 7.84–7.82 (d, <i>J</i> = 8.8 Hz, 2H), 7.37–7.34 (m, 1H), 7.01–6.99 (d, <i>J</i> = 8.8 Hz, 2H), 6.83–6.81 (d, <i>J</i> = 8.8 Hz, 1H), 4.97 (s, 1H), 4.02–3.99 (d, 1H), 3.96 (s, 3H), 3.71–3.68 (d, 1H), 3.48–3.22 (m, 4H), 2.60–2.36 (m, 3H), 2.28–2.18 (m, 1H), 1.87–1.50 (m, 10H), 1.44 (s, 9H), 1.40 (s, 2H). MS <i>m</i>/<i>z</i> 646 [M + H]<sup>+</sup> calcd for C<sub>32</sub>H<sub>43</sub>N<sub>3</sub>O<sub>9</sub>S.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 3-[4-[(6-Methoxy-3-pyridyl)oxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>19g</b>)</h4><div class="NLM_p last">A solution of compound <b>29g</b> (215 mg, 0.33 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19g</b> (91.8 mg, 60%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.02–8.01 (d, <i>J</i> = 2.8 Hz, 1H), 7.84–7.82 (d, <i>J</i> = 8.8 Hz, 2H), 7.56–7.53 (m, 1H), 7.12–7.10 (d, <i>J</i> = 8.8 Hz, 2H), 6.93–6.90 (d, <i>J</i> = 9.2 Hz, 1H), 3.95 (s, 3H), 3.22–3.12 (m, 4H), 2.59–2.53 (m, 2H), 2.45–2.40 (m, 1H), 2.29–2.25 (d, <i>J</i> = 14.4 Hz, 1H), 1.88–1.81 (m, 3H), 1.73–1.62 (m, 3H). MS <i>m</i>/<i>z</i> 462 [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>27</sub>N<sub>3</sub>O<sub>6</sub>S.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>tert</i>-Butyl 3-[4-(3-Methoxyphenoxy)phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>29h</b>)</h4><div class="NLM_p last">To a solution of compound <b>27</b> (60 mg, 0.111 mmol) in DMF (3 mL) was added <i>m</i>-methoxyl phenol (42 mg, 3 equiv) and Cs<sub>2</sub>CO<sub>3</sub> (108 mg, 3 equiv), then the reaction mixture was stirred at 80 °C overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>29h</b> (60 mg, 83%) as a white solid. MS <i>m</i>/<i>z</i> 645 [M + H]<sup>+</sup> calcd for C<sub>33</sub>H<sub>44</sub>N<sub>2</sub>O<sub>9</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 3-[4-(3-Methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>19h</b>)</h4><div class="NLM_p last">A solution of compound <b>29h</b> (60 mg, 0.093 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19h</b> (36.8 mg, 86%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.83–7.81 (d, <i>J</i> = 8.4 Hz, 2H), 7.39–7.35 (t, 1H), 7.13–7.11 (d, <i>J</i> = 8.8 Hz, 2H), 6.87–6.85 (d, <i>J</i> = 8.4 Hz, 1H), 7.83–7.81 (d, <i>J</i> = 6.4 Hz, 2H), 3.82 (s, 3H), 3.20–3.14 (m, 4H), 2.59–2.26 (m, 4H), 1.86–1.73 (m, 3H), 1.71–1.64 (m, 3H). MS <i>m</i>/<i>z</i> 460 [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>28</sub>N<sub>2</sub>O<sub>6</sub>S.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>tert</i>-Butyl 3-[4-(2-Methoxyphenoxy)phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>29i</b>)</h4><div class="NLM_p last">To a solution of compound <b>27</b> (60 mg, 0.111 mmol) in DMF (3 mL) was added <i>o</i>-methoxylphenol (42 mg, 3 equiv) and Cs<sub>2</sub>CO<sub>3</sub> (108 mg, 3 equiv), then the reaction mixture was stirred at 80 °C overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>29i</b> (58 mg, 81%) as a white solid. MS <i>m</i>/<i>z</i> 645 [M + H]<sup>+</sup> calcd for C<sub>33</sub>H<sub>44</sub>N<sub>2</sub>O<sub>9</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 3-[4-(2-Methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>19i</b>)</h4><div class="NLM_p last">A solution of compound <b>29i</b> (58 mg, 0.090 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19i</b> (33.1 mg, 81%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.89–7.76 (d, <i>J</i> = 8.4 Hz, 2H), 7.33–7.31 (t, 1H), 7.20–7.18 (d, <i>J</i> = 8.4 Hz, 1H), 7.14–7.13 (d, <i>J</i> = 7.2 Hz, 1H), 7.06–7.04 (t, 1H), 6.99–6.97 (d, <i>J</i> = 8.4 Hz, 2H), 3.78 (s, 3H), 3.23–3.13 (m, 4H), 2.59–2.24 (m, 4H), 1.82–1.79 (m, 3H), 1.70–1.64 (m, 3H). MS <i>m</i>/<i>z</i> 460 [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>28</sub>N<sub>2</sub>O<sub>6</sub>S.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>tert</i>-Butyl 3-(Tetrahydropyran-2-yloxycarbamoyl)-3-[4-[[4-(trifluoromethoxy)phenyl]methoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-8-carboxylate (<b>30a</b>)</h4><div class="NLM_p last">To a solution of (4-(trifluoromethoxy)phenyl)methanol (107 mg, 5 equiv) in THF (5 mL) was added NaH (14 mg, 5 equiv), and the mixture was stirred at RT for 0.5 h. Then, compound <b>27</b> (60 mg, 0.111 mmol) was added and the reaction mixture was stirred at 80 °C overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>30a</b> (20 mg, 89%) as a pale-yellow oil. MS <i>m</i>/<i>z</i> 713 [M + H]<sup>+</sup> calcd for C<sub>34</sub>H<sub>43</sub>F<sub>3</sub>N<sub>2</sub>O<sub>9</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 3-[4-[[4-(Trifluoromethoxy)phenyl]methoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>17</b>)</h4><div class="NLM_p last">A solution of compound <b>30a</b> (70 mg, 0.098 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>17</b> (48.4 mg, 93%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.78–7.76 (d, <i>J</i> = 8.0 Hz, 2H), 7.55–7.53 (d, <i>J</i> = 8.4 Hz, 2H), 7.29–7.27 (d, <i>J</i> = 8.0 Hz, 2H), 7.17–7.15 (d, <i>J</i> = 8.0 Hz, 2H), 5.19 (s, 2H), 3.14–3.09 (m, 4H), 2.54–2.20 (m, 4H), 1.78–1.73 (m, 3H), 1.65–1.59 (m, 3H). MS <i>m</i>/<i>z</i> 529 [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>27</sub>F<sub>3</sub>N<sub>2</sub>O<sub>6</sub>S.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>tert</i>-Butyl 3-(4-Benzyloxyphenyl)sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>30b</b>)</h4><div class="NLM_p last">To a solution of phenylmethanol (80 mg, 5 equiv) in THF (5 mL) was added NaH (18 mg, 5 equiv), and the mixture was stirred at RT for 0.5 h. Then, compound <b>27</b> (80 mg, 0.148 mmol) was added and the reaction mixture was stirred at 80 °C overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>30b</b> (72 mg, 77%) as a pale-yellow oil. MS <i>m</i>/<i>z</i> 629 [M + H]<sup>+</sup> calcd for C<sub>33</sub>H<sub>44</sub>N<sub>2</sub>O<sub>8</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 3-(4-Benzyloxyphenyl)sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>19m</b>)</h4><div class="NLM_p last">A solution of compound <b>30b</b> (36 mg, 0.057 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19m</b> (24.1 mg, 94%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.81–7.78 (d, <i>J</i> = 8.8 Hz, 2H), 7.48–7.34 (m, 5H), 7.21–7.19 (d, <i>J</i> = 8.8 Hz, 2H), 5.22 (s, 2H), 3.19–3.13 (m, 4H), 2.58–2.23 (m, 4H), 1.83–1.62 (m, 6H). MS <i>m</i>/<i>z</i> 445 [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub>S.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>tert</i>-Butyl 3-[4-[2-(2-Oxopyrrolidin-1-yl)ethoxy]phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>31</b>)</h4><div class="NLM_p last">To a solution of 1-(2-hydroxyethyl)pyrrolidin-2-one (191 mg, 4 equiv) in DMF (5 mL) was added NaH (36 mg, 4 equiv), and the mixture was stirred at RT for 0.5 h. Then, compound <b>27</b> (200 mg, 0.37 mmol) was added and then the reaction mixture was stirred at 90 °C overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE = 2:1) to give pure compound <b>31</b> (119 mg, 50%) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.7 (m, 1H), 7.82 (m, 2H), 6.97 (m, 2H), 4.97 (s, 1H), 4.17–4.09 (m, 3H), 4.03–3.98 (m, 1H), 3.70 (s, 3H) 3.58–3.55 (m, 2H), 3.44–3.27 (m, 4H), 2.96–2.88 (d, 1H), 2,57–2.34 (m, 5H), 1.84–1.56 (m, 11H), 1.43 (s, 9H), 1.39 (m, 2H). MS <i>m</i>/<i>z</i> 650 [M + H]<sup>+</sup> calcd for C<sub>32</sub>H<sub>47</sub>N<sub>3</sub>O<sub>9</sub>S.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 3-[4-[2-(2-Oxopyrrolidin-1-yl)ethoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>19o</b>)</h4><div class="NLM_p last">A solution of compound <b>31</b> (119 mg, 0.183 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by prep-HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19o</b> (40.70 mg, 48%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.76–7.74 (d, <i>J</i> = 8 Hz, 2H), 7.10–7.08 (d, <i>J</i> = 8 Hz, 2H), 4.24–4.21 (m, 2H), 3.70–3.59 (m, 2H), 3.58–3.30 (m, 2H), 3.29–3.09 (m, 4H), 2.53–2.48 (m, 2H), 2.40–2.34 (m, 3H), 2.23–2.20 (d, <i>J</i> = 12 Hz, 1H), 2.06–2.01 (m, 2H), 1.82–1.75 (m, 3H), 1.67–1.57 (m, 3H). MS <i>m</i>/<i>z</i> 466 [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>31</sub>N<sub>3</sub>O<sub>6</sub>S.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>tert</i>-Butyl 3-[4-(4-Methoxycarbonylphenoxy)phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>32a</b>)</h4><div class="NLM_p last">To a solution of compound <b>27</b> (300 mg, 0.56 mmol) in DMF (5 mL) was added methyl 4-hydroxybenzoate (170 mg, 2 equiv) and Cs<sub>2</sub>CO<sub>3</sub> (362 mg, 2 equiv), then the reaction mixture was stirred at 90 °C overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE = 2:1) to give pure compound <b>32a</b> (221 mg, 59%) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.60 (d, 1H), 8.08–8.06 (d, <i>J</i> = 8.8 Hz, 2H), 7.86–7.84 (m, 2H), 7.10–7.05 (m, 4H), 4.94 (s, 1H), 3.99–3.93 (m, 1H), 3.90 (s, 3H), 3.67–3.64 (m, 1H), 3.46–3.21 (m, 4H), 2.56–2.16 (m, 4H), 1.84–1.46 (m, 10H), 1.41 (s, 9H), 1.39–1.38 (m, 2H). MS <i>m</i>/<i>z</i> 673 [M + H]<sup>+</sup> calcd for C<sub>34</sub>H<sub>44</sub>N<sub>2</sub>O<sub>10</sub>S.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4-[4-[[8-<i>tert</i>-Butoxycarbonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]benzoic Acid (<b>33a</b>)</h4><div class="NLM_p last">To a solution of compound <b>32a</b> (140 mg, 0.208 mmol) in THF/H<sub>2</sub>O (3:1, 12 mL) was added LiOH·H<sub>2</sub>O (85 mg, 10 equiv), then the reaction mixture was stirred at RT for 4 h. After TLC (PE/AE 2:1) showed the starting material was consumed, then the mixture was diluted with water and adjusted pH to 2–3 with 1 N HCl and the mixture was extracted with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product <b>33a</b> as a pale-yellow oil which was used for the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.70 (d, 1H), 8.08–8.06 (d, <i>J</i> = 8.8 Hz, 2H), 7.86–7.84 (m, 2H), 7.10–7.05 (m, 4H), 4.94 (s, 1H), 3.99–3.93 (m, 1H), 3.67–3.64 (m, 1H), 3.46–3.21 (m, 4H), 2.56–2.16 (m, 4H), 1.84–1.46 (m, 10H), 1.41 (s, 9H), 1.39–1.38 (d, 2H). MS <i>m</i>/<i>z</i> 659 [M + H]<sup>+</sup> calcd for C<sub>33</sub>H<sub>42</sub>N<sub>2</sub>O<sub>10</sub>S.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>tert</i>-Butyl 3-[4-[4-(Methylcarbamoyl)phenoxy]phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>34a</b>)</h4><div class="NLM_p last">To a solution of compound <b>33a</b> (140 mg, 0.213 mmol) in DMF (5 mL) was added EDC·HCl (82 mg, 2 equiv), HOBt (57 mg, 2 equiv), CH<sub>3</sub>NH·HCl (66 mg, 2 equiv), and NMM (65 mg, 3 equiv) at RT, then the mixture was stirred at RT overnight. The mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product <b>34a</b> (80 mg, 56%) as a pale-yellow oil which was used the next step without further purification. MS <i>m</i>/<i>z</i> 672 [M + H]<sup>+</sup> calcd for C<sub>34</sub>H<sub>45</sub>N<sub>3</sub>O<sub>9</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 4-[4-[[3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-<i>N</i>-methyl-benzamide (<b>19d</b>)</h4><div class="NLM_p last">A solution of compound <b>34a</b> (80 mg, 0.119 mmol) in HCl/dioxane (2 N, 3 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19d</b> (28.3 mg, 49%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.90–7.87 (d, <i>J</i> = 8.8 Hz, 2H), 7.83–7.81 (d, <i>J</i> = 8.8 Hz, 2H), 7.17–7.13 (m, 4H), 3.18–3.09 (m, 4H), 2.91 (s, 3H), 2.58–2.50 (m, 2H), 2.42–2.35 (m, 1H), 2.27–2.23 (d, <i>J</i> = 14.4 Hz, 1H), 1.85–1.78 (m, 3H), 1.69–1.59 (m, 3H). MS <i>m</i>/<i>z</i> 488 [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>29</sub>N<sub>3</sub>O<sub>6</sub>S.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>tert</i>-Butyl 3-[4-[4-(Pyrrolidine-1-carbonyl)phenoxy]phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>34b</b>)</h4><div class="NLM_p last">To a solution of compound <b>33a</b> (60 mg, 0.091 mmol) in DMF (5 mL) was added EDC·HCl (35 mg, 2 equiv), HOBt (24 mg, 2 equiv), pyrrolidine (13 mg, 2 equiv), and NMM (28 mg, 3 equiv) at RT, then the mixture was stirred at RT overnight. After TLC (PE/AE 1:1) showed the starting material was consumed, then the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by preparative TLC (AE) to give pure compound <b>34b</b> (58 mg, 89%) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.93–7.90 (m, 2H), 7.67–7.65 (d, <i>J</i> = 8.4 Hz, 2H), 7.22–7.16 (m, 4H), 4.99 (s, 1H), 4.15–4.12 (m, 1H), 3.64–3.52 (m, 6H), 3.33 (s, 3H), 2.57–2.48 (m, 3H), 2.26–2.22 (d, 1H), 2.02–1.95 (m, 4H), 1.80–1.58 (m, 10H), 1.46 (s, 9H), 1.37 (s, 2H). MS <i>m</i>/<i>z</i> 712 [M + H]<sup>+</sup> calcd for C<sub>37</sub>H<sub>49</sub>N<sub>3</sub>O<sub>9</sub>S.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 3-[4-[4-(Pyrrolidine-1-carbonyl)phenoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>19e</b>)</h4><div class="NLM_p last">A solution of compound <b>34b</b> (58 mg, 0.082 mmol) in HCl/dioxane (2 N, 3 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19e</b> (31.7 mg, 74%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.87–7.85 (d, <i>J</i> = 8.4 Hz, 2H), 7.67–7.65 (d, <i>J</i> = 8.8 Hz, 2H), 7.22–7.18 (m, 4H), 3.64–3.61 (m, 2H), 3.55–3.52 (m, 2H), 3.21–3.14 (m, 4H), 2.58–2.54 (m, 2H), 2.31–2.27 (m, 1H), 2.03–2.01 (d, 1H), 1.96–1.95 (m, 4H), 1.85–1.84 (m, 3H), 1.66–1.63 (m, 3H). MS <i>m</i>/<i>z</i> 528 [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>33</sub>N<sub>3</sub>O<sub>6</sub>S.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>tert</i>-Butyl 3-[4-(3-Methoxycarbonylphenoxy)phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>32b</b>)</h4><div class="NLM_p last">To a solution of compound <b>27</b> (200 mg, 0.37 mmol) in DMF (3 mL) was added methyl 3-hydroxybenzoate (169 mg, 3 equiv) and Cs<sub>2</sub>CO<sub>3</sub> (361 mg, 3 equiv), then the reaction mixture was stirred at 80 °C overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>32b</b> (125 mg, 50%) as a white solid. MS <i>m</i>/<i>z</i> 673 [M + H]<sup>+</sup>calcd for C<sub>34</sub>H<sub>44</sub>N<sub>2</sub>O<sub>10</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 3-[4-[[8-<i>tert</i>-Butoxycarbonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]benzoic Acid (<b>33b</b>)</h4><div class="NLM_p last">To a solution of compound <b>32b</b> (102 mg, 0.152 mmol) in THF/H<sub>2</sub>O (3:2, 8 mL) was added LiOH·H<sub>2</sub>O (64 mg, 10 equiv). The resulting mixture was stirred at RT for 4 h, after LC-MS showed the staring materials were consumed completely, then the mixture was diluted with water and adjusted pH to 2–3 with 1 N HCl and the mixture was extracted with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product <b>33b</b> (100 mg, 100%) which was used in the next step. MS <i>m</i>/<i>z</i> 659 [M + H]<sup>+</sup> calcd for C<sub>33</sub>H<sub>42</sub>N<sub>2</sub>O<sub>10</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> <i>tert</i>-Butyl 3-[4-[3-(Methylcarbamoyl)phenoxy]phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>34c</b>)</h4><div class="NLM_p last">To a solution of compound <b>33b</b> (40 mg, 0.061 mmol) in ACN (5 mL) was added Et<sub>3</sub>N (12 mg, 2 equiv) and CH<sub>3</sub>NH·HCl (7.3 mg, 2 equiv) at RT, then HATU (23 mg, 1.1 equiv) was added, the mixture was stirred at RT overnight. The mixture was extracted with EtOAc, and the organic layer was washed with brine, 2 N HCl, H<sub>2</sub>O, NaHCO<sub>3</sub> (aq), and H<sub>2</sub>O, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by preparative TLC (AE) to obtain pure product <b>34c</b> (35 mg, 85%) as a pale-yellow oil. MS <i>m</i>/<i>z</i> 672 [M + H]<sup>+</sup>: calcd for C<sub>34</sub>H<sub>45</sub>N<sub>3</sub>O<sub>9</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 3-[4-[[3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-<i>N</i>-methyl-benzamide (<b>19j</b>)</h4><div class="NLM_p last">A solution of compound <b>34c</b> (35 mg, 0.052 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19j</b> (10.0 mg, 39%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.82–7.80 (d, <i>J</i> = 8.8 Hz, 2H), 6.70–6.68 (d, <i>J</i> = 7.6 Hz, 1H), 7.55–7.51 (m, 2H), 7.29–7.27 (m, 1H), 7.11–7.10 (d, <i>J</i> = 8.8 Hz, 2H), 3.15–3.11 (m, 4H), 2.89 (s, 3H), 2.55–2.22 (m, 4H), 1.82–1.79 (m, 3H), 1.67–1.60 (m, 3H). MS <i>m</i>/<i>z</i> 488 [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>29</sub>N<sub>3</sub>O<sub>6</sub>S.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>tert</i>-Butyl 3-[4-(3-Methoxy-4-methoxycarbonyl-phenoxy)phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>32c</b>)</h4><div class="NLM_p last">To a suspension of methyl 4-hydroxy-2-methoxy-benzoate (95 mg, 0.52 mmol) and compound <b>27</b> (120 mg, 0.26 mmol) in DMA (4 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (255 mg, 0.78 mmol). The sealed vial was irradiated in the microwave on a Biotage Smith Synthesis at 120 °C for 2 h. The resulting mixture was cooled to RT quenched by adding water. The organic layer was separated, and the aqueous layer was extracted three times with EA. The combined organic layers were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to afford the desired crude product which was purified by column chromatography to give the compound <b>32c</b> (80 mg, 44%). MS <i>m</i>/<i>z</i> 563 [M-139] calcd for C<sub>35</sub>H<sub>46</sub>N<sub>2</sub>O<sub>11</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 4-[4-[[8-<i>tert</i>-Butoxycarbonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-2-methoxy-benzoic Acid (<b>33c</b>)</h4><div class="NLM_p last">To a solution of compound <b>32c</b> (80 mg, 0.11 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 16 mL) was added LiOH·H<sub>2</sub>O (47 mg, 10 equiv). The resulting mixture was stirred at RT for 4 h, after TLC (PE/EA 5:1) showed the staring materials were consumed completely, then the mixture was diluted with water and adjusted pH to 3–4 with 1 N HCl and the mixture was extracted with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product <b>33c</b> (65 mg, 86%) as a pale-yellow oil which was used directly in the next step. MS <i>m</i>/<i>z</i> 505 [M-183] calcd for C<sub>34</sub>H<sub>44</sub>N<sub>2</sub>O<sub>11</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>tert</i>-Butyl 3-[4-[3-Methoxy-4-(methylcarbamoyl)phenoxy]phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>34d</b>)</h4><div class="NLM_p last">To a solution of compound <b>33c</b> (65 mg, 0.09 mmol) in DMF (10 mL) was added EDC·HCl (47 mg, 0.24 mmol), HOBt (32 mg, 0.24 mmol), CH<sub>3</sub>NH<sub>2</sub> HCl (20 mg, 0.24 mmol), and NMM (41 mg, 0.4 mmol), then the mixture was stirred at RT overnight. The mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by preparative TLC to give the compound <b>34d</b> (40 mg, 63%) as a pale-yellow solid. MS <i>m</i>/<i>z</i> 646 [M-55] calcd for C<sub>35</sub>H<sub>47</sub>N<sub>3</sub>O<sub>10</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 4-[4-[[3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-2-methoxy-<i>N</i>-methyl-benzamide (<b>19l</b>)</h4><div class="NLM_p last">A solution of compound <b>34d</b> (40 mg, 0.057 mmol) in HCl/dioxane (10 mL, 2 N) was stirred at RT for 2 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to afford <b>19l</b> (18.2 mg, 62%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.00 (d, <i>J</i> = 8.4 Hz, 1H), 7.86–7.84 (m, 2H), 7.20–7.16 (m, 2H), 6.91 (d, <i>J</i> = 2.0 Hz, 1H), 6.77–6.74 (m, 1H), 3.95 (s, 3H), 3.19–3.12 (m, 4H), 2.95 (s, 3H), 2.57–2.26 (m, 4H), 1.86–1.81 (m, 3H), 1.64–1.61 (m, 3H). MS <i>m</i>/<i>z</i> 518 [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>31</sub>N<sub>3</sub>O<sub>7</sub>S.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> O8-<i>tert</i>-Butyl O3-Methyl 3-(3-Bromophenyl)sulfonyl-8-azaspiro[4.5]decane-3,8-dicarboxylate (<b>35a</b>)</h4><div class="NLM_p last">To a solution of compound <b>24</b> (600 mg, 2.0 mmol) in THF (40 mL) was added LDA (8 mL, 1.25 M, 10 mmol) at −78 °C. After stirring at −78 °C for 1 h, the compound 3-bromobenzenesulfonyl fluoride (1.2 g, 5.0 mmol) was added to the solution and the reaction was stirred at −78 °C for 1 h. Then the mixture was stirred at RT overnight. After TLC (PE/AE 5:1) showed the starting material was consumed, the mixture was quenched with aqueous NH<sub>4</sub>Cl and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by column chromatography to give pure compound <b>35a</b> (680 mg, 67%) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.96 (s, 1H), 7.84–7.80 (m, 1H), 7.77–7.75 (m, 1H), 7.51–7.42 (m, 1H), 3.70 (s, 3H), 3.42–3.32 (m, 4H), 2.53–2.32 (m, 4H), 1.62–1.57 (m, 4H), 1.45 (s, 9H), 1.35–1.29 (m, 2H). MS <i>m</i>/<i>z</i> 460 [M-55] calcd for C<sub>22</sub>H<sub>30</sub>BrNO<sub>6</sub>S.</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> O8-<i>tert</i>-Butyl O3-Methyl 3-[3-(4-methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3,8-dicarboxylate (<b>36a</b>)</h4><div class="NLM_p last">To a suspension of compound <b>35a</b> (288 mg, 0.56 mmol) and 4-methoxyphenol (150 mg, 1.2 mmol) in dioxane (15 mL) was added CuI (57.3 mg, 0.30 mmol), <i>N</i>,<i>N</i>′-dimethylglycine (84 mg, 0.60 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (980 mg, 3.0 mmol). The mixture was stirred at reflux under N<sub>2</sub> overnight. The resulting mixture was cooled to RT, and water was added. The organic layer was separated, and the aqueous layer was extracted three times with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure and purified by column chromatography to afford the desired product <b>36a</b> (130 mg, 42%). MS <i>m</i>/<i>z</i> 504 [M-55] calcd for C<sub>29</sub>H<sub>37</sub>NO<sub>8</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 8-<i>tert</i>-Butoxycarbonyl-3-[3-(4-methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carboxylic Acid (<b>37a</b>)</h4><div class="NLM_p last">To a solution of compound <b>36a</b> (210 mg, 0.38 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 8 mL) was added LiOH·H<sub>2</sub>O (163 mg, 10 equiv). The resulting mixture was stirred at RT for 4 h, after TLC (PE/AE 5:1) showed the staring materials were consumed completely, then the mixture was diluted with water and adjusted pH to 3–4 with 1 N HCl and the mixture was extracted with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product <b>37a</b> (160 mg, 77%) as a pale-yellow oil which was used directly in the next step. MS <i>m</i>/<i>z</i> 490 [M-55] calcd for C<sub>28</sub>H<sub>35</sub>NO<sub>8</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> <i>tert</i>-Butyl 3-[3-(4-Methoxyphenoxy)phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>38a</b>)</h4><div class="NLM_p last">To a solution of compound <b>37a</b> (160 mg, 0.29 mmol) in DMF (15 mL) was added EDC·HCl (115.2 mg, 0.6 mmol), HOBt (80 mg, 0.6 mmol), THPONH<sub>2</sub> (70.2 mg, 0.6 mmol), and NMM (101 mg, 1.0 mmol), then the mixture was stirred at RT overnight. The mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by preparative TLC to give the compound <b>38a</b> (154 mg, 82%) as a pale-yellow solid. MS <i>m</i>/<i>z</i> 505 [M-139] calcd for C<sub>33</sub>H<sub>44</sub>N<sub>2</sub>O<sub>9</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 3-[3-(4-Methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>14</b>)</h4><div class="NLM_p last">A solution of compound <b>38a</b> (154 mg, 0.24 mmol) in HCl/dioxane (10 mL, 1 N) was stirred at RT for 2 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>14</b> (65 mg, 59%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.54–7.52 (m, 2H), 7.33 (s, 1H), 7.32–7.28 (m, 1H), 7.06–7.03 (m, 2H), 6.99–6.97 (m, 2H), 3.86 (s, 3H), 3.17–3.12 (m, 4H), 2.55–2.52 (m, 2H), 2.42–2.20 (m, 2H), 1.83–1.79 (m, 3H), 1.68–1.61 (m, 3H). MS <i>m</i>/<i>z</i> 461 [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>28</sub>N<sub>2</sub>O<sub>6</sub>S.</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> O8-<i>tert</i>-Butyl O3-Methyl 3-(2-Fluorophenyl)sulfonyl-8-azaspiro[4.5]decane-3,8-dicarboxylate (<b>35b</b>)</h4><div class="NLM_p last">To a solution of compound <b>24</b> (342 mg, 1.15 mmol) in THF (15 mL) was added LDA (1.4 mL, 1.2 M, 1.62 mmol) at −78 °C. After stirring at −78 °C for 1 h, the compound 2-fluorobenzenesulfonyl fluoride (289 mg, 1.62 mmol) was added to the solution, the reaction was stirred at −78 °C for 1 h, and then the mixture was stirred at RT overnight. After TLC (PE/AE 5:1) showed the starting material was consumed, the mixture was quenched with aqueous NH<sub>4</sub>Cl and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by column chromatography to give pure compound <b>35b</b> (135 mg, 26%) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.85–7.81 (m, 1H), 7.68–7.67 (m, 1H), 7.35–7.31 (m, 1H), 7.25–7.21 (m, 1H), 3.68 (s, 3H), 3.37–3.29 (m, 4H), 2.58–2.40 (m, 4H), 1.86–1.53 (m, 4H), 1.45 (s, 9H), 1.36–1.33 (m, 2H). MS <i>m</i>/<i>z</i> 400 [M-55] calcd for C<sub>22</sub>H<sub>30</sub>FNO<sub>6</sub>S.</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> O8-<i>tert</i>-Butyl O3-Methyl 3-[2-(4-Methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3,8-dicarboxylate (<b>36b</b>)</h4><div class="NLM_p last">To a suspension of compound <b>35b</b> (120 mg, 0.26 mmol) and 4-methoxyphenol (65 mg, 0.52 mmol) in DMF (4 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (200 mg, 0.6 mmol). The mixture was stirred at 100 °C under N<sub>2</sub> overnight. The resulting mixture was cooled to RT, and water was added. The organic layer was separated, and the aqueous layer was extracted three times with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure and purified by preparative TLC to afford the desired product <b>36b</b> (110 mg, 75%). MS <i>m</i>/<i>z</i> 504 [M-55] calcd for C<sub>29</sub>H<sub>37</sub>NO<sub>8</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 8-<i>tert</i>-Butoxycarbonyl-3-[2-(4-methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carboxylic Acid (<b>37b</b>)</h4><div class="NLM_p last">To a solution of compound <b>36b</b> (110 mg, 0.2 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 8 mL) was added LiOH·H<sub>2</sub>O (86 mg, 10 equiv). The resulting mixture was stirred at RT for 4 h, after TLC (PE/AE 5:1) showed the staring materials were consumed completely, then the mixture was diluted with water and adjusted pH to 3–4 with 1 N HCl, and the mixture was extracted with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product <b>37b</b> (110 mg, ∼100%) as a pale-yellow oil which was used directly in the next step. MS <i>m</i>/<i>z</i> 490 [M-55] calcd for C<sub>28</sub>H<sub>35</sub>NO<sub>8</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> <i>tert</i>-Butyl 3-[2-(4-Methoxyphenoxy)phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>38b</b>)</h4><div class="NLM_p last">To a solution of compound <b>37b</b> (110 mg, 0.2 mmol) in DMF (10 mL) was added EDC·HCl (77 mg, 0.4 mmol), HOBt (540 mg, 0.4 mmol), THPONH<sub>2</sub> (47 mg, 0.4 mmol), and NMM (61 mg, 0.6 mmol), then the mixture was stirred at RT overnight. The mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product <b>38b</b> (150 mg, ∼100%) as a pale-yellow oil which was used directly in the next step. MS <i>m</i>/<i>z</i> 505 [M-139] calcd for C<sub>33</sub>H<sub>44</sub>N<sub>2</sub>O<sub>9</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 3-[2-(4-Methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>15</b>)</h4><div class="NLM_p last">A solution of compound <b>38b</b> (150 mg, 0.2 mmol) in HCl/dioxane (10 mL, 2 N) was stirred at RT for 2 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>14</b> (27.6 mg, 30%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.92–7.90 (m, 1H), 7.58–7.56 (m, 1H), 7.20–7.12 (m, 3H), 7.00–6.98 (m, 2H), 6.85–6.83 (m, 1H), 3.81 (s, 3H), 3.16–3.04 (m, 4H), 2.73–2.67 (m, 2H), 2.53–2.49 (m, 2H), 1.85–1.79 (m, 3H), 1.66–1.63 (m, 3H). MS <i>m</i>/<i>z</i> 461 [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>28</sub>N<sub>2</sub>O<sub>6</sub>S.</div></div><div id="sec4_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> O8-<i>tert</i>-Butyl O3-Methyl 3-(3-Chloro-4-fluoro-phenyl)sulfonyl-8-azaspiro[4.5]decane-3,8-dicarboxylate (<b>35c</b>)</h4><div class="NLM_p last">To a solution of compound <b>24</b> (0.8 g, 2.7 mmol) in THF (20 mL) was added LDA (3.5 mL, 1.1 M, 3.8 mmol) at −78 °C. After stirring at −78 °C for 1 h, the compound 3-chloro-4-fluoro-benzenesulfonyl fluoride (790 mg, 3.7 mmol) was added to the solution, the reaction was stirred at −78 °C for 1 h, and then the mixture was stirred at RT overnight. After TLC (PE/EA = 5:1) showed the starting material was consumed, the mixture was quenched with aqueous NH<sub>4</sub>Cl and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by column chromatography to give pure compound <b>35c</b> (620 mg, 46%) as a pale-yellow oil. MS <i>m</i>/<i>z</i> 434 [M-55]: 434 calcd for C<sub>22</sub>H<sub>29</sub>ClFNO<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> O8-<i>tert</i>-Butyl O3-Methyl 3-[3-Chloro-4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3,8-dicarboxylate (<b>36c</b>)</h4><div class="NLM_p last">To a suspension of compound <b>35c</b> (100 mg, 0.2 mmol) and 4-(trifluoromethoxy)phenol (72 mg, 0.2 mmol) in DMF (4 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (196 mg, 0.6 mmol). The mixture was stirred at 80 °C under N<sub>2</sub> overnight. The resulting mixture was cooled to RT, and water was added. The organic layer was separated, and the aqueous layer was extracted three times with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to afford the desired crude product which was purified by preparative TLC to give the compound <b>36c</b> (68 mg, 55%). MS <i>m</i>/<i>z</i> 592 [M-55] calcd for C<sub>29</sub>H<sub>33</sub>ClF<sub>3</sub>NO<sub>8</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 8-<i>tert</i>-Butoxycarbonyl-3-[3-chloro-4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carboxylic Acid (<b>37c</b>)</h4><div class="NLM_p last">To a solution of compound <b>36c</b> (68 mg, 0.11 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 16 mL) was added LiOH·H<sub>2</sub>O (50 mg, 10 equiv). The resulting mixture was stirred at RT for 4 h, after TLC (PE/EA 5:1) showed the staring material was consumed completely, then the mixture was diluted with water and adjusted pH to 3–4 with 1 N HCl and the mixture was extracted with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product <b>37c</b> (80 mg, ∼100%) as a pale-yellow oil which was used directly in the next step. MS <i>m</i>/<i>z</i> 578 [M-55] calcd for C<sub>28</sub>H<sub>31</sub>ClF<sub>3</sub>NO<sub>8</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> <i>tert</i>-Butyl 3-[3-Chloro-4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>38c</b>)</h4><div class="NLM_p last">To a solution of compound <b>37c</b> (8 mg, 0.11 mmol) in DMF (30 mL) was added EDC·HCl (0.38 g, 0.2 mmol), HOBt (27 g, 0.2 mmol), THPONH<sub>2</sub> (31 g, 0.2 mmol), and NMM (41 mg, 0.4 mmol), then the mixture was stirred at RT overnight. The mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by column to give the compound <b>38c</b> (70 mg, 85%) as a pale-yellow solid. MS <i>m</i>/<i>z</i> 593 [M-139] calcd for C<sub>33</sub>H<sub>40</sub>ClF<sub>3</sub>N<sub>2</sub>O<sub>9</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 3-[3-Chloro-4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>19p</b>)</h4><div class="NLM_p last">A solution of compound <b>38c</b> (70 mg, 0.095 mmol) in HCl/dioxane (10 mL, 1 N) was stirred at RT for 3 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain <b>19p</b> (23.2 mg, 45%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.98 (d, <i>J</i> = 2 Hz, 1H), 7.75–7.72 (m, 1H), 7.40–7.37 (m, 2H), 7.23–7.19 (m, 2H), 7.09–7.07 (m, 1H), 3.21–3.14 (m, 4H), 2.57–2.26 (m, 4H), 1.87–1.83 (m, 3H), 1.71–1.62 (m, 3H). MS <i>m</i>/<i>z</i> 549 [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>24</sub>ClF<sub>3</sub>N<sub>2</sub>O<sub>6</sub>S.</div></div><div id="sec4_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> <i>tert</i>-Butyl 3-(4-Benzyloxyphenyl)sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>39</b>)</h4><div class="NLM_p last">To a solution of phenylmethanol (450 mg, 5 equiv) in THF (5 mL) was added NaH (100 mg, 5 equiv), and the mixture was stirred at RT for 0.5 h. Then, compound <b>27</b> (450 mg, 0.833 mmol) was added and the reaction mixture was stirred at 80 °C overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>39</b> (460 mg, 88%) as a white solid. MS <i>m</i>/<i>z</i> 629 [M + H]<sup>+</sup> calcd for C<sub>33</sub>H<sub>44</sub>N<sub>2</sub>O<sub>8</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> <i>tert</i>-Butyl 3-(4-Hydroxyphenyl)sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>40</b>)</h4><div class="NLM_p last">To a solution of compound <b>39</b> (460 mg, 0.732 mmol) in MeOH (20 mL) was added Pd/C (0.5 g) at RT at H<sub>2</sub> atmosphere, then the mixture was stirred at RT for 1 h until TLC (PE/AE 2:1) showed the starting material was consumed, then filtered, and the filtrate was concentrated to give the crude compound <b>40</b> (320 mg, 81%) which was used for the next step without further purification. MS <i>m</i>/<i>z</i> 539 [M + H]<sup>+</sup> calcd for C<sub>26</sub>H<sub>38</sub>N<sub>2</sub>O<sub>8</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>tert</i>-Butyl 3-[4-(2-Ethoxycarbonylphenoxy)phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>41a</b>)</h4><div class="NLM_p last">To a solution of compound <b>40</b> (80 mg, 0.148 mmol) in DMF (3 mL) was added ethyl 2-fluorobenzoate (76 mg, 3 equiv) and Cs<sub>2</sub>CO<sub>3</sub> (144 mg, 3 equiv), then the reaction mixture was stirred at 80 °C overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>41a</b> (68 mg, 67%) as a white solid. MS <i>m</i>/<i>z</i> 687 [M + H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>46</sub>N<sub>2</sub>O<sub>10</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 2-[4-[[8-<i>tert</i>-Butoxycarbonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]benzoic Acid (<b>42a</b>)</h4><div class="NLM_p last">To a solution of compound <b>41a</b> (79 mg, 0.115 mmol) in THF/H<sub>2</sub>O (3:1, 12 mL) was added LiOH·H<sub>2</sub>O (50 mg, 10 equiv). The resulting mixture was stirred at RT overnight, after LC-MS showed the staring materials were consumed completely, then the mixture was diluted with water and adjusted pH to 2–3 with 1 N HCl and the mixture was extracted with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product <b>42a</b> (76 mg, 100%) which was used in the next step. MS <i>m</i>/<i>z</i> 659 [M + H]<sup>+</sup> calcd for C<sub>33</sub>H<sub>42</sub>N<sub>2</sub>O<sub>10</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> <i>tert</i>-Butyl 3-[4-[2-(Methylcarbamoyl)phenoxy]phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>43a</b>)</h4><div class="NLM_p last">To a solution of compound <b>42a</b> (76 mg, 0.116 mmol) in DMF (5 mL) was added EDC·HCl (45 mg, 2 equiv), HOBt (31 mg, 2 equiv), CH<sub>3</sub>NH·HCl (15.54 mg, 2 equiv), and NMM (35 mg, 3 equiv) at RT, then the mixture was stirred at RT overnight. The mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by preparative TLC (AE) to obtain pure product <b>43a</b> (20 mg, 26%) as a pale-yellow oil. MS <i>m</i>/<i>z</i> 672 [M + H]<sup>+</sup> calcd for C<sub>34</sub>H<sub>45</sub>N<sub>3</sub>O<sub>9</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 2-[4-[[3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-<i>N</i>-methyl-benzamide (<b>19k</b>)</h4><div class="NLM_p last">A solution of compound <b>43a</b> (20 mg, 0.030 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19k</b> (8.4 mg, 56%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.82–7.79 (d, <i>J</i> = 8.8 Hz, 2H), 7.73–7.71 (d, <i>J</i> = 7.6 Hz, 1H), 7.55–7.53 (d, <i>J</i> = 8.8 Hz, 1H), 7.38–7.34 (t, 1H), 7.15–7.13 (d, <i>J</i> = 7.6 Hz, 1H), 7.10–7.08 (d, <i>J</i> = 8.4 Hz, 2H), 3.16–3.11 (m, 4H), 2.78 (s, 3H), 2.54–2.22 (m, 4H), 1.84–1.79 (m, 3H), 1.68–1.62 (m, 3H). MS <i>m</i>/<i>z</i> 488 [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>29</sub>N<sub>3</sub>O<sub>6</sub>S.</div></div><div id="sec4_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> <i>tert</i>-Butyl 3-[4-[(4-Methoxycarbonylphenyl)methoxy]phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>41b</b>)</h4><div class="NLM_p last">To a solution of compound <b>40</b> (120 mg, 0.223 mmol) in DMF (5 mL) was added K<sub>2</sub>CO<sub>3</sub> (62 mg, 2 equiv), then compound methyl 4-(bromomethyl)benzoate (51 mg, 1.0 equiv) in DMF (2 mL) was added slowly at 0 °C. The resulting mixture was stirred at RT overnight, after TLC (PE:AE = 2:1) showed the staring materials were consumed completely, the mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by preparative TLC (PE:AE = 1:1) to obtain pure product <b>41b</b> (61 mg, 40%) as a white solid. MS <i>m</i>/<i>z</i> 687 [M + H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>46</sub>N<sub>2</sub>O<sub>10</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 4-[[4-[[8-<i>tert</i>-Butoxycarbonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]methyl]benzoic Acid (<b>42b</b>)</h4><div class="NLM_p last">To a solution of compound <b>41b</b> (61 mg, 0.089 mmol) in THF/H<sub>2</sub>O (3:1, 12 mL) was added LiOH·H<sub>2</sub>O (38 mg, 10 equiv). The resulting mixture was stirred at RT overnight, after LC-MS showed the staring materials were consumed completely, then the mixture was diluted with water and adjusted pH to 2–3 with 1 N HCl and the mixture was extracted with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product <b>42b</b> (60 mg, 100%) which was used in the next step. MS <i>m</i>/<i>z</i> 673 [M + H]<sup>+</sup> calcd for C<sub>34</sub>H<sub>44</sub>N<sub>2</sub>O<sub>10</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> <i>tert</i>-Butyl 3-[4-[[4-(Methylcarbamoyl)phenyl]methoxy]phenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>43b</b>)</h4><div class="NLM_p last">To a solution of compound <b>42b</b> (60 mg, 0.089 mmol) in DMF (5 mL) was added EDC·HCl (35 mg, 2 equiv), HOBt (24 mg, 2 equiv), CH<sub>3</sub>NH·HCl (12.0 mg, 2 equiv), and NMM (27 mg, 3 equiv) at RT, then the mixture was stirred at RT overnight. The mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by preparative TLC (AE) to obtain pure product <b>43b</b> (40 mg, 66%) as a white solid. MS <i>m</i>/<i>z</i> 686 [M + H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>47</sub>N<sub>3</sub>O<sub>9</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 4-[[4-[[3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]methyl]-<i>N</i>-methyl-benzamide (<b>19n</b>)</h4><div class="NLM_p last">A solution of compound <b>43b</b> (40 mg, 0.058 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>19n</b> (25.3 mg, 87%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.87–7.85 (d, <i>J</i> = 8.0 Hz, 2H), 7.81–7.79 (d, <i>J</i> = 8.8 Hz, 2H), 7.58–7.56 (d, <i>J</i> = 8.0 Hz, 2H), 7.22–7.20 (d, <i>J</i> = 8.4 Hz, 2H), 5.29 (s, 2H), 3.18–3.14 (m, 4H), 2.94 (s, 3H), 2.57–2.23 (m, 4H), 1.85–1.63 (m, 6H). MS <i>m</i>/<i>z</i> 502 [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>31</sub>N<sub>3</sub>O<sub>6</sub>S.</div></div><div id="sec4_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> <i>tert</i>-Butyl 3-(Tetrahydropyran-2-yloxycarbamoyl)-3-[4-[[4-(trifluoromethoxy)phenyl]methylamino]phenyl]sulfonyl-8-azaspiro[4.5]decane-8-carboxylate (<b>44</b>)</h4><div class="NLM_p last">The mixture of compound <b>27</b> (50 mg, 0.093 mmol) and [4-(trifluoromethoxy)phenyl]methanamine (178 mg, 0.93 mmol) was stirred at 110 °C overnight. The mixture was quenched with water and extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by preparative TLC to give the compound <b>44</b> (25 mg, 38%) as a pale-yellow solid. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.70 (d, <i>J</i> = 8.8 Hz, 2H), 7.04–7.00 (m, 4H), 6.98–6.93 (m, 2H), 3.83 (s, 3H), 3.69 (s, 3H), 3.46–3.24 (m, 6H), 2.53–2.40 (m, 3H), 2.30 (d, <i>J</i> = 14.4 Hz, 1H), 1.76–1.74 (m, 1H), 1.74–1.70 (m, 7H), 1.32 (s, 14H), 1.31–1.25 (m, 3H). MS <i>m</i>/<i>z</i> 572 [M-139] for C<sub>34</sub>H<sub>44</sub>F<sub>3</sub>N<sub>3</sub>O<sub>8</sub>S.</div></div><div id="sec4_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 3-[4-[[4-(Trifluoromethoxy)phenyl]methylamino]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>18</b>)</h4><div class="NLM_p last">A solution of compound <b>44</b> (30 mg, 0.037 mmol) in HCl/dioxane (2 N, 10 mL) was stirred at RT for 2 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>18</b> (7.6 mg, 40%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.52–7.50 (d, <i>J</i> = 8 Hz, 2H), 7.45–7.43 (d, <i>J</i> = 8 Hz, 2H), 7.24–7.22 (d, <i>J</i> = 8 Hz, 2H), 6.68–6.66 (d, <i>J</i> = 8 Hz, 2H), 4.43 (s, 2H), 3.20–3.00 (m, 4H), 2.55–2.40 (m, 2H), 2.40–2.30 (m, 1H), 2.19–2.15 (m, 1H), 1.80–1.65 (m, 3H), 1.65–1.50 (m, 3H). MS <i>m</i>/<i>z</i> 528 [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>28</sub>F<sub>3</sub>N<sub>3</sub>O<sub>5</sub>S.</div></div><div id="sec4_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> O8-<i>tert</i>-Butyl O3-Methyl 3-[4-(4-Methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3,8-dicarboxylate (<b>45</b>)</h4><div class="NLM_p last">To a solution of compound <b>25</b> (900 mg, 1.97 mmol) in DMF (120 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (1.92 g, 5.9 mol) and 4-methoxyphenol (490 mg, 3.95 mmol), and the reaction mixture was stirred at 60 °C for 2 h. The mixture was diluted with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by column chromatography to give the compound <b>45</b> (600 mg, 54%) as a pale-yellow oil. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.72 (d, <i>J</i> = 8.8 Hz, 2H), 7.03–6.97 (m, 6H), 3.77 (s, 3H), 3.61 (s, 3H), 3.27–3.25 (m, 6H), 3.16–3.08 (m, 6H), 2.49–2.33 (m, 4H), 1.83–1.76 (m, 4H), 1.66–1.58 (m, 5H). MS <i>m</i>/<i>z</i> 560 [M + H]<sup>+</sup> calcd for C<sub>29</sub>H<sub>37</sub>NO<sub>8</sub>S.</div></div><div id="sec4_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Methyl 3-[4-(4-Methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carboxylate (<b>46</b>)</h4><div class="NLM_p last">A solution of compound <b>45</b> (500 mg, 0.89 mmol) in HCl/dioxane (4 M, 6 mL) was stirred at RT for 3 h. The reaction mixture was concentrated to give the compound <b>46</b> (500 mg, crude). MS <i>m</i>/<i>z</i> 460 [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>29</sub>NO<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Methyl 3-[4-(4-Methoxyphenoxy)phenyl]sulfonyl-8-methyl-8-azaspiro[4.5]decane-3-carboxylate (<b>47</b>)</h4><div class="NLM_p last">To a solution of compound <b>46</b> (181 mg, 0.39 mmol) in CH<sub>3</sub>CN (10 mL) was added K<sub>2</sub>CO<sub>3</sub> (107 mg, 0.78 mmol) and MeI (28 mg, 0.19 mmol). The reaction mixture was stirred at RT for 30 min. After TLC showed that most of starting material was consumed, the mixture was diluted with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound <b>47</b> (110 mg, 60%) as a pale-yellow oil. MS <i>m</i>/<i>z</i> 474 [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>31</sub>NO<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> 3-[4-(4-Methoxyphenoxy)phenyl]sulfonyl-8-methyl-8-azaspiro[4.5]decane-3-carboxylic Acid (<b>48</b>)</h4><div class="NLM_p last">To a solution of compound <b>47</b> (110 mg, 0.23 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 8 mL) was added LiOH·H<sub>2</sub>O (195 mg, 4.6 mmol). The resulting mixture was refluxed overnight. After TLC showed that most of the starting materials were consumed completely, the mixture was diluted with water and adjusted pH to 2–3. The mixture was extract with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product <b>48</b> (100 mg, 94%) as a pale-yellow solid. MS <i>m</i>/<i>z</i> 460 [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>29</sub>NO<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> 3-[4-(4-Methoxyphenoxy)phenyl]sulfonyl-8-methyl-<i>N</i>-tetrahydropyran-2-yloxy-8-azaspiro[4.5]decane-3-carboxamide (<b>49</b>)</h4><div class="NLM_p last">To a solution of compound <b>48</b> (100 mg, 0.22 mmol) in DMF (10 mL) was added EDCl (84 mg, 0.44 mmol), HOBt (59 mg, 0.44 mmol), THPONH<sub>2</sub> (51.5 mg, 0.44 mmol), and NMM (66 mg, 0.66 mmol). The mixture was stirred at RT overnight. The mixture was diluted with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by column chromatography to give the compound <b>49</b> (78 mg, 64%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.83–7.80 (m, 2H), 7.06–6.98 (m, 6H), 4.94 (m, 1H), 4.10–4.00 (m, 1H), 3.81 (s, 3H), 3.57–3.54 (m, 1H), 3.30 (s, 3H), 2.85–2.60 (m, 3H), 2.54–2.31 (m, 5H), 2.19–2.14 (m, 1H), 1.82–1.50 (m, 11H). MS <i>m</i>/<i>z</i> 559 [M + H]<sup>+</sup> calcd for C<sub>29</sub>H<sub>38</sub>N<sub>2</sub>O<sub>7</sub>S.</div></div><div id="sec4_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 3-[4-(4-Methoxyphenoxy)phenyl]sulfonyl-8-methyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>20a</b>)</h4><div class="NLM_p last">A solution of compound <b>49</b> (78 mg, 0.14 mmol) in HCl/dioxane (4M, 10 mL) was stirred at RT for 3 h, the reaction mixture was concentrated to give the compound <b>20a</b> (14.7 mg, 22%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.79–7.73 (m, 2H), 7.02–7.00 (m, 6H), 3.80 (s, 3H), 3.41–3.38 (m, 2H), 3.02–2.84 (m, 2H), 2.84–2.82 (m, 3H), 2.67–2.48 (m, 2H), 2.47–2.18 (m, 2H), 1.86–1.61 (m, 5H), 1.59–1.56 (m,1H). MS <i>m</i>/<i>z</i> 475 [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>30</sub>N<sub>2</sub>O<sub>6</sub>S.</div></div><div id="sec4_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> 3-[4-(4-Methoxyphenoxy)phenyl]sulfonyl-8-(3,3,3-trifluoropropyl)-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>20b</b>)</h4><div class="NLM_p last">To a solution of compound <b>13</b> (50 mg, 0.109 mmol) and K<sub>2</sub>CO<sub>3</sub> (45 mg, 3 equiv) in DMF (5 mL) was added 3-bromo-1,1,1-trifluoropropane (19 mg, 1 equiv) at RT, then the mixture was stirred at RT overnight. After LC-MS showed the starting material was consumed, the mixture was quenched with water, extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to give pure compound <b>20b</b> (7.5 mg, 12%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.81–7.79 (d, <i>J</i> = 7.2 Hz, 2H), 7.09–7.01 (m, 6H), 3.84 (s, 3H), 3.55–3.42 (m, 4H), 3.09 (m, 2H), 2.87–2.75 (m, 2H), 2.60–2.24 (m, 4H), 1.96–1.72 (m, 6H). MS <i>m</i>/<i>z</i> 557 [M + H]<sup>+</sup> calcd for C<sub>26</sub>H<sub>31</sub>F<sub>3</sub>N<sub>2</sub>O<sub>6</sub>S.</div></div><div id="sec4_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> 8-Acetyl-3-[4-(4-methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid (<b>20c</b>)</h4><div class="NLM_p last">To a solution of compound <b>13</b> (20 mg, 0.043 mmol) and pyridine (7 mg, 2 equiv) in DMF (3 mL) was added acetyl chloride (4 mg, 1.2 equiv) at 0 °C, then the mixture was stirred at 0 °C for 5 min. After LC-MS showed the starting material was consumed, the mixture was quenched with water, extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to give pure compound <b>20c</b> (7.0 mg, 32%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.71–7.69 (d, <i>J</i> = 8 Hz, 2H), 7.05–6.95 (m, 6H), 3.85 (s, 3H), 3.70–3.35 (m, 4H), 2.59–2.37 (m, 3H), 2.31–2.21 (m, 1H), 2.14 (s, 3H), 1.78–1.41 (m, 6H). MS <i>m</i>/<i>z</i> 503 [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>30</sub>N<sub>2</sub>O<sub>7</sub>S.</div></div><div id="sec4_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> <i>tert</i>-Butyl 3-[4-(4-Methoxybenzoyl)oxyphenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>50a</b>)</h4><div class="NLM_p last">To a solution of compound <b>40</b> (60 mg, 0.151 mmol) and Et<sub>3</sub>N (46 mg, 3 equiv) in DCM (5 mL) was added 4-methoxybenzoyl chloride (31 mg, 1.2 equiv) at RT, then the mixture was stirred at RT overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was extracted with DCM, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>50a</b> (38 mg, 38%) as a pale-yellow oil. MS <i>m</i>/<i>z</i> 673 [M + H]<sup>+</sup> calcd for C<sub>34</sub>H<sub>44</sub>N<sub>2</sub>O<sub>10</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> [4-[[3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenyl] 4-methoxybenzoate (<b>21a</b>)</h4><div class="NLM_p last">A solution of compound <b>50a</b> (38 mg, 0.057 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>21a</b> (22 mg, 79%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.18–8.15 (m, 2H), 7.98–7.96 (d, <i>J</i> = 8.8 Hz, 2H), 7.53–7.51 (d, <i>J</i> = 8.8 Hz, 2H), 7.12–7.10 (m, 2H), 3.93 (s, 3H), 3.23–3.14 (m, 4H), 2.65–2.58 (m, 2H), 2.49–2.42 (m, 1H), 2.32–2.28 (d, <i>J</i> = 14.0 Hz, 1H), 1.90–1.64 (m, 6H). MS <i>m</i>/<i>z</i> 489 [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>28</sub>N<sub>2</sub>O<sub>7</sub>S.</div></div><div id="sec4_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> O1-Benzyl O4-[4-[[8-<i>tert</i>-Butoxycarbonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenyl] benzene-1,4-dicarboxylate (<b>50b</b>)</h4><div class="NLM_p last">To a solution of compound <b>40</b> (320 mg, 0.595 mmol) and Et<sub>3</sub>N (120 mg, 2 equiv) in DCM (20 mL) was added benzyl 4-chlorocarbonylbenzoate (<b>Int. 1</b>, synthesis described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) (200 mg, 1.2 equiv) at 0–5 °C, and then the mixture was stirred at RT overnight. After TLC (PE/AE 2:1) showed the starting material was consumed, the mixture was extracted with DCM, and the organic layer was washed with NaHCO<sub>3</sub> (aqueous), brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude compound which was purified by preparative TLC (PE/AE 2:1) to give pure compound <b>50b</b> (340 mg, 74%) as a pale-yellow solid. MS <i>m</i>/<i>z</i> 777 [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>48</sub>N<sub>2</sub>O<sub>11</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> 4-[4-[[8-<i>tert</i>-Butoxycarbonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]carbonylbenzoic Acid (<b>51</b>)</h4><div class="NLM_p last">To a solution of compound <b>50b</b> (340 mg, 0.438 mmol) in MeOH (20 mL) was added Pd/C (0.5 g) at RT at H<sub>2</sub> atmosphere, then the mixture was stirred at RT for 1 h until TLC (PE/AE 2:1) showed the starting material was consumed, then filtered, and the filtrate was concentrated to give the crude compound <b>51</b> (270 mg, 90%) which was used for the next step without further purification. MS <i>m</i>/<i>z</i> 687 [M + H]<sup>+</sup> calcd for C<sub>34</sub>H<sub>42</sub>N<sub>2</sub>O<sub>11</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> <i>tert</i>-Butyl 3-[4-[4-(Methylcarbamoyl)benzoyl]oxyphenyl]sulfonyl-3-(tetrahydropyran-2-yloxycarbamoyl)-8-azaspiro[4.5]decane-8-carboxylate (<b>52</b>)</h4><div class="NLM_p last">To a solution of compound <b>51</b> (45 mg, 0.066 mmol) in ACN (5 mL) was added Et<sub>3</sub>N (14 mg, 2 equiv) and CH<sub>3</sub>NH·HCl (6.7 mg, 1.5 equiv) at RT, then HATU (28 mg, 1.1 equiv) was added and the mixture was stirred at RT overnight. The mixture was extracted with EtOAc, and the organic layer was washed with brine, 2 N HCl, H<sub>2</sub>O, NaHCO<sub>3</sub> (aq), and H<sub>2</sub>O, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by preparative TLC (AE) to obtain pure product <b>52</b> (24 mg, 52%) as a pale-yellow solid. MS <i>m</i>/<i>z</i> 700 [M + H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>45</sub>N<sub>3</sub>O<sub>10</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> [4-[[3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenyl] 4-(methylcarbamoyl)benzoate (<b>21b</b>)</h4><div class="NLM_p last">A solution of compound <b>52</b> (24 mg, 0.034 mmol) in HCl/dioxane (2 N, 5 mL) was stirred at RT for 1 h, then concentrated to give the crude product which was purified by preparative HPLC (general procedure described in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>21b</b> (15.0 mg, 83%) as a red solid. <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.26–8.24 (d, <i>J</i> = 8.4 Hz, 2H), 7.98–7.94 (t, 4H), 7.54–7.51 (d, <i>J</i> = 8.8 Hz, 2H), 3.17–3.11 (m, 4H), 2.93 (s, 3H), 2.57–2.25 (m, 4H), 1.85–1.61 (m, 6H). MS <i>m</i>/<i>z</i> 516 [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>29</sub>N<sub>3</sub>O<sub>7</sub>S.</div></div><div id="sec4_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> 4-[4-[[(3<i>R</i>)-3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-<i>N</i>-methyl-benzamide (<b>5</b>)</h4><div class="NLM_p last">From racemic mixture <b>19d</b> (360 mg), pure enantiomer <b>5</b> (150 mg) was obtained by SFC (see protocol in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). According to SFC purification method, Rt is 2.99, and enantiomeric excess (ee) is 100%. Its optical rotation is [α]<sub>D</sub> = +16.66 (see protocol in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). LCMS for quality control. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 488.2 calcd for C<sub>24</sub>H<sub>29</sub>N<sub>3</sub>O6<sub>S</sub>. Purity is 98.77% according to HPLC analytical method (described above, general procedure), where Rt is 1.55. <sup>1</sup>H NMR (MeOD, 400 MHz).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div></div><div id="sec4_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> 4-[4-[[(3<i>S</i>)-3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-<i>N</i>-methyl-benzamide (<b>22</b>)</h4><div class="NLM_p">From racemic mixture <b>19d</b> (360 mg), pure enantiomer <b>22</b> (180 mg) was obtained by SFC (see protocol in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). According to SFC purification method, Rt is 6.19, and enantiomeric excess (ee) is 100%. Its optical rotation is [α]<sub>D</sub> = −17.10 (see protocol in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>)</div><div class="NLM_p last">LCMS for quality control. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 488.2 calcd for C<sub>24</sub>H<sub>29</sub>N<sub>3</sub>O6<sub>S</sub>. Purity is 99.49% according to HPLC analytical method (described above, general procedure), where Rt is 1.65. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.92 (d, <i>J</i> = 8 Hz, 2H), 7.85 (d, <i>J</i> = 8 Hz, 2H), 7.20–7.16 (m, 4H), 3.25–3.05 (m, 4H), 3.13 (s, 3H), 2.60–2.50 (m, 2H), 2.50–2.30 (m, 1H), 2.30–2.20 (m, 1H), 1.80–1.75 (m, 3H), 1.75–1.55 (m, 3H).</div></div></div><div id="sec4_88_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> MMP-3 and MMP-10 Enzyme Activity Assays</h3><div class="NLM_p last">MMP-3 and MMP-10 enzyme activities were measured using a specific fluorescence-labeled substrate (R&D Systems, catalogue no. ES002). MMP-10 was activated with 2 mM APMA (2 h, 37 °C) and MMP-3 with 5 μg/mL chymotrypsin (30 min, 37 °C). Active MMP-3 (2 nM) or MMP-10 (2 nM) (R&D Systems) were incubated in assay buffer (50 mM Tris-HCl, 150 mM NaCl, 10 mM CaCl<sub>2</sub>, and 0.05% Brij-35 pH 7.4) with the MMP substrate (1.5 and 6 μM for MMP-10 and MMP-3, respectively), and enzyme activity was measured every minute for 1 h (37 °C) in black 96-well plates using an Envision plate reader (PerkinElmer). Enzyme activity was calculated from the linear kinetic slope of the substrate consumption after a lag period of 5 min from the start of the reaction.</div></div><div id="sec4_88_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> Blood Sampling and Laboratory Assessments</h3><div class="NLM_p last">Fasting blood samples from healthy volunteers were collected with 0.129 mmol/L sodium citrate (9:1 proportion) by a standard procedure (cubital vein puncture with butterfly) and immediately used for thromboelastometry assays or centrifuged at 2200<i>g</i> at room for coagulation laboratory tests. Informed consent was obtained from each subject, and the protocol was approved by the Ethics Committee of the Universidad de Navarra (Pamplona, Spain).</div></div><div id="sec4_88_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> Antifibrinolytic Effect on Whole Blood Clot Formation and Lysis</h3><div class="NLM_p">Thromboelastometry is a viscoelastometric method for hemostasis testing in whole blood. TEM measures the interactions of coagulation factors, inhibitors, and cellular components during the phases of clotting and subsequent lysis over time. The rheological conditions of this method mimic the sluggish flow of blood in veins.</div><div class="NLM_p last">Citrated blood samples from healthy volunteers and mice were assayed with a ROTEM analyzer (Pentapharm GmbH, Germany). In a prewarmed cuvette and holder were pipetted 1 μL of tPA (150000 U/mL), 20 μL of Start-tem reagent (Pentapharm GmbH, Germany), 20 μL of In-tem reagent (Pentapharm GmbH, Germany), 3 μL of DMSO (SIGMA) or test compounds in DMSO, and 300 μL of prewarmed citrated blood. The cup holder containing the sample mixture was placed immediately in the appropriate channel. The measurement was recorded for 60 min to allow clot formation and lysis. The results are expressed as the effective concentration to delay lysis time by 50% (EC<sub>50</sub>LT).</div></div><div id="sec4_88_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> hERG Blockade Assay</h3><div class="NLM_p last">The effect of the compound on the hERG potassium channel was determined using a PredictorTM hERG fluorescence polarization commercial assay kit (Life Technologies, catalogue no. PV5365). The assay was carried out in black 384-well plates (Corning, catalogue no. 3677 PS), monitoring changes in the fluorescence polarization properties of the labeled hERG ligand between its soluble and bound states. The compounds, which will compete with the fluorescently labeled hERG, were solubilized in 100% DMSO across a 16-point concentration curve and then diluted 1:25 with hERG assay buffer. The assay contained 5 μL/well of studied compound, 10 μL/well of hERG membranes, and 5 μL/well of hERG Tracer Red. The plate was incubated 2 h at RT and protected from light. Fluorescence polarization signals were recorded with an Envision plate reader (PerkinElmer).</div></div><div id="sec4_88_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> CYP Inhibition</h3><div class="NLM_p last">The inhibitory effect of the compounds on five human cytochrome P450s (1A2, 2C9, 2C19, 2D6, and 3A4) was evaluated in human liver microsomes at WuXi (<a href="http://www.wuxi.com/" class="extLink">http://www.wuxi.com/</a>). Compounds were prepared at 10 μM, and the corresponding substrates for each P450 isoform (20 μL) were incubated with 140 μL of liver microsomes (0.286 mg/mL; BD Gentest) and NADPH cofactor (20 μL, 1 mM) for 10 min at 37 °C. The reaction was terminated by adding 400 μL of cold stop solution (200 ng/mL tolbutamide in ACN), and samples were centrifuged at 1500<i>g</i> for 20 min. Supernatants were analyzed by LC-MS/MS (Shimadzu LC 20-AD–API 4000) using the peak area ratio of the analyte/internal standard. Compounds and positive controls were tested in duplicate. The percentage of inhibition was calculated as the ratio of substrate metabolite detected in treated and nontreated wells.</div></div><div id="sec4_88_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> PAMPA Permeability</h3><div class="NLM_p last">The permeability of compounds was evaluated with the parallel artificial membrane permeation assay (PAMPA) as an in vitro model of passive diffusion and the analysis carried out at WuXi (<a href="http://www.wuxi.com/" class="extLink">http://www.wuxi.com/</a>). Donor solutions (150 μL; 10 μM in PBS) were added to each well of the donor plate, whose PVDF membrane was precoated with 5 μL of a 1% lecithin/dodecane mixture. PBS (300 μL) was added to each well of the PTFE acceptor plate. The donor and acceptor plate were combined together and incubated for 4 h at RT with shaking at 150 rpm. After removing the plates from the incubator, the acceptor samples were prepared by mixing 270 μL of the acceptor solution with 30 μL of ACN (containing an internal standard). The donor samples were prepared by mixing 20 μL of the donor solution from each well with 250 μL of PBS (DF:13.5) and 30 μL of ACN (containing an internal standard). Donor and acceptor samples were analyzed by LC-MS/MS (Shimadzu LC 10-AD–API 4000) using the peak area ratio of the analyte/internal standard. Compounds and positive controls were tested in duplicate.</div></div><div id="sec4_88_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> Metabolic Stability</h3><div class="NLM_p last">Test compounds (1 μM, 5% MeOH in potassium phosphate buffer) were incubated with human (catalogue no. 452161 from BD Gentest), mouse (catalogue no. M1000, Xenotech), and rat (catalogue no. RTMCPL, Gibco) liver microsomes at 37 °C for 10 min. Liver microsomes were at a final assay concentration of 0.7 mg protein/mL. The reaction was started by the addition of 90 μL of NADP cofactor solution and stopped by the addition of 300 μL of stop solution (acetonitrile at 4 °C, including 100 ng/mL tolbutamide as an internal standard) after 20 min of incubation. The samples were shaken for 5 min and then centrifuged for 20 min at 1500<i>g</i>. A 100 μL aliquot of the supernatant was transferred to eight new 96-well plates with 300 μL of HPLC water and centrifuged at 1500<i>g</i> for LC-MS/MS analysis (Shimadzu LC 10-AD–API 4000). An injection volume of 10 μL was added to a Phenomenex Synergi C18 column eluting with formic acid in water or acetonitrile at a flow rate of 800 μL/min. The percent loss of parent compound was calculated from the peak area ratio of the analyte/internal standard. Compounds and positive controls were tested in duplicate.</div></div><div id="sec4_88_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> Antifibrinolytic Effect in Vivo</h3><div class="NLM_p last">Two-month-old wild-type male C57BL6 mice (Harlan Iberica, Barcelona, Spain), housed in the Center for Applied Medical Research (CIMA, Pamplona, Spain) animal facilities, were randomly allocated into each of the experimental groups (<i>n</i> = 10, sample size estimated from preliminary experiments). Experiments were performed in accordance with European Directive 2010/63/EU for the care and use of laboratory animals and were approved by the University of Navarra Animal Research Review Committee.</div></div><div id="sec4_88_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> Tail Bleeding Assay</h3><div class="NLM_p last">Bleeding time was evaluated in 2-month-old wild-type C57BL6 (<i>n</i> ≥ 10) mice by removing the tail tip. Mice (20–25 g) were anesthetized with 2.5% isoflurane and maintained at 37 °C on heating pads. The hemostatic efficacy was evaluated in the hyperfibrinolytic bleeding model with tPA to prolong bleeding time due to excessive fibrinolysis. First, the femoral vein was exposed and cannulated with a saline-filled polyurethane catheter (Microcannula 72–9030, Harvard Apparatus) to facilitate the administration of agents. The catheter was connected to a syringe pump (AL-1000, WPI) for the infusion of 200 μL (10% bolus, 90% perfusion during 40 min) of the test agents. Then, tPA (0.5 mg/kg) was injected into the ocular plexus, and 5 min after tPA administration, saline or the different compounds were infused through the femoral catheter to ensure systemic distribution of all the agents. Five minutes later, 5 mm of the tail tip was removed using a scalpel blade, and the tail tip was bathed in 1 mL of sterile saline at 37 °C. The time of bleeding was defined as the interval between initial transections and the first visual cessation of bleeding, which was measured for up to 30 min. A value of 30 min was assigned to those animals bleeding longer than the observation period. Blood lost was defined as the amount of blood collected during 30 min and quantified in a spectrophotometer (Tecan Sunrise, Switzerland) against a standard curve generated with known quantities of blood.</div></div><div id="sec4_88_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i125" class="anchor-spacer"></div><h3 class="article-section__title" id="_i125"> Anatomopathological Analysis</h3><div class="NLM_p last">Twenty-four hours after administration of the compounds (10 mg/kg), lungs, kidneys, brain, and liver were extracted for anatomopathological analysis. The samples were fixed in 4% formaldehyde and sent to the University of Zaragoza. After their inclusion, cutting, and staining (Hematoxylin-Eosin), the anatomopathological examination of these preparations was made by the Anatomopathological Diagnosis Service for Laboratory Animals (DAPAL, University of Zaragoza).</div></div><div id="sec4_88_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i126" class="anchor-spacer"></div><h3 class="article-section__title" id="_i126"> Caco-2 Permeability</h3><div class="NLM_p last">This study was conducted at WuXi AppTec (<a href="http://www.wuxiapptec.com/" class="extLink">http://www.wuxiapptec.com/</a>). Caco-2 cells (ATCC) were seeded onto polyethylene membranes (PET) in 96-well BD insert plates at 1 × 10<sup>5</sup> cells/cm<sup>2</sup>, and the medium was changed every 4 days until the 21st to 28th day for confluent cell monolayer formation. Test compounds were diluted with transport buffer (HBSS pH 7.4) from a 0.2 mM stock solution to a concentration of 2 μM (final DMSO concentration adjusted to 1%) and applied to the apical surface of the cell monolayer, and compound permeation into the basolateral compartment was measured (A to B direction, <i>n</i> = 3). The assay was performed in the reverse direction to investigate P-gp-mediated efflux (B to A direction, <i>n</i> = 3). The permeation was assessed over a 120 min incubation at 37 °C and 5% CO<sub>2</sub> with a relative humidity of 95%. Concentrations of test compounds in starting solution, donor solution, receiver solution, and cell lysate solution were quantified by LC-MS/MS methodologies (Shimadzu LC 20-AD–API 4000) using the peak area ratio of the analyte/internal standard. Permeation of Lucifer Yellow through the monolayer was measured to evaluate cellular integrity.</div></div><div id="sec4_88_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i127" class="anchor-spacer"></div><h3 class="article-section__title" id="_i127"> hERG Channel Test Using Manual Patch Clamp</h3><div class="NLM_p last">This study was conducted at WuXi AppTec (<a href="http://www.wuxiapptec.com/" class="extLink">http://www.wuxiapptec.com/</a>) using CHO cells with stable expression of the hERG potassium channel (Aviva Biosciences). Cells were cultured in a humidified and air-controlled (5% CO<sub>2</sub>) incubator at 37 °C. Compound <b>2</b> was diluted at different concentrations, with a final DMSO concentration in the extracellular solution of 0.3% for <b>2</b> and of 0.1% for amitriptyline (positive control). The external solution consisted of 145 mM NaCl, 4 mM KCl, 2 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 10 mM HEPES, and 10 mM glucose (pH 7.4 and ∼295 mOsm). The internal solution consisted of 120 mM KCl, 31.25 mM KOH, 5.374 mM CaCl<sub>2</sub>, 1.75 mM MgCl<sub>2</sub>, 4 mM Na<sub>2</sub>ATP, 10 mM HEPES, and 10 mM EGTA (pH 7.2 and ∼285 mOsm). The assay was performed at room temperature using the whole cell patch clamp technique with an EPC 10 USB patch clamp amplifier and controlled with Patchmaster Pro 2.40 software. For quality control, minimum seal resistance was set at 500 MOhms, and minimum specific hERG current (precompound) was 0.4 nA. Data analysis was carried out using Patchmaster Pro 2.40 software, Excel 2003 (Microsoft), and GraphPad Prism 5.0.</div></div><div id="sec4_88_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i128" class="anchor-spacer"></div><h3 class="article-section__title" id="_i128"> Kinetic Solubility</h3><div class="NLM_p last">This study was conducted at WuXi AppTec (<a href="http://www.wuxiapptec.com/" class="extLink">http://www.wuxiapptec.com/</a>). After shaking a 200 μM concentration of test compound for 24 h at pH 7.4 (50 mM phosphate buffer), kinetic solubility was sampled after filtration. The concentration was determined by UV and calibrated using a three-point standard curve (1, 20, and 200 μM).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i129"><a href="/doi/suppl/10.1021/jm501940y">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45745" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45745" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Details about purification methods, SFC methods, optical rotation, purities, and HPLC traces for final compounds, synthesis and crystallographic data for <b>23b</b>, and MMPs selectivity profiling. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501940y/suppl_file/jm501940y_si_001.pdf">jm501940y_si_001.pdf (1.96 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm501940y" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57774" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57774" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">José A. Páramo</span> - <span class="hlFld-Affiliation affiliation">Hematology Service, Clínica
Universidad de Navarra, University of Navarra. Avenida Pio XII 36, E-31008 Pamplona, Spain</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d6bcb7a6b7a4b7bbb996a3b8b7a0f8b3a5"><span class="__cf_email__" data-cfemail="c8a2a9b8a9baa9a5a788bda6a9bee6adbb">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julen Oyarzabal</span> - <span class="hlFld-Affiliation affiliation">†Atherosclerosis Research Laboratory, ‡Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied
Medical Research (CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, 4th Avenue, Tianjin 300456, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Hematology Service, Clínica
Universidad de Navarra, University of Navarra. Avenida Pio XII 36, E-31008 Pamplona, Spain</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#660c130a0308091f07141c0704070a2613080710480315"><span class="__cf_email__" data-cfemail="90fae5fcf5feffe9f1e2eaf1f2f1fcd0e5fef1e6bef5e3">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Josune Orbe</span> - <span class="hlFld-Affiliation affiliation">†Atherosclerosis Research Laboratory, ‡Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied
Medical Research (CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, 4th Avenue, Tianjin 300456, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Hematology Service, Clínica
Universidad de Navarra, University of Navarra. Avenida Pio XII 36, E-31008 Pamplona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juan A. Sánchez-Arias</span> - <span class="hlFld-Affiliation affiliation">†Atherosclerosis Research Laboratory, ‡Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied
Medical Research (CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, 4th Avenue, Tianjin 300456, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Hematology Service, Clínica
Universidad de Navarra, University of Navarra. Avenida Pio XII 36, E-31008 Pamplona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Obdulia Rabal</span> - <span class="hlFld-Affiliation affiliation">†Atherosclerosis Research Laboratory, ‡Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied
Medical Research (CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, 4th Avenue, Tianjin 300456, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Hematology Service, Clínica
Universidad de Navarra, University of Navarra. Avenida Pio XII 36, E-31008 Pamplona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">José A. Rodríguez</span> - <span class="hlFld-Affiliation affiliation">†Atherosclerosis Research Laboratory, ‡Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied
Medical Research (CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, 4th Avenue, Tianjin 300456, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Hematology Service, Clínica
Universidad de Navarra, University of Navarra. Avenida Pio XII 36, E-31008 Pamplona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Agustina Salicio</span> - <span class="hlFld-Affiliation affiliation">†Atherosclerosis Research Laboratory, ‡Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied
Medical Research (CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, 4th Avenue, Tianjin 300456, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Hematology Service, Clínica
Universidad de Navarra, University of Navarra. Avenida Pio XII 36, E-31008 Pamplona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ana Ugarte</span> - <span class="hlFld-Affiliation affiliation">†Atherosclerosis Research Laboratory, ‡Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied
Medical Research (CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, 4th Avenue, Tianjin 300456, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Hematology Service, Clínica
Universidad de Navarra, University of Navarra. Avenida Pio XII 36, E-31008 Pamplona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Miriam Belzunce</span> - <span class="hlFld-Affiliation affiliation">†Atherosclerosis Research Laboratory, ‡Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied
Medical Research (CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, 4th Avenue, Tianjin 300456, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Hematology Service, Clínica
Universidad de Navarra, University of Navarra. Avenida Pio XII 36, E-31008 Pamplona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Musheng Xu</span> - <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, 4th Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Wu</span> - <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, 4th Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haizhong Tan</span> - <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, 4th Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongyu Ma</span> - <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, 4th Avenue, Tianjin 300456, PR China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2412e7396-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i130">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23506" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23506" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Lara Montori and Irene de Miguel for their excellent technical assistance. This study has been funded through the Foundation for Applied Medical Research, University of Navarra (Pamplona, Spain), Ministerio de Economía y Competitividad (FIS PI12/00710), and FSE (Inncorpora-Torres Quevedo grant), PTQ-11-04781 (O.R.) and PTQ-12-05641 (A.U.).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i131" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i131"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i132" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i132"> Abbreviations Used</h2><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">matrix metalloproteinase</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism and excretion</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyranyl</p></td></tr><tr><td class="NLM_term">TACE</td><td class="NLM_def"><p class="first last">TNF-α converting enzyme</p></td></tr><tr><td class="NLM_term">PAMPA</td><td class="NLM_def"><p class="first last">parallel artificial membrane permeability assay</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butoxycarbonyl</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">Et<sub>3</sub>N</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">PE</td><td class="NLM_def"><p class="first last">petroleum ether</p></td></tr><tr><td class="NLM_term">AE/EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">Rt</td><td class="NLM_def"><p class="first last">retention time</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisopropylamide</p></td></tr><tr><td class="NLM_term">EDC·HCl</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">THP-O-NH<sub>2</sub></td><td class="NLM_def"><p class="first last"><i>N</i>-(tetrahydro-2<i>H</i>-pyran-2-yloxy)amine</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine</p></td></tr><tr><td class="NLM_term">m-CPBA</td><td class="NLM_def"><p class="first last"><i>m</i>-chloroperbenzoic acid</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">PVDF</td><td class="NLM_def"><p class="first last">polyvinylidene difluoride (PVDF)</p></td></tr><tr><td class="NLM_term">PTFE</td><td class="NLM_def"><p class="first last">polytetrafluoroethylene</p></td></tr><tr><td class="NLM_term">PAI</td><td class="NLM_def"><p class="first last">plasminogen activator inhibitors</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i133">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44820" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44820" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 33 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Kauvar, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefering, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, C. E.</span><span> </span><span class="NLM_article-title">Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations</span> <span class="citation_source-journal">J. Trauma: Inj., Infect., Crit. Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">S3</span><span class="NLM_x">–</span> <span class="NLM_lpage">S11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2006&pages=S3-S11&author=D.+S.+Kauvarauthor=R.+Leferingauthor=C.+E.+Wade&title=Impact+of+hemorrhage+on+trauma+outcome%3A+an+overview+of+epidemiology%2C+clinical+presentations%2C+and+therapeutic+considerations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKauvar%26aufirst%3DD.%2BS.%26aulast%3DLefering%26aufirst%3DR.%26aulast%3DWade%26aufirst%3DC.%2BE.%26atitle%3DImpact%2520of%2520hemorrhage%2520on%2520trauma%2520outcome%253A%2520an%2520overview%2520of%2520epidemiology%252C%2520clinical%2520presentations%252C%2520and%2520therapeutic%2520considerations%26jtitle%3DJ.%2520Trauma%253A%2520Inj.%252C%2520Infect.%252C%2520Crit.%2520Care%26date%3D2006%26volume%3D60%26spage%3DS3%26epage%3DS11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis</span>.  <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span><span class="NLM_month">Mar</span><span class="NLM_day">26</span>,  <span class="NLM_volume">72</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span>)  <span class="NLM_fpage">585</span><span class="NLM_x">–</span> <span class="NLM_lpage">617</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=585-617&issue=5&author=P.+L.+McCormack&title=Tranexamic+acid%3A+a+review+of+its+use+in+the+treatment+of+hyperfibrinolysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DTranexamic%2520acid%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520treatment%2520of%2520hyperfibrinolysis%26jtitle%3DDrugs%26date%3D2012%26volume%3D72%26issue%3D5%26spage%3D585%26epage%3D617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Mannucci, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levi, M.</span><span> </span><span class="NLM_article-title">Prevention and treatment of major blood loss</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">2301</span><span class="NLM_x">–</span> <span class="NLM_lpage">2311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1056%2FNEJMra067742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=17538089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVKku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=2301-2311&author=P.+M.+Mannucciauthor=M.+Levi&title=Prevention+and+treatment+of+major+blood+loss"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention and treatment of major blood loss</span></div><div class="casAuthors">Mannucci, Pier Mannuccio; Levi, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2301-2311</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  In a medical setting, surgery is the most common cause of major blood loss, defined as a loss of 20% of total blood vol. or more.  In particular, cardiovascular procedures, liver transplantation and hepatic resections, and major orthopedic procedures including hip and knee replacement and spine surgery, are assocd. with severe bleeding.  The medications that have been most extensively evaluated as hemostatic agents include the antifibrinolytic lysine analogs aminocaproic acid and tranexamic acid; aprotinin, a bovine-derived protease inhibitor; and desmopressin, a synthetic analog of the antidiuretic hormone that raises the plasma levels of factor VIII and von Willebrand factor.  In addn., recombinant activated factor VII appears to be efficacious in an array of clin. situations assocd. with severe hemorrhage.  The authors review the therapeutic benefits of hemostatic drugs and consider the risk of adverse events.  In particular, the authors consider thrombotic complications, which constitute a major concern when agents that potentiate hemostasis are administered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGparywhZH_RD7Vg90H21EOLACvtfcHk0lgOBgOA-8z-Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVKku7Y%253D&md5=b8d5b6f843deb7a5ee51f4988fa35276</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMra067742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra067742%26sid%3Dliteratum%253Aachs%26aulast%3DMannucci%26aufirst%3DP.%2BM.%26aulast%3DLevi%26aufirst%3DM.%26atitle%3DPrevention%2520and%2520treatment%2520of%2520major%2520blood%2520loss%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D2301%26epage%3D2311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettersen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evertsson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pahlén, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonforsen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plowright, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boström, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fex, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thelin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgendorf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlund, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindberg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafsson, D.</span><span> </span><span class="NLM_article-title">Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein–Protein Interaction</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">538</span><span class="NLM_x">–</span> <span class="NLM_lpage">543</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml400526d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=538-543&author=L.+Chengauthor=D.+Pettersenauthor=B.+Ohlssonauthor=P.+Schellauthor=M.+Karleauthor=E.+Evertssonauthor=S.+Pahl%C3%A9nauthor=M.+Jonforsenauthor=A.+T.+Plowrightauthor=J.+Bostr%C3%B6mauthor=T.+Fexauthor=A.+Thelinauthor=C.+Hilgendorfauthor=Y.+Xueauthor=G.+Wahlundauthor=W.+Lindbergauthor=L.+O.+Larssonauthor=D.+Gustafsson&title=Discovery+of+the+Fibrinolysis+Inhibitor+AZD6564%2C+Acting+via+Interference+of+a+Protein%E2%80%93Protein+Interaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fml400526d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400526d%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DPettersen%26aufirst%3DD.%26aulast%3DOhlsson%26aufirst%3DB.%26aulast%3DSchell%26aufirst%3DP.%26aulast%3DKarle%26aufirst%3DM.%26aulast%3DEvertsson%26aufirst%3DE.%26aulast%3DPahl%25C3%25A9n%26aufirst%3DS.%26aulast%3DJonforsen%26aufirst%3DM.%26aulast%3DPlowright%26aufirst%3DA.%2BT.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26aulast%3DFex%26aufirst%3DT.%26aulast%3DThelin%26aufirst%3DA.%26aulast%3DHilgendorf%26aufirst%3DC.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DWahlund%26aufirst%3DG.%26aulast%3DLindberg%26aufirst%3DW.%26aulast%3DLarsson%26aufirst%3DL.%2BO.%26aulast%3DGustafsson%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520the%2520Fibrinolysis%2520Inhibitor%2520AZD6564%252C%2520Acting%2520via%2520Interference%2520of%2520a%2520Protein%25E2%2580%2593Protein%2520Interaction%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D538%26epage%3D543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Hochschwender, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laursen, R. A.</span><span> </span><span class="NLM_article-title">The lysine binding sites of human plasminogen</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">256</span><span class="NLM_x">, </span> <span class="NLM_fpage">11172</span><span class="NLM_x">–</span> <span class="NLM_lpage">11176</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1981&pages=11172-11176&author=S.+M.+Hochschwenderauthor=R.+A.+Laursen&title=The+lysine+binding+sites+of+human+plasminogen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHochschwender%26aufirst%3DS.%2BM.%26aulast%3DLaursen%26aufirst%3DR.%2BA.%26atitle%3DThe%2520lysine%2520binding%2520sites%2520of%2520human%2520plasminogen%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1981%26volume%3D256%26spage%3D11172%26epage%3D11176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Lecker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romaschin, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazer, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orser, B. A.</span><span> </span><span class="NLM_article-title">Tranexamic acid concentrations associated with human seizures inhibit glycine receptors</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">4654</span><span class="NLM_x">–</span> <span class="NLM_lpage">4666</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1172%2FJCI63375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=23187124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVakt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2012&pages=4654-4666&author=I.+Leckerauthor=D.+S.+Wangauthor=A.+D.+Romaschinauthor=M.+Petersonauthor=C.+D.+Mazerauthor=B.+A.+Orser&title=Tranexamic+acid+concentrations+associated+with+human+seizures+inhibit+glycine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tranexamic acid concentrations associated with human seizures inhibit glycine receptors</span></div><div class="casAuthors">Lecker, Irene; Wang, Dian-Shi; Romaschin, Alexander D.; Peterson, Mark; Mazer, C. David; Orser, Beverley A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4654-4666</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Antifibrinolytic drugs are widely used to reduce blood loss during surgery.  One serious adverse effect of these drugs is convulsive seizures; however, the mechanisms underlying such seizures remain poorly understood.  The antifibrinolytic drugs tranexamic acid (TXA) and ε-aminocaproic acid (EACA) are structurally similar to the inhibitory neurotransmitter glycine.  Since reduced function of glycine receptors causes seizures, we hypothesized that TXA and EACA inhibit the activity of glycine receptors.  Here we demonstrate that TXA and EACA are competitive antagonists of glycine receptors in mice.  We also showed that the general anesthetic isoflurane, and to a lesser extent propofol, reverses TXA inhibition of glycine receptor-mediated current, suggesting that these drugs could potentially be used to treat TXA-induced seizures.  Finally, we measured the concn. of TXA in the cerebrospinal fluid (CSF) of patients undergoing major cardiovascular surgery.  Surprisingly, peak TXA concn. in the CSF occurred after termination of drug infusion and in one patient coincided with the onset of seizures.  Collectively, these results show that concns. of TXA equiv. to those measured in the CSF of patients inhibited glycine receptors.  Furthermore, isoflurane or propofol may prevent or reverse TXA-induced seizures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog0xnAywntZ7Vg90H21EOLACvtfcHk0lgOBgOA-8z-Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVakt7fJ&md5=a5308863d129437b3c32a618ac77fcaa</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1172%2FJCI63375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI63375%26sid%3Dliteratum%253Aachs%26aulast%3DLecker%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DD.%2BS.%26aulast%3DRomaschin%26aufirst%3DA.%2BD.%26aulast%3DPeterson%26aufirst%3DM.%26aulast%3DMazer%26aufirst%3DC.%2BD.%26aulast%3DOrser%26aufirst%3DB.%2BA.%26atitle%3DTranexamic%2520acid%2520concentrations%2520associated%2520with%2520human%2520seizures%2520inhibit%2520glycine%2520receptors%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D122%26spage%3D4654%26epage%3D4666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">585</span><span class="NLM_x">–</span> <span class="NLM_lpage">617</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.2165%2F11209070-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=22397329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVOhsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=585-617&author=P.+L.+McCormack&title=Tranexamic+acid%3A+a+review+of+its+use+in+the+treatment+of+hyperfibrinolysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis</span></div><div class="casAuthors">McCormack, Paul L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">585-617</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Tranexamic acid, a synthetic deriv. of the amino acid lysine, is an antifibrinolytic agent that acts by binding to plasminogen and blocking the interaction of plasmin(ogen) with fibrin, thereby preventing dissoln. of the fibrin clot.  Tranexamic acid (Transamin) is indicated in Japan for use in certain conditions with abnormal bleeding or bleeding tendencies in which local or systemic hyperfibrinolysis is considered to be involved.  This article reviews the efficacy and tolerability of tranexamic acid in conditions amenable to antifibrinolytic therapy and briefly overviews the pharmacol. properties of the drug.  In large, randomized controlled trials, tranexamic acid generally significantly reduced perioperative blood loss compared with placebo in a variety of surgical procedures, including cardiac surgery with or without cardiopulmonary bypass, total hip and knee replacement and prostatectomy.  In many instances, tranexamic acid also reduced transfusion requirements assocd. with surgery.  It also reduced blood loss in gynaecol. bleeding disorders, such as heavy menstrual bleeding, postpartum hemorrhage and bleeding irregularities caused by contraceptive implants.  Tranexamic acid significantly reduced all-cause mortality and death due to bleeding in trauma patients with significant bleeding, particularly when administered early after injury.  It was also effective in traumatic hyphaema, gastrointestinal bleeding and hereditary angioneurotic edema.  While it reduces rebleeding in subarachnoid hemorrhage, it may increase ischemic complications.  Pharmacoeconomic analyses predicted that tranexamic acid use in surgery and trauma would be very cost effective and potentially life saving.  In direct comparisons with other marketed agents, tranexamic acid was at least as effective as ε-aminocaproic acid and more effective than desmopressin in surgical procedures.  It was more effective than desmopressin, etamsylate, flurbiprofen, mefenamic acid and norethisterone, but less effective than the levonorgestrel-releasing intra-uterine device in heavy menstrual bleeding and was as effective as prednisolone in traumatic hyphaema.  Tranexamic acid was generally well tolerated.  Most adverse events in clin. trials were of mild or moderate severity; severe or serious events were rare.  Therefore, while high-quality published evidence is limited for some approved indications, tranexamic acid is an effective and well tolerated antifibrinolytic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlJr4XyAhuZbVg90H21EOLACvtfcHk0lgBkBWNnJuAhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVOhsbs%253D&md5=7ec7b17f913eea281e7be0be28495574</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2165%2F11209070-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11209070-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DTranexamic%2520acid%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520treatment%2520of%2520hyperfibrinolysis%26jtitle%3DDrugs%26date%3D2012%26volume%3D72%26spage%3D585%26epage%3D617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shakur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bautista, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caballero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coats, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sayed, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogichaishvili, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iribhogbe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izurieta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khamis, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komolafe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrero, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mejía-Mantilla, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olaomi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olldashi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramana, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravi, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yutthakasemsunt, S.</span><span> </span><span class="NLM_article-title">Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=23-32&author=H.+Shakurauthor=I.+Robertsauthor=R.+Bautistaauthor=J.+Caballeroauthor=T.+Coatsauthor=Y.+Dewanauthor=H.+El-Sayedauthor=T.+Gogichaishviliauthor=S.+Guptaauthor=J.+Herreraauthor=B.+Huntauthor=P.+Iribhogbeauthor=M.+Izurietaauthor=H.+Khamisauthor=E.+Komolafeauthor=M.+A.+Marreroauthor=J.+Mej%C3%ADa-Mantillaauthor=J.+Mirandaauthor=C.+Moralesauthor=O.+Olaomiauthor=F.+Olldashiauthor=P.+Perelauthor=R.+Petoauthor=P.+V.+Ramanaauthor=R.+R.+Raviauthor=S.+Yutthakasemsunt&title=Effects+of+tranexamic+acid+on+death%2C+vascular+occlusive+events%2C+and+blood+transfusion+in+trauma+patients+with+significant+haemorrhage+%28CRASH-2%29%3A+a+randomised%2C+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShakur%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DI.%26aulast%3DBautista%26aufirst%3DR.%26aulast%3DCaballero%26aufirst%3DJ.%26aulast%3DCoats%26aufirst%3DT.%26aulast%3DDewan%26aufirst%3DY.%26aulast%3DEl-Sayed%26aufirst%3DH.%26aulast%3DGogichaishvili%26aufirst%3DT.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DHerrera%26aufirst%3DJ.%26aulast%3DHunt%26aufirst%3DB.%26aulast%3DIribhogbe%26aufirst%3DP.%26aulast%3DIzurieta%26aufirst%3DM.%26aulast%3DKhamis%26aufirst%3DH.%26aulast%3DKomolafe%26aufirst%3DE.%26aulast%3DMarrero%26aufirst%3DM.%2BA.%26aulast%3DMej%25C3%25ADa-Mantilla%26aufirst%3DJ.%26aulast%3DMiranda%26aufirst%3DJ.%26aulast%3DMorales%26aufirst%3DC.%26aulast%3DOlaomi%26aufirst%3DO.%26aulast%3DOlldashi%26aufirst%3DF.%26aulast%3DPerel%26aufirst%3DP.%26aulast%3DPeto%26aufirst%3DR.%26aulast%3DRamana%26aufirst%3DP.%2BV.%26aulast%3DRavi%26aufirst%3DR.%2BR.%26aulast%3DYutthakasemsunt%26aufirst%3DS.%26atitle%3DEffects%2520of%2520tranexamic%2520acid%2520on%2520death%252C%2520vascular%2520occlusive%2520events%252C%2520and%2520blood%2520transfusion%2520in%2520trauma%2520patients%2520with%2520significant%2520haemorrhage%2520%2528CRASH-2%2529%253A%2520a%2520randomised%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D23%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Ker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, I.</span><span> </span><span class="NLM_article-title">Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis</span> <span class="citation_source-journal">BMJ [Br. Med. J.]</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">e3054</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2012&pages=e3054&author=K.+Kerauthor=P.+Edwardsauthor=P.+Perelauthor=H.+Shakurauthor=I.+Roberts&title=Effect+of+tranexamic+acid+on+surgical+bleeding%3A+systematic+review+and+cumulative+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKer%26aufirst%3DK.%26aulast%3DEdwards%26aufirst%3DP.%26aulast%3DPerel%26aufirst%3DP.%26aulast%3DShakur%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DI.%26atitle%3DEffect%2520of%2520tranexamic%2520acid%2520on%2520surgical%2520bleeding%253A%2520systematic%2520review%2520and%2520cumulative%2520meta-analysis%26jtitle%3DBMJ%2520%255BBr.%2520Med.%2520J.%255D%26date%3D2012%26volume%3D344%26spage%3De3054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fergusson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hébert, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazer, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fremes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacAdams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murkin, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duke, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arellano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blajchman, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussières, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martineau, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robblee, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clinch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pretorius, R.</span><span> </span><span class="NLM_article-title">BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery</span> <span class="citation_source-journal">N. Engl J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">2319</span><span class="NLM_x">–</span> <span class="NLM_lpage">2331</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1056%2FNEJMoa0802395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=18480196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVOhs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=2319-2331&author=D.+A.+Fergussonauthor=P.+C.+H%C3%A9bertauthor=C.+D.+Mazerauthor=S.+Fremesauthor=C.+MacAdamsauthor=J.+M.+Murkinauthor=K.+Teohauthor=P.+C.+Dukeauthor=R.+Arellanoauthor=M.+A.+Blajchmanauthor=J.+S.+Bussi%C3%A8resauthor=D.+C%C3%B4t%C3%A9author=J.+Karskiauthor=R.+Martineauauthor=J.+A.+Robbleeauthor=M.+Rodgerauthor=G.+Wellsauthor=J.+Clinchauthor=R.+Pretorius&title=BART+Investigators.+A+comparison+of+aprotinin+and+lysine+analogues+in+high-risk+cardiac+surgery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of aprotinin and lysine analogues in high-risk cardiac surgery</span></div><div class="casAuthors">Fergusson, Dean A.; Hebert, Paul C.; Mazer, C. David; Fremes, Stephen; MacAdams, Charles; Murkin, John M.; Teoh, Kevin; Duke, Peter C.; Arellano, Ramiro; Blajchman, Morris A.; Bussieres, Jean S.; Cote, Dany; Karski, Jacek; Martineau, Raymond; Robblee, James A.; Rodger, Marc; Wells, George; Clinch, Jennifer; Pretorius, Roanda</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2319-2331</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Antifibrinolytic agents are commonly used during cardiac surgery to minimize bleeding and to reduce exposure to blood products.  We sought to det. whether aprotinin was superior to either tranexamic acid or aminocaproic acid in decreasing massive postoperative bleeding and other clin. important consequences.  Methods: In this multicenter, blinded trial, we randomly assigned 2331 high-risk cardiac surgical patients to one of three groups: 781 received aprotinin, 770 received tranexamic acid, and 780 received aminocaproic acid.  The primary outcome was massive postoperative bleeding.  Secondary outcomes included death from any cause at 30 days.  Results: The trial was terminated early because of a higher rate of death in patients receiving aprotinin.  A total of 74 patients (9.5%) in the aprotinin group had massive bleeding, as compared with 93 (12.1%) in the tranexamic acid group and 94 (12.1%) in the aminocaproic acid group (relative risk in the aprotinin group for both comparisons, 0.79; 95% confidence interval [CI], 0.59 to 1.05).  At 30 days, the rate of death from any cause was 6.0% in the aprotinin group, as compared with 3.9% in the tranexamic acid group (relative risk, 1.55; 95% CI, 0.99 to 2.42) and 4.0% in the aminocaproic acid group (relative risk, 1.52; 95% CI, 0.98 to 2.36).  The relative risk of death in the aprotinin group, as compared with that in both groups receiving lysine analogs, was 1.53 (95% CI, 1.06 to 2.22).  Conclusions: Despite the possibility of a modest redn. in the risk of massive bleeding, the strong and consistent neg. mortality trend assocd. with aprotinin, as compared with the lysine analogs, precludes its use in high-risk cardiac surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobzx5n_vlwt7Vg90H21EOLACvtfcHk0ljmpe1ySPPr2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVOhs74%253D&md5=8e2950a4ef6dd058bdc748eb2a3f27de</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0802395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0802395%26sid%3Dliteratum%253Aachs%26aulast%3DFergusson%26aufirst%3DD.%2BA.%26aulast%3DH%25C3%25A9bert%26aufirst%3DP.%2BC.%26aulast%3DMazer%26aufirst%3DC.%2BD.%26aulast%3DFremes%26aufirst%3DS.%26aulast%3DMacAdams%26aufirst%3DC.%26aulast%3DMurkin%26aufirst%3DJ.%2BM.%26aulast%3DTeoh%26aufirst%3DK.%26aulast%3DDuke%26aufirst%3DP.%2BC.%26aulast%3DArellano%26aufirst%3DR.%26aulast%3DBlajchman%26aufirst%3DM.%2BA.%26aulast%3DBussi%25C3%25A8res%26aufirst%3DJ.%2BS.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DD.%26aulast%3DKarski%26aufirst%3DJ.%26aulast%3DMartineau%26aufirst%3DR.%26aulast%3DRobblee%26aufirst%3DJ.%2BA.%26aulast%3DRodger%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DG.%26aulast%3DClinch%26aufirst%3DJ.%26aulast%3DPretorius%26aufirst%3DR.%26atitle%3DBART%2520Investigators.%2520A%2520comparison%2520of%2520aprotinin%2520and%2520lysine%2520analogues%2520in%2520high-risk%2520cardiac%2520surgery%26jtitle%3DN.%2520Engl%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D2319%26epage%3D2331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mangano, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudor, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietzel, C.</span><span> </span><span class="NLM_article-title">The risk associated with aprotinin in cardiac surgery</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">354</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1056%2FNEJMoa051379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=16436767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1yitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2006&pages=353-365&author=D.+T.+Manganoauthor=I.+C.+Tudorauthor=C.+Dietzel&title=The+risk+associated+with+aprotinin+in+cardiac+surgery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">The risk associated with aprotinin in cardiac surgery</span></div><div class="casAuthors">Mangano, Dennis T.; Tudor, Lulia C.; Dietzel, Cynthia</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-365</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The majority of patients undergoing surgical treatment for ST-elevation myocardial infarction receive antifibrinolytic therapy to limit blood loss.  This approach appears counterintuitive to the accepted medical treatment of the same condition - namely, fibrinolysis to limit thrombosis.  Despite this concern, no independent, large-scale safety assessment has been undertaken.  METHODS In this observational study involving 4374 patients undergoing revascularization, we prospectively assessed three agents (aprotinin [1295 patients], aminocaproic acid [883], and tranexamic acid [822]) as compared with no agent (1374 patients) with regard to serious outcomes by propensity and multivariable methods.  (Although aprotinin is a serine protease inhibitor, here we use the term antifibrinolytic therapy to include all three agents.) RESULTS In propensity-adjusted, multivariable logistic regression (C-index, 0.72), use of aprotinin was assocd. with a doubling in the risk of renal failure requiring dialysis among patients undergoing complex coronary-artery surgery (odds ratio, 2.59; 95 % confidence interval, 1.36 to 4.95) or primary surgery (odds ratio, 2.34; 95 % confidence interval, 1.27 to 4.31).  Similarly, use of aprotinin in the latter group was assocd. with a 55 % increase in the risk of myocardial infarction or heart failure (P < 0.001) and a 181 % increase in the risk of stroke or encephalopathy (P = 0.001).  Neither aminocaproic acid nor tranexamic acid was assocd. with an increased risk of renal, cardiac, or cerebral events.  Adjustment according to propensity score for the use of any one of the three agents as compared with no agent yielded nearly identical findings.  All the agents reduced blood loss.  CONCLUSIONS The assocn. between aprotinin and serious end-organ damage indicates that continued use is not prudent.  In contrast, the less expensive generic medications aminocaproic acid and tranexamic acid are safe alternatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk_HvNJKezFLVg90H21EOLACvtfcHk0ljmpe1ySPPr2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1yitw%253D%253D&md5=69529f9034301d12408aba2ab9dcb485</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa051379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa051379%26sid%3Dliteratum%253Aachs%26aulast%3DMangano%26aufirst%3DD.%2BT.%26aulast%3DTudor%26aufirst%3DI.%2BC.%26aulast%3DDietzel%26aufirst%3DC.%26atitle%3DThe%2520risk%2520associated%2520with%2520aprotinin%2520in%2520cardiac%2520surgery%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D354%26spage%3D353%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span>European Medicines Agency Recommends Lifting Suspension of Aprotinin; <span class="NLM_publisher-name">European Medicines Agency</span>, <span class="NLM_month">Feb</span><span class="NLM_day">17</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.ema.europa.eu/ema/pages/news_and_events/news/2012/02/news_detail_001447.jsp" class="extLink">http://www.ema.europa.eu/ema/pages/news_and_events/news/2012/02/news_detail_001447.jsp</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=European+Medicines+Agency+Recommends+Lifting+Suspension+of+Aprotinin%3B+European+Medicines+Agency%2C+Feb17%2C+2012%3B+http%3A%2F%2Fwww.ema.europa.eu%2Fema%2Fpages%2Fnews_and_events%2Fnews%2F2012%2F02%2Fnews_detail_001447.jsp."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Medicines%2520Agency%2520Recommends%2520Lifting%2520Suspension%2520of%2520Aprotinin%26pub%3DEuropean%2520Medicines%2520Agency%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Lijnen, H. R.</span><span> </span><span class="NLM_article-title">Matrix metalloproteinases and cellular fibrinolytic activity</span> <span class="citation_source-journal">Biochemistry (Moscow)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">92</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1023%2FA%3A1013908332232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=11841344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVSksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=92-98&author=H.+R.+Lijnen&title=Matrix+metalloproteinases+and+cellular+fibrinolytic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinases and cellular fibrinolytic activity</span></div><div class="casAuthors">Lijnen, H. R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry (Moscow, Russian Federation)(Translation of Biokhimiya (Moscow, Russian Federation))</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">92-98</span>CODEN:
                <span class="NLM_cas:coden">BIORAK</span>;
        ISSN:<span class="NLM_cas:issn">0006-2979</span>.
    
            (<span class="NLM_cas:orgname">MAIK Nauka/Interperiodica Publishing</span>)
        </div><div class="casAbstract">A review with 51 refs.  Several mol. interactions between the matrix metalloproteinase (MMP) and the plasminogen/plasmin (fibrinolytic) system may affect cellular fibrinolysis.  MMP-3 (stromelysin-1) specifically hydrolyzes urokinase (u-PA), yielding a 17-kDa N-terminal fragment contg. the functionally intact receptor (u-PAR)-binding sequence and a 32-kDa C-terminal fragment contg. the intact serine proteinase domain.  MMP-3 generates an angiostatin-like fragment (contg. kringles 1-4 with the cellular binding domains) from plasminogen.  Treatment with MMP-3 of monocytoid THP-1 cells satd. with bound plasminogen, results in a dose-dependent redn. of the amt. of u-PA-activatable plasminogen.  Treatment with MMP-3 of cell-bound u-PA, in contrast, does not alter cell-assocd. u-PA activity.  These data thus indicate that MMP-3 may down-regulate cell-assocd. plasmin activity by decreasing the amt. of activatible plasminogen, without affecting cell-bound u-PA activity.  MMP-3 also specifically interacts with the main inhibitors of the fibrinolytic system.  Thus, MMP-3 specifically hydrolyzes human α2-antiplasmin (α2-AP), the main physiol. plasmin inhibitor.  α2-AP cleaved by MMP-3 no longer forms a stable complex with plasmin and no longer interacts with plasminogen.  Cleavage and inactivation of α2-AP by MMP-3 may constitute a mechanism favoring local plasmin-mediated proteolysis.  Furthermore, MMP-3 specifically hydrolyzes and inactivates human plasminogen activator inhibitor-1 (PAI-1).  Stable PAI-1 bound to vitronectin is cleaved and inactivated by MMP-3 in a comparable manner as free PAI-1; the cleaved protein, however, does not bind to vitronectin.  Cleavage and inactivation of PAI-1 by MMP-3 may thus constitute a mechanism decreasing the antiproteolytic activity of PAI-1 and impairing the potential inhibitory effect of vitronectin-bound PAI-1 on cell adhesion and/or migration.  These mol. interactions of MMP-3 with enzymes, substrates and inhibitors of the fibrinolytic system may thus play a role in the regulation of (cellular) fibrinolysis.  Furthermore, the temporal and topog. expression pattern of MMP components, as well as studies in gene-deficient mice, suggest a functional role in neointima formation after vascular injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh4KTQowH26bVg90H21EOLACvtfcHk0ljmpe1ySPPr2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVSksL4%253D&md5=d69319d37b3c978edf8675270dfc0931</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1023%2FA%3A1013908332232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1013908332232%26sid%3Dliteratum%253Aachs%26aulast%3DLijnen%26aufirst%3DH.%2BR.%26atitle%3DMatrix%2520metalloproteinases%2520and%2520cellular%2520fibrinolytic%2520activity%26jtitle%3DBiochemistry%2520%2528Moscow%2529%26date%3D2002%26volume%3D67%26spage%3D92%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Orbe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrenetxe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivien, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orset, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birkland, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purroy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez de Lizarrondo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angles-Cano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Páramo, J. A.</span><span> </span><span class="NLM_article-title">Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">2909</span><span class="NLM_x">–</span> <span class="NLM_lpage">2919</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2011&pages=2909-2919&author=J.+Orbeauthor=J.+Barrenetxeauthor=J.+A.+Rodriguezauthor=D.+Vivienauthor=C.+Orsetauthor=W.+C.+Parksauthor=T.+P.+Birklandauthor=R.+Serranoauthor=A.+Purroyauthor=S.+Martinez+de+Lizarrondoauthor=E.+Angles-Canoauthor=J.+A.+P%C3%A1ramo&title=Matrix+metalloproteinase-10+effectively+reduces+infarct+size+in+experimental+stroke+by+enhancing+fibrinolysis+via+a+thrombin-activatable+fibrinolysis+inhibitor-mediated+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrbe%26aufirst%3DJ.%26aulast%3DBarrenetxe%26aufirst%3DJ.%26aulast%3DRodriguez%26aufirst%3DJ.%2BA.%26aulast%3DVivien%26aufirst%3DD.%26aulast%3DOrset%26aufirst%3DC.%26aulast%3DParks%26aufirst%3DW.%2BC.%26aulast%3DBirkland%26aufirst%3DT.%2BP.%26aulast%3DSerrano%26aufirst%3DR.%26aulast%3DPurroy%26aufirst%3DA.%26aulast%3DMartinez%2Bde%2BLizarrondo%26aufirst%3DS.%26aulast%3DAngles-Cano%26aufirst%3DE.%26aulast%3DP%25C3%25A1ramo%26aufirst%3DJ.%2BA.%26atitle%3DMatrix%2520metalloproteinase-10%2520effectively%2520reduces%2520infarct%2520size%2520in%2520experimental%2520stroke%2520by%2520enhancing%2520fibrinolysis%2520via%2520a%2520thrombin-activatable%2520fibrinolysis%2520inhibitor-mediated%2520mechanism%26jtitle%3DCirculation%26date%3D2011%26volume%3D124%26spage%3D2909%26epage%3D2919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Xue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zygun, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demchuk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, V. W.</span><span> </span><span class="NLM_article-title">Contributions of multiple proteases to neurotoxicity in a mouse model of intracerebral haemorrhage</span> <span class="citation_source-journal">Brain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2009&pages=26-36&author=M.+Xueauthor=Y.+Fanauthor=S.+Liuauthor=D.+A.+Zygunauthor=A.+Demchukauthor=V.+W.+Yong&title=Contributions+of+multiple+proteases+to+neurotoxicity+in+a+mouse+model+of+intracerebral+haemorrhage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZygun%26aufirst%3DD.%2BA.%26aulast%3DDemchuk%26aufirst%3DA.%26aulast%3DYong%26aufirst%3DV.%2BW.%26atitle%3DContributions%2520of%2520multiple%2520proteases%2520to%2520neurotoxicity%2520in%2520a%2520mouse%2520model%2520of%2520intracerebral%2520haemorrhage%26jtitle%3DBrain%26date%3D2009%26volume%3D132%26spage%3D26%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Coussens, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fingleton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matrisian, L. M.</span><span> </span><span class="NLM_article-title">Matrix metalloproteinase inhibitors and cancer: trials and tribulations</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">2387</span><span class="NLM_x">–</span> <span class="NLM_lpage">2392</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1126%2Fscience.1067100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=11923519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BD38XisFSmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2002&pages=2387-2392&author=L.+M.+Coussensauthor=B.+Fingletonauthor=L.+M.+Matrisian&title=Matrix+metalloproteinase+inhibitors+and+cancer%3A+trials+and+tribulations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer therapy: matrix metalloproteinase inhibitors and cancer: trials and tribulations</span></div><div class="casAuthors">Coussens, Lisa M.; Fingleton, Barbara; Matrisian, Lynn M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">5564</span>),
    <span class="NLM_cas:pages">2387-2392</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  For at least 30 yr, matrix metalloproteinases (MMPs) have been heralded as promising targets for cancer therapy on the basis of their massive up-regulation in malignant tissues and their unique ability to degrade all components of the extracellular matrix.  Preclin. studies testing the efficacy of MMP suppression in tumor models were so compelling that synthetic metalloproteinase inhibitors (MPI) were rapidly developed and routed into human clin. trials.  The results of these trials have been disappointing.  Here we review the studies that brought MPI into clin. testing and discuss the design and outcome of the trials in light of new information about the cellular source, substrates, and mode of action of MMPs at different stages of tumor progression.  The important lessons learned from the MPI experience may be of great value for future studies of MPI and for cancer drug development in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquzqvwAiv5frVg90H21EOLACvtfcHk0ljF7SIdlVEymw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisFSmtb0%253D&md5=be0d4cfc46c6c451a2374e3545cb4ec6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscience.1067100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1067100%26sid%3Dliteratum%253Aachs%26aulast%3DCoussens%26aufirst%3DL.%2BM.%26aulast%3DFingleton%26aufirst%3DB.%26aulast%3DMatrisian%26aufirst%3DL.%2BM.%26atitle%3DMatrix%2520metalloproteinase%2520inhibitors%2520and%2520cancer%253A%2520trials%2520and%2520tribulations%26jtitle%3DScience%26date%3D2002%26volume%3D295%26spage%3D2387%26epage%3D2392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Krzeski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckland-Wright, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bálint, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cline, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beary, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aronstein, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spector, T. D.</span><span> </span><span class="NLM_article-title">Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">R109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=R109&author=P.+Krzeskiauthor=C.+Buckland-Wrightauthor=G.+B%C3%A1lintauthor=G.+A.+Clineauthor=K.+Stonerauthor=R.+Lyonauthor=J.+Bearyauthor=W.+S.+Aronsteinauthor=T.+D.+Spector&title=Development+of+musculoskeletal+toxicity+without+clear+benefit+after+administration+of+PG-116800%2C+a+matrix+metalloproteinase+inhibitor%2C+to+patients+with+knee+osteoarthritis%3A+a+randomized%2C+12-month%2C+double-blind%2C+placebo-controlled+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrzeski%26aufirst%3DP.%26aulast%3DBuckland-Wright%26aufirst%3DC.%26aulast%3DB%25C3%25A1lint%26aufirst%3DG.%26aulast%3DCline%26aufirst%3DG.%2BA.%26aulast%3DStoner%26aufirst%3DK.%26aulast%3DLyon%26aufirst%3DR.%26aulast%3DBeary%26aufirst%3DJ.%26aulast%3DAronstein%26aufirst%3DW.%2BS.%26aulast%3DSpector%26aufirst%3DT.%2BD.%26atitle%3DDevelopment%2520of%2520musculoskeletal%2520toxicity%2520without%2520clear%2520benefit%2520after%2520administration%2520of%2520PG-116800%252C%2520a%2520matrix%2520metalloproteinase%2520inhibitor%252C%2520to%2520patients%2520with%2520knee%2520osteoarthritis%253A%2520a%2520randomized%252C%252012-month%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2007%26volume%3D9%26spage%3DR109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Vandenbroucke, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libert, C.</span><span> </span><span class="NLM_article-title">Is there new hope for therapeutic matrix metalloproteinase inhibition?</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">904</span><span class="NLM_x">–</span> <span class="NLM_lpage">927</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=904-927&author=R.+E.+Vandenbrouckeauthor=C.+Libert&title=Is+there+new+hope+for+therapeutic+matrix+metalloproteinase+inhibition%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVandenbroucke%26aufirst%3DR.%2BE.%26aulast%3DLibert%26aufirst%3DC.%26atitle%3DIs%2520there%2520new%2520hope%2520for%2520therapeutic%2520matrix%2520metalloproteinase%2520inhibition%253F%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D904%26epage%3D927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Orbe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez-Arias, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salicio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belzunce, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugarte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H. C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabal, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paramo, J. A.</span><span> </span><span class="NLM_article-title">Discovery and safety profiling of a potent pre-clinical candidate, (4-[4-[[(3<i>R</i>)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-<i>N</i>-methyl-benzamide) (CM-352), for the prevention and treatment of hemorrhage</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1021/jm501939z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501939z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Orbeauthor=J.+A.+Rodriguezauthor=J.+A.+Sanchez-Ariasauthor=A.+Salicioauthor=M.+Belzunceauthor=A.+Ugarteauthor=H.+C.+Y.+Changauthor=O.+Rabalauthor=J.+Oyarzabalauthor=J.+A.+Paramo&title=Discovery+and+safety+profiling+of+a+potent+pre-clinical+candidate%2C+%284-%5B4-%5B%5B%283R%29-3-%28hydroxycarbamoyl%29-8-azaspiro%5B4.5%5Ddecan-3-yl%5Dsulfonyl%5Dphenoxy%5D-N-methyl-benzamide%29+%28CM-352%29%2C+for+the+prevention+and+treatment+of+hemorrhage&doi=10.1021%2Fjm501939z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm501939z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501939z%26sid%3Dliteratum%253Aachs%26aulast%3DOrbe%26aufirst%3DJ.%26aulast%3DRodriguez%26aufirst%3DJ.%2BA.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DSalicio%26aufirst%3DA.%26aulast%3DBelzunce%26aufirst%3DM.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DH.%2BC.%2BY.%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DParamo%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520and%2520safety%2520profiling%2520of%2520a%2520potent%2520pre-clinical%2520candidate%252C%2520%25284-%255B4-%255B%255B%25283R%2529-3-%2528hydroxycarbamoyl%2529-8-azaspiro%255B4.5%255Ddecan-3-yl%255Dsulfonyl%255Dphenoxy%255D-N-methyl-benzamide%2529%2520%2528CM-352%2529%252C%2520for%2520the%2520prevention%2520and%2520treatment%2520of%2520hemorrhage%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26doi%3D10.1021%2Fjm501939z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Lund, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bugge, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frandsen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degen, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dano, K.</span><span> </span><span class="NLM_article-title">Functional overlap between two classes of matrix-degrading proteases in wound healing</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4645</span><span class="NLM_x">–</span> <span class="NLM_lpage">4656</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=4645-4656&author=L.+R.+Lundauthor=J.+Romerauthor=T.+H.+Buggeauthor=B.+L.+Nielsenauthor=T.+L.+Frandsenauthor=J.+L.+Degenauthor=R.+W.+Stephensauthor=K.+Dano&title=Functional+overlap+between+two+classes+of+matrix-degrading+proteases+in+wound+healing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLund%26aufirst%3DL.%2BR.%26aulast%3DRomer%26aufirst%3DJ.%26aulast%3DBugge%26aufirst%3DT.%2BH.%26aulast%3DNielsen%26aufirst%3DB.%2BL.%26aulast%3DFrandsen%26aufirst%3DT.%2BL.%26aulast%3DDegen%26aufirst%3DJ.%2BL.%26aulast%3DStephens%26aufirst%3DR.%2BW.%26aulast%3DDano%26aufirst%3DK.%26atitle%3DFunctional%2520overlap%2520between%2520two%2520classes%2520of%2520matrix-degrading%2520proteases%2520in%2520wound%2520healing%26jtitle%3DEMBO%2520J.%26date%3D1999%26volume%3D18%26spage%3D4645%26epage%3D4656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Yadav, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, V. M.</span><span> </span><span class="NLM_article-title">Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1704</span><span class="NLM_x">–</span> <span class="NLM_lpage">1722</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.2174%2F092986711795471329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=21428880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslOiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1704-1722&author=R.+K.+Yadavauthor=S.+P.+Guptaauthor=P.+K.+Sharmaauthor=V.+M.+Patil&title=Recent+advances+in+studies+on+hydroxamates+as+matrix+metalloproteinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review</span></div><div class="casAuthors">Yadav, R. K.; Gupta, S. P.; Sharma, P. K.; Patil, V. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1704-1722</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs) are a large family of calcium-dependent zinc- contg. endopeptidases, which are responsible for the tissue remodeling and degrdn. of the extracellular matrix (ECM), including collagens, elastins, gelatin, matrix glycoproteins, and proteoglycan.  The inappropriate expression of these MMPs constitutes part of the pathogenic mechanism in several diseases, therefore they are subject to inhibition.  They can be inhibited by endogenous proteinase inhibitors such as 2-macroglobulin or by the family of tissue inhibitors of metalloproteinases (TIMPs), which are glycoproteins of mol. wt. 21-30 kDa, consisting of 184-194 amino acid residues.  Recently, many different classes of synthetic inhibitors have been developed in which the hydroxamic acidbased class of compds. (hydroxamates) have been most widely studied, as their hydroxamic acid group (CONHOH) enables them to act as a bidentate ligand with the zinc ion present in MMPs, leading to much stronger interaction with the receptor as compared to any other class of inhibitors.  The present review describes in detail the recent development on this class of MMP inihibitors.  Compds. like 12,17e, f, g and h, 45j, 45k, 50f, 62a, 63a, and 63b have been reported to be highly promising for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_CdMJAf2dWbVg90H21EOLACvtfcHk0ljZ60QeSWZb0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslOiu7c%253D&md5=a9a615faba9fca05433b6e2a452e2e56</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F092986711795471329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795471329%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DR.%2BK.%26aulast%3DGupta%26aufirst%3DS.%2BP.%26aulast%3DSharma%26aufirst%3DP.%2BK.%26aulast%3DPatil%26aufirst%3DV.%2BM.%26atitle%3DRecent%2520advances%2520in%2520studies%2520on%2520hydroxamates%2520as%2520matrix%2520metalloproteinase%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D1704%26epage%3D1722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Becker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villamil, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barta, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedell, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCrescenzo, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freskos, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getman, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heintz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carron, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munie, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swearingen, C. A.</span><span> </span><span class="NLM_article-title">Synthesis and Structure–Activity Relationships of β- and α-Piperidine Sulfone Hydroxamic Acid Matrix Metalloproteinase Inhibitors with Oral Antitumor Efficacy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6713</span><span class="NLM_x">–</span> <span class="NLM_lpage">6730</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0500875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6713-6730&author=D.+P.+Beckerauthor=C.+I.+Villamilauthor=T.+E.+Bartaauthor=L.+J.+Bedellauthor=T.+L.+Boehmauthor=G.+A.+DeCrescenzoauthor=J.+N.+Freskosauthor=D.+P.+Getmanauthor=S.+Hockermanauthor=R.+Heintzauthor=S.+C.+Howardauthor=M.+H.+Liauthor=J.+J.+McDonaldauthor=C.+P.+Carronauthor=C.+L.+Funckes-Shippyauthor=P.+P.+Mehtaauthor=G.+E.+Munieauthor=C.+A.+Swearingen&title=Synthesis+and+Structure%E2%80%93Activity+Relationships+of+%CE%B2-+and+%CE%B1-Piperidine+Sulfone+Hydroxamic+Acid+Matrix+Metalloproteinase+Inhibitors+with+Oral+Antitumor+Efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Fjm0500875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0500875%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DD.%2BP.%26aulast%3DVillamil%26aufirst%3DC.%2BI.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DBedell%26aufirst%3DL.%2BJ.%26aulast%3DBoehm%26aufirst%3DT.%2BL.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DFreskos%26aufirst%3DJ.%2BN.%26aulast%3DGetman%26aufirst%3DD.%2BP.%26aulast%3DHockerman%26aufirst%3DS.%26aulast%3DHeintz%26aufirst%3DR.%26aulast%3DHoward%26aufirst%3DS.%2BC.%26aulast%3DLi%26aufirst%3DM.%2BH.%26aulast%3DMcDonald%26aufirst%3DJ.%2BJ.%26aulast%3DCarron%26aufirst%3DC.%2BP.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DMehta%26aufirst%3DP.%2BP.%26aulast%3DMunie%26aufirst%3DG.%2BE.%26aulast%3DSwearingen%26aufirst%3DC.%2BA.%26atitle%3DSynthesis%2520and%2520Structure%25E2%2580%2593Activity%2520Relationships%2520of%2520%25CE%25B2-%2520and%2520%25CE%25B1-Piperidine%2520Sulfone%2520Hydroxamic%2520Acid%2520Matrix%2520Metalloproteinase%2520Inhibitors%2520with%2520Oral%2520Antitumor%2520Efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6713%26epage%3D6730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Becker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barta, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedell, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carron, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCrescenzo, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easton, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freskos, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathis, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munie, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swearingen, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villamil, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, J.</span><span> </span><span class="NLM_article-title">Orally Active MMP-1 Sparing α-Tetrahydropyranyl and α-Piperidinyl Sulfone Matrix Metalloproteinase (MMP) Inhibitors with Efficacy in Cancer, Arthritis, and Cardiovascular Disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6653</span><span class="NLM_x">–</span> <span class="NLM_lpage">6680</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100669j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGjtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6653-6680&author=D.+P.+Beckerauthor=T.+E.+Bartaauthor=L.+J.+Bedellauthor=T.+L.+Boehmauthor=B.+R.+Bondauthor=J.+Carrollauthor=C.+P.+Carronauthor=G.+A.+DeCrescenzoauthor=A.+M.+Eastonauthor=J.+N.+Freskosauthor=C.+L.+Funckes-Shippyauthor=M.+Heronauthor=S.+Hockermanauthor=C.+P.+Howardauthor=J.+R.+Kieferauthor=M.+H.+Liauthor=K.+J.+Mathisauthor=J.+J.+McDonaldauthor=P.+P.+Mehtaauthor=G.+E.+Munieauthor=T.+Sunyerauthor=C.+A.+Swearingenauthor=C.+I.+Villamilauthor=D.+Welschauthor=J.+M.+Williamsauthor=Y.+Yuauthor=J.+Yao&title=Orally+Active+MMP-1+Sparing+%CE%B1-Tetrahydropyranyl+and+%CE%B1-Piperidinyl+Sulfone+Matrix+Metalloproteinase+%28MMP%29+Inhibitors+with+Efficacy+in+Cancer%2C+Arthritis%2C+and+Cardiovascular+Disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Active MMP-1 Sparing α-Tetrahydropyranyl and α-Piperidinyl Sulfone Matrix Metalloproteinase (MMP) Inhibitors with Efficacy in Cancer, Arthritis, and Cardiovascular Disease</span></div><div class="casAuthors">Becker, Daniel P.; Barta, Thomas E.; Bedell, Louis J.; Boehm, Terri L.; Bond, Brian R.; Carroll, Jeffery; Carron, Chris P.; De Crescenzo, Gary A.; Easton, Alan M.; Freskos, John N.; Funckes-Shippy, Chris L.; Heron, Marcia; Hockerman, Susan; Howard, Carol Pearcy; Kiefer, James R.; Li, Madeleine H.; Mathis, Karl J.; McDonald, Joseph J.; Mehta, Pramod P.; Munie, Grace E.; Sunyer, Teresa; Swearingen, Craig A.; Villamil, Clara I.; Welsch, Dean; Williams, Jennifer M.; Yu, Ying; Yao, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6653-6680</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-hydroxy aryloxyarylsulfonyl pyrancarboxamides and piperidinecarboxamides such as I (R = MeOCH2CH2, cyclopropyl) are prepd. as selective matrix metalloproteinase (MMP) inhibitors avoiding nonselective MMP (in particular, MMP-1) inhibition for use as antitumor, antiarthritic, and cardiovascular agents.  The inhibition of MMPs 1, 2, 3, 7, 8, 9, 13, and 14 by N-hydroxy aryloxyarylsulfonyl pyrancarboxamides and piperidinecarboxamides is detd. as well as their calcd. lipophilicities; the pharmacokinetics, inhibition of human prostate, breast, and lung cancer cells, inhibition of cartilage degrdn., inhibition of ventricular dilation after myocardial infarction, and DSC calorimetric measurements for selected compds. are detd.  I (R = MeOCH2CH2) (SC-78080/SD-2590) was selected for development as an anticancer agent, while I (R = cyclopropyl) and an N-hydroxy trifluoromethylphenoxyphenylsulfonyl pyrancarboxamide were selected as backup compds.  The structure of I (R = MeOCH2CH2) bound to MMP-13 is detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY0b9GTt27EbVg90H21EOLACvtfcHk0ljGGaJD4uAW_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGjtbnJ&md5=0ee6c0fea7d5e86ff75095615dac8ec6</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fjm100669j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100669j%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DD.%2BP.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DBedell%26aufirst%3DL.%2BJ.%26aulast%3DBoehm%26aufirst%3DT.%2BL.%26aulast%3DBond%26aufirst%3DB.%2BR.%26aulast%3DCarroll%26aufirst%3DJ.%26aulast%3DCarron%26aufirst%3DC.%2BP.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DEaston%26aufirst%3DA.%2BM.%26aulast%3DFreskos%26aufirst%3DJ.%2BN.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DHeron%26aufirst%3DM.%26aulast%3DHockerman%26aufirst%3DS.%26aulast%3DHoward%26aufirst%3DC.%2BP.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DM.%2BH.%26aulast%3DMathis%26aufirst%3DK.%2BJ.%26aulast%3DMcDonald%26aufirst%3DJ.%2BJ.%26aulast%3DMehta%26aufirst%3DP.%2BP.%26aulast%3DMunie%26aufirst%3DG.%2BE.%26aulast%3DSunyer%26aufirst%3DT.%26aulast%3DSwearingen%26aufirst%3DC.%2BA.%26aulast%3DVillamil%26aufirst%3DC.%2BI.%26aulast%3DWelsch%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DJ.%26atitle%3DOrally%2520Active%2520MMP-1%2520Sparing%2520%25CE%25B1-Tetrahydropyranyl%2520and%2520%25CE%25B1-Piperidinyl%2520Sulfone%2520Matrix%2520Metalloproteinase%2520%2528MMP%2529%2520Inhibitors%2520with%2520Efficacy%2520in%2520Cancer%252C%2520Arthritis%252C%2520and%2520Cardiovascular%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6653%26epage%3D6680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Lollini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eugui, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womble, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J.</span><span> </span><span class="NLM_article-title">Disease modification by RS-130830, a collagenase-3 selective inhibitor, in experimental osteoarthritis (OA)</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">S87</span><div class="note"><p class="first last">abstract 341</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=S87&issue=Suppl&author=L.+Lolliniauthor=J.+Hallerauthor=E.+M.+Euguiauthor=S.+W.+Wombleauthor=R.+Martinauthor=J.+Campbell&title=Disease+modification+by+RS-130830%2C+a+collagenase-3+selective+inhibitor%2C+in+experimental+osteoarthritis+%28OA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLollini%26aufirst%3DL.%26aulast%3DHaller%26aufirst%3DJ.%26aulast%3DEugui%26aufirst%3DE.%2BM.%26aulast%3DWomble%26aufirst%3DS.%2BW.%26aulast%3DMartin%26aufirst%3DR.%26aulast%3DCampbell%26aufirst%3DJ.%26atitle%3DDisease%2520modification%2520by%2520RS-130830%252C%2520a%2520collagenase-3%2520selective%2520inhibitor%252C%2520in%2520experimental%2520osteoarthritis%2520%2528OA%2529%26jtitle%3DArthritis%2520Rheum.%26date%3D1997%26volume%3D40%26issue%3DSuppl%26spage%3DS87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Aranapakam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosu, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingboe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandanayaka, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skotnicki, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiJoseph, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharr, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Killar, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowling, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tillett, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDevitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z. B.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2376</span><span class="NLM_x">–</span> <span class="NLM_lpage">2396</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0205550" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2376-2396&author=V.+Aranapakamauthor=J.+M.+Davisauthor=G.+T.+Grosuauthor=J.+Bakerauthor=J.+Ellingboeauthor=A.+Zaskauthor=J.+I.+Levinauthor=V.+P.+Sandanayakaauthor=M.+Duauthor=J.+S.+Skotnickiauthor=J.+F.+DiJosephauthor=A.+Sungauthor=M.+A.+Sharrauthor=L.+M.+Killarauthor=T.+Walterauthor=G.+Jinauthor=R.+Cowlingauthor=J.+Tillettauthor=W.+Zhaoauthor=J.+McDevittauthor=Z.+B.+Xu&title=Synthesis+and+structure-activity+relationship+of+N-substituted+4-arylsulfonylpiperidine-4-hydroxamic+acids+as+novel%2C+orally+active+matrix+metalloproteinase+inhibitors+for+the+treatment+of+osteoarthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm0205550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0205550%26sid%3Dliteratum%253Aachs%26aulast%3DAranapakam%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26aulast%3DGrosu%26aufirst%3DG.%2BT.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DEllingboe%26aufirst%3DJ.%26aulast%3DZask%26aufirst%3DA.%26aulast%3DLevin%26aufirst%3DJ.%2BI.%26aulast%3DSandanayaka%26aufirst%3DV.%2BP.%26aulast%3DDu%26aufirst%3DM.%26aulast%3DSkotnicki%26aufirst%3DJ.%2BS.%26aulast%3DDiJoseph%26aufirst%3DJ.%2BF.%26aulast%3DSung%26aufirst%3DA.%26aulast%3DSharr%26aufirst%3DM.%2BA.%26aulast%3DKillar%26aufirst%3DL.%2BM.%26aulast%3DWalter%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DG.%26aulast%3DCowling%26aufirst%3DR.%26aulast%3DTillett%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DMcDevitt%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%2BB.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520of%2520N-substituted%25204-arylsulfonylpiperidine-4-hydroxamic%2520acids%2520as%2520novel%252C%2520orally%2520active%2520matrix%2520metalloproteinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520osteoarthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2376%26epage%3D2396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandanayaka, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, J. I.</span><span> </span><span class="NLM_article-title">Synthesis and activity of quinolinylmethyl P1′ alpha-sulfone piperidine hydroxamate inhibitors of TACE</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3445</span><span class="NLM_x">–</span> <span class="NLM_lpage">3348</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3445-3348&author=C.+Zhangauthor=F.+Loveringauthor=M.+Behnkeauthor=A.+Zaskauthor=V.+Sandanayakaauthor=L.+Sunauthor=Y.+Zhuauthor=W.+Xuauthor=Y.+Zhangauthor=J.+I.+Levin&title=Synthesis+and+activity+of+quinolinylmethyl+P1%E2%80%B2+alpha-sulfone+piperidine+hydroxamate+inhibitors+of+TACE"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBehnke%26aufirst%3DM.%26aulast%3DZask%26aufirst%3DA.%26aulast%3DSandanayaka%26aufirst%3DV.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLevin%26aufirst%3DJ.%2BI.%26atitle%3DSynthesis%2520and%2520activity%2520of%2520quinolinylmethyl%2520P1%25E2%2580%25B2%2520alpha-sulfone%2520piperidine%2520hydroxamate%2520inhibitors%2520of%2520TACE%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3445%26epage%3D3348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pikul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almstead, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natchus, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anastasio, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhail, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snider, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taiwo, Y. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunaway, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mieling, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janusz, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang-Weigand, S.</span><span> </span><span class="NLM_article-title">Design and synthesis of piperazine-based matrix metalloproteinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">380</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990366q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=369-380&author=M.+Chengauthor=B.+Deauthor=S.+Pikulauthor=N.+G.+Almsteadauthor=M.+G.+Natchusauthor=M.+V.+Anastasioauthor=S.+J.+McPhailauthor=C.+E.+Sniderauthor=Y.+O.+Taiwoauthor=L.+Chenauthor=C.+M.+Dunawayauthor=F.+Guauthor=M.+E.+Dowtyauthor=G.+E.+Mielingauthor=M.+J.+Januszauthor=S.+Wang-Weigand&title=Design+and+synthesis+of+piperazine-based+matrix+metalloproteinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm990366q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990366q%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDe%26aufirst%3DB.%26aulast%3DPikul%26aufirst%3DS.%26aulast%3DAlmstead%26aufirst%3DN.%2BG.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DAnastasio%26aufirst%3DM.%2BV.%26aulast%3DMcPhail%26aufirst%3DS.%2BJ.%26aulast%3DSnider%26aufirst%3DC.%2BE.%26aulast%3DTaiwo%26aufirst%3DY.%2BO.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDunaway%26aufirst%3DC.%2BM.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DMieling%26aufirst%3DG.%2BE.%26aulast%3DJanusz%26aufirst%3DM.%2BJ.%26aulast%3DWang-Weigand%26aufirst%3DS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520piperazine-based%2520matrix%2520metalloproteinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D369%26epage%3D380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span> <span class="citation_source-book">The Practice of Medicinal Chemistry</span>; <span class="NLM_contrib-group">Wermuth, C. G.</span>, Ed.; <span class="NLM_publisher-name">Elsevier Academic Press</span>: <span class="NLM_publisher-loc">San Diego</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=C.+G.+Wermuth&title=The+Practice+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThe%2520Practice%2520of%2520Medicinal%2520Chemistry%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26pub%3DElsevier%2520Academic%2520Press%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Zheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tice, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span> </span><span class="NLM_article-title">The use of spirocyclic scaffolds in drug discovery</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3673</span><span class="NLM_x">–</span> <span class="NLM_lpage">3682</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1016%2Fj.bmcl.2014.06.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=25052427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFykt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3673-3682&author=Y.+Zhengauthor=C.+M.+Ticeauthor=S.+B.+Singh&title=The+use+of+spirocyclic+scaffolds+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The use of spirocyclic scaffolds in drug discovery</span></div><div class="casAuthors">Zheng, Yajun; Tice, Colin M.; Singh, Suresh B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3673-3682</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Owing to their inherent three-dimensionality and structural novelty, spiro scaffolds have been increasingly utilized in drug discovery.  In this brief review, we highlight selected examples from the primary medicinal chem. literature during the last three years to demonstrate the versatility of spiro scaffolds.  With recent progress in synthetic methods providing access to spiro building blocks, spiro scaffolds are likely to be used more frequently in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqzTjJrsRkyLVg90H21EOLACvtfcHk0lhuERn1FRaLVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFykt7bM&md5=9a2a644cf2b97edf7876b43b6457f6d5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.081%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DTice%26aufirst%3DC.%2BM.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DThe%2520use%2520of%2520spirocyclic%2520scaffolds%2520in%2520drug%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3673%26epage%3D3682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Kolodziej, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockerman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCrescenzo, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischke, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munie, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stehle, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swearingen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, D. P.</span><span> </span><span class="NLM_article-title">MMP-13 selective isonipecotamide alpha-sulfone hydroxamates</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3561</span><span class="NLM_x">–</span> <span class="NLM_lpage">3564</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3561-3564&author=S.+A.+Kolodziejauthor=S.+L.+Hockermanauthor=G.+A.+DeCrescenzoauthor=J.+J.+McDonaldauthor=D.+A.+Mischkeauthor=G.+E.+Munieauthor=T.+R.+Fletcherauthor=N.+Stehleauthor=C.+Swearingenauthor=D.+P.+Becker&title=MMP-13+selective+isonipecotamide+alpha-sulfone+hydroxamates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKolodziej%26aufirst%3DS.%2BA.%26aulast%3DHockerman%26aufirst%3DS.%2BL.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DMcDonald%26aufirst%3DJ.%2BJ.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DMunie%26aufirst%3DG.%2BE.%26aulast%3DFletcher%26aufirst%3DT.%2BR.%26aulast%3DStehle%26aufirst%3DN.%26aulast%3DSwearingen%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DD.%2BP.%26atitle%3DMMP-13%2520selective%2520isonipecotamide%2520alpha-sulfone%2520hydroxamates%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3561%26epage%3D3564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zapico, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Sanmartín, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipiak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbajo, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schott, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pineda-Lucena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martínez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Santamaría, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pascual-Teresa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, A.</span><span> </span><span class="NLM_article-title">Potent “clicked” MMP2 inhibitors: synthesis, molecular modeling and biological exploration</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">4587</span><span class="NLM_x">–</span> <span class="NLM_lpage">4599</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=4587-4599&author=J.+M.+Zapicoauthor=P.+Serraauthor=J.+Garc%C3%ADa-Sanmart%C3%ADnauthor=K.+Filipiakauthor=R.+J.+Carbajoauthor=A.+K.+Schottauthor=A.+Pineda-Lucenaauthor=A.+Mart%C3%ADnezauthor=S.+Mart%C3%ADn-Santamar%C3%ADaauthor=B.+de+Pascual-Teresaauthor=A.+Ramos&title=Potent+%E2%80%9Cclicked%E2%80%9D+MMP2+inhibitors%3A+synthesis%2C+molecular+modeling+and+biological+exploration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZapico%26aufirst%3DJ.%2BM.%26aulast%3DSerra%26aufirst%3DP.%26aulast%3DGarc%25C3%25ADa-Sanmart%25C3%25ADn%26aufirst%3DJ.%26aulast%3DFilipiak%26aufirst%3DK.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DSchott%26aufirst%3DA.%2BK.%26aulast%3DPineda-Lucena%26aufirst%3DA.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DMart%25C3%25ADn-Santamar%25C3%25ADa%26aufirst%3DS.%26aulast%3Dde%2BPascual-Teresa%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DA.%26atitle%3DPotent%2520%25E2%2580%259Cclicked%25E2%2580%259D%2520MMP2%2520inhibitors%253A%2520synthesis%252C%2520molecular%2520modeling%2520and%2520biological%2520exploration%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2011%26volume%3D9%26spage%3D4587%26epage%3D4599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fabre, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipiak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zapico, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbajo, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schott, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martínez-Alcázar, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suárez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pineda-Lucena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pascual-Teresa, B.</span><span> </span><span class="NLM_article-title">Progress towards water-soluble triazole-based selective MMP-2 inhibitors</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">6623</span><span class="NLM_x">–</span> <span class="NLM_lpage">6641</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=6623-6641&author=B.+Fabreauthor=K.+Filipiakauthor=J.+M.+Zapicoauthor=N.+D%C3%ADazauthor=R.+J.+Carbajoauthor=A.+K.+Schottauthor=M.+P.+Mart%C3%ADnez-Alc%C3%A1zarauthor=D.+Su%C3%A1rezauthor=A.+Pineda-Lucenaauthor=A.+Ramosauthor=B.+de+Pascual-Teresa&title=Progress+towards+water-soluble+triazole-based+selective+MMP-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFabre%26aufirst%3DB.%26aulast%3DFilipiak%26aufirst%3DK.%26aulast%3DZapico%26aufirst%3DJ.%2BM.%26aulast%3DD%25C3%25ADaz%26aufirst%3DN.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DSchott%26aufirst%3DA.%2BK.%26aulast%3DMart%25C3%25ADnez-Alc%25C3%25A1zar%26aufirst%3DM.%2BP.%26aulast%3DSu%25C3%25A1rez%26aufirst%3DD.%26aulast%3DPineda-Lucena%26aufirst%3DA.%26aulast%3DRamos%26aufirst%3DA.%26aulast%3Dde%2BPascual-Teresa%26aufirst%3DB.%26atitle%3DProgress%2520towards%2520water-soluble%2520triazole-based%2520selective%2520MMP-2%2520inhibitors%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26spage%3D6623%26epage%3D6641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Orbe Lopategui, J.; Oyarzabal Santamarina, J.; Páramo Fernández, J. A.; Rodríguez García, J. A.</span><span> </span><span class="NLM_article-title">New antifibrinolytic compounds</span>. WO 2014012964 (A1), <span class="NLM_month">July</span><span class="NLM_day">17</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+Orbe+Lopategui&author=J.+Oyarzabal+Santamarina&author=J.+A.+P%C3%A1ramo+Fern%C3%A1ndez&author=J.+A.+Rodr%C3%ADguez+Garc%C3%ADa&title=New+antifibrinolytic+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOrbe%2BLopategui%26aufirst%3DJ.%26atitle%3DNew%2520antifibrinolytic%2520compounds%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Bertini, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calderone, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fragai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchinat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terni, B.</span><span> </span><span class="NLM_article-title">Crystal Structure of the Catalytic Domain of Human Matrix Metalloproteinase 10</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">336</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">716</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2004&pages=707-716&author=I.+Bertiniauthor=V.+Calderoneauthor=M.+Fragaiauthor=C.+Luchinatauthor=S.+Manganiauthor=B.+Terni&title=Crystal+Structure+of+the+Catalytic+Domain+of+Human+Matrix+Metalloproteinase+10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBertini%26aufirst%3DI.%26aulast%3DCalderone%26aufirst%3DV.%26aulast%3DFragai%26aufirst%3DM.%26aulast%3DLuchinat%26aufirst%3DC.%26aulast%3DMangani%26aufirst%3DS.%26aulast%3DTerni%26aufirst%3DB.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Catalytic%2520Domain%2520of%2520Human%2520Matrix%2520Metalloproteinase%252010%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D336%26spage%3D707%26epage%3D716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Schechter, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, A.</span><span> </span><span class="NLM_article-title">On the size of the active site in proteases. I. Papain</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1967</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1016%2FS0006-291X%2867%2980055-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=6035483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADyaF2sXktVyhsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1967&pages=157-162&author=I.+Schechterauthor=A.+Berger&title=On+the+size+of+the+active+site+in+proteases.+I.+Papain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">On the size of the active site in proteases.  I.  Papain</span></div><div class="casAuthors">Schechter, Israel; Berger, Arieh</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-62</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">The action of papain on 40 diastereoisomeric peptides of alanine, ranging in length from Ala2 to Ala6, was studied to investigate the size of the active site.  The variations observed in the rates of hydrolysis lead to the conclusion that papain has a large active site which extends over ∼25 A. and can be divided into 7 "subsites," each accommodating 1 amino acid residue of the peptide substrate.  The subsites are located on both sides of the catalytic site, 4 on the one side and 3 on the other.  It is postulated that a long "groove" analogous to that found by x-ray analysis in lysozyme is present.  The substrate is believed to fit into the groove, binding to several subsites of specific geometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_kZeRVAOVyrVg90H21EOLACvtfcHk0lgyAGJkb3cKAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXktVyhsrg%253D&md5=a58ceccdbb5cc5c021af06912835f77c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2867%2980055-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252867%252980055-X%26sid%3Dliteratum%253Aachs%26aulast%3DSchechter%26aufirst%3DI.%26aulast%3DBerger%26aufirst%3DA.%26atitle%3DOn%2520the%2520size%2520of%2520the%2520active%2520site%2520in%2520proteases.%2520I.%2520Papain%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1967%26volume%3D27%26spage%3D157%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rabal, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span> </span><span class="NLM_article-title">Using novel descriptor accounting for ligand–receptor interactions to define and visually explore biologically relevant chemical space</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1086</span><span class="NLM_x">–</span> <span class="NLM_lpage">1102</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci200627v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1SmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=1086-1102&author=O.+Rabalauthor=J.+Oyarzabal&title=Using+novel+descriptor+accounting+for+ligand%E2%80%93receptor+interactions+to+define+and+visually+explore+biologically+relevant+chemical+space"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">Using Novel Descriptor Accounting for Ligand-Receptor Interactions To Define and Visually Explore Biologically Relevant Chemical Space</span></div><div class="casAuthors">Rabal, Obdulia; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1086-1102</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The definition and pragmatic implementation of biol. relevant chem. space is crit. in addressing navigation strategies in the overlapping regions where chem. and therapeutically relevant targets reside and, therefore, also key to performing an efficient drug discovery project.  Here, we describe the development and implementation of a simple and robust method for representing biol. relevant chem. space as a general ref. according to current knowledge, independently of any ref. space, and analyzing chem. structures accordingly.  Underlying our method is the generation of a novel descriptor (LiRIf) that converts structural information into a one-dimensional string accounting for the plausible ligand-receptor interactions as well as for topol. information.  Capitalizing on ligand-receptor interactions as a descriptor enables the clustering, profiling, and comparison of libraries of compds. from a chem. biol. and medicinal chem. perspective.  In addn., as a case study, R-groups anal. is performed to identify the most populated ligand-receptor interactions according to different target families (GPCR, kinases, etc.), as well as to evaluate the coverage of biol. relevant chem. space by structures annotated in different databases (ChEMBL, Glida, etc.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGropZIPrOWgqrVg90H21EOLACvtfcHk0lgyAGJkb3cKAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1SmsLw%253D&md5=4530a7810f4b920b6cf1de72dea4cb39</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1021%2Fci200627v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200627v%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DOyarzabal%26aufirst%3DJ.%26atitle%3DUsing%2520novel%2520descriptor%2520accounting%2520for%2520ligand%25E2%2580%2593receptor%2520interactions%2520to%2520define%2520and%2520visually%2520explore%2520biologically%2520relevant%2520chemical%2520space%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D1086%26epage%3D1102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rabal, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span> </span><span class="NLM_article-title">Biologically relevant chemical space navigator: from patent and structure–activity relationship analysis to library acquisition and design</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3123</span><span class="NLM_x">–</span> <span class="NLM_lpage">3137</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci3004539" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslWksbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=3123-3137&author=O.+Rabalauthor=J.+Oyarzabal&title=Biologically+relevant+chemical+space+navigator%3A+from+patent+and+structure%E2%80%93activity+relationship+analysis+to+library+acquisition+and+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Biologically Relevant Chemical Space Navigator: From Patent and Structure-Activity Relationship Analysis to Library Acquisition and Design</span></div><div class="casAuthors">Rabal, Obdulia; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3123-3137</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new and versatile visualization tool, based on a descriptor accounting for ligand-receptor interactions (LiRIf), is introduced for guiding medicinal chemists in analyzing the R-groups from a congeneric series.  Anal. is performed in a ref.-independent scenario where the whole biol. relevant chem. space (BRCS) is represented.  Using a real project-based data set, the authors show the impact of this tool on four key navigation strategies for the drug discovery process.  First, this navigator analyzes competitors' patents, including a comparison of patents coverage and the identification of the most frequent fragments.  Second, the tool analyzes the structure-activity relationship (SAR) leading to the representation of ref.-independent activity landscapes that enable the identification not only of crit. ligand-receptor interactions (LRI) and substructural features but also of activity cliffs.  Third, this navigator enables comparison of libraries, thus selecting com. available mols. that complement unexplored spaces or areas of interest.  Finally, this tool also enables the design of new analogs, which is based on reaction types and the exploration purpose (focused or diverse), selecting the most appropriate reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIldm-mo1cdrVg90H21EOLACvtfcHk0lgyAGJkb3cKAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslWksbfP&md5=7ee9cb508b97b607067b519d580cab08</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1021%2Fci3004539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci3004539%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DOyarzabal%26aufirst%3DJ.%26atitle%3DBiologically%2520relevant%2520chemical%2520space%2520navigator%253A%2520from%2520patent%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520analysis%2520to%2520library%2520acquisition%2520and%2520design%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D3123%26epage%3D3137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8a'],'ref9':['cit9'],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29a','cit29b'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33a','cit33b']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 17 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Obdulia Rabal, Edurne San José-Enériz, Xabier Agirre, Juan Antonio Sánchez-Arias, Irene de Miguel, Raquel Ordoñez, Leire Garate, Estíbaliz Miranda, Elena Sáez, Amaia Vilas-Zornoza, Antonio Pineda-Lucena, Ander Estella, Feifei Zhang, Wei Wu, Musheng Xu, Felipe Prosper, <span class="NLM_string-name hlFld-ContribAuthor">Julen Oyarzabal</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 3392-3426. <a href="https://doi.org/10.1021/acs.jmedchem.0c02255" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02255</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02255%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNovel%252BEpigenetic%252BInhibitors%252BTargeting%252BHistone%252BDeacetylases%25252C%252BDNA%252BMethyltransferase%252B1%25252C%252Band%252BLysine%252BMethyltransferase%252BG9a%252Bwith%252BIn%252BVivo%252BEfficacy%252Bin%252BMultiple%252BMyeloma%26aulast%3DRabal%26aufirst%3DObdulia%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29122020%26date%3D04032021%26volume%3D64%26issue%3D6%26spage%3D3392%26epage%3D3426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Chen, Hao Xiong, Jing-Fang Yang, Xiao-Lei Zhu, Ren-Yu Qu, <span class="NLM_string-name hlFld-ContribAuthor">Guang-Fu Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Diaryl Ether: A Privileged Scaffold for Drug and Agrochemical Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Agricultural and Food Chemistry</span><span> <strong>2020,</strong> <em>68 </em>
                                    (37)
                                     , 9839-9877. <a href="https://doi.org/10.1021/acs.jafc.0c03369" title="DOI URL">https://doi.org/10.1021/acs.jafc.0c03369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jafc.0c03369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jafc.0c03369%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Agricultural%2520and%2520Food%2520Chemistry%26atitle%3DDiaryl%252BEther%25253A%252BA%252BPrivileged%252BScaffold%252Bfor%252BDrug%252Band%252BAgrochemical%252BDiscovery%26aulast%3DChen%26aufirst%3DTao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27052020%26date%3D11082020%26date%3D11082020%26date%3D29082020%26date%3D11082020%26volume%3D68%26issue%3D37%26spage%3D9839%26epage%3D9877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jiabin Ni, Bekzod Nishonov, Azizbek Pardaev, <span class="NLM_string-name hlFld-ContribAuthor">Ao Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed Ring-Opening Coupling of gem-Difluorocyclopropanes for the Construction of 2-Fluoroallylic Sulfones. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (21)
                                     , 13646-13654. <a href="https://doi.org/10.1021/acs.joc.9b01897" title="DOI URL">https://doi.org/10.1021/acs.joc.9b01897</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b01897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b01897%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPalladium-Catalyzed%252BRing-Opening%252BCoupling%252Bof%252Bgem-Difluorocyclopropanes%252Bfor%252Bthe%252BConstruction%252Bof%252B2-Fluoroallylic%252BSulfones%26aulast%3DNi%26aufirst%3DJiabin%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12072019%26date%3D03102019%26date%3D20092019%26volume%3D84%26issue%3D21%26spage%3D13646%26epage%3D13654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Irene de Miguel, Josune Orbe, Juan A. Sánchez-Arias, José A. Rodríguez, Agustina Salicio, Obdulia Rabal, Miriam Belzunce, Elena Sáez, Musheng Xu, Wei Wu, Haizhong Tan, Hongyu Ma, José A. Páramo, <span class="NLM_string-name hlFld-ContribAuthor">Julen Oyarzabal</span>. </span><span class="cited-content_cbyCitation_article-title">Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (5)
                                     , 428-433. <a href="https://doi.org/10.1021/acsmedchemlett.7b00549" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00549</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00549%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPhenotypic%252BScreening%252BTo%252BDiscover%252BNovel%252BChemical%252BSeries%252Bas%252BEfficient%252BAntihemorrhagic%252BAgents%26aulast%3Dde%2BMiguel%26aufirst%3DIrene%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D30122017%26date%3D16042018%26date%3D23042018%26date%3D16042018%26volume%3D9%26issue%3D5%26spage%3D428%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jiabin Ni, Yu Xue, Liping Sun, <span class="NLM_string-name hlFld-ContribAuthor">Ao Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Cu-Mediated Sulfonyl Radical-Enabled 5-exo-trig Cyclization of Alkenyl Aldehydes: Access to Sulfonylmethyl 1H-Indenes. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (8)
                                     , 4598-4605. <a href="https://doi.org/10.1021/acs.joc.8b00341" title="DOI URL">https://doi.org/10.1021/acs.joc.8b00341</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b00341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b00341%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCu-Mediated%252BSulfonyl%252BRadical-Enabled%252B5-exo-trig%252BCyclization%252Bof%252BAlkenyl%252BAldehydes%25253A%252BAccess%252Bto%252BSulfonylmethyl%252B1H-Indenes%26aulast%3DNi%26aufirst%3DJiabin%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D06022018%26date%3D06042018%26date%3D28032018%26volume%3D83%26issue%3D8%26spage%3D4598%26epage%3D4605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Hermant</span>, <span class="hlFld-ContribAuthor ">Damien  Bosc</span>, <span class="hlFld-ContribAuthor ">Catherine  Piveteau</span>, <span class="hlFld-ContribAuthor ">Ronan  Gealageas</span>, <span class="hlFld-ContribAuthor ">BaoVy  Lam</span>, <span class="hlFld-ContribAuthor ">Cyril  Ronco</span>, <span class="hlFld-ContribAuthor ">Matthieu  Roignant</span>, <span class="hlFld-ContribAuthor ">Hasina  Tolojanahary</span>, <span class="hlFld-ContribAuthor ">Ludovic  Jean</span>, <span class="hlFld-ContribAuthor ">Pierre-Yves  Renard</span>, <span class="hlFld-ContribAuthor ">Mohamed  Lemdani</span>, <span class="hlFld-ContribAuthor ">Marilyne  Bourotte</span>, <span class="hlFld-ContribAuthor ">Adrien  Herledan</span>, <span class="hlFld-ContribAuthor ">Corentin  Bedart</span>, <span class="hlFld-ContribAuthor ">Alexandre  Biela</span>, <span class="hlFld-ContribAuthor ">Florence  Leroux</span>, <span class="hlFld-ContribAuthor ">Benoit  Deprez</span>, and <span class="hlFld-ContribAuthor ">Rebecca  Deprez-Poulain</span>  . </span><span class="cited-content_cbyCitation_article-title">Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (21)
                                     , 9067-9089. <a href="https://doi.org/10.1021/acs.jmedchem.7b01444" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01444</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01444%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DControlling%252BPlasma%252BStability%252Bof%252BHydroxamic%252BAcids%25253A%252BA%252BMedChem%252BToolbox%26aulast%3DHermant%26aufirst%3DPaul%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D28092017%26date%3D24102017%26date%3D09112017%26date%3D06102017%26volume%3D60%26issue%3D21%26spage%3D9067%26epage%3D9089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Josune  Orbe</span>, <span class="hlFld-ContribAuthor ">José A.  Rodríguez</span>, <span class="hlFld-ContribAuthor ">Juan A.  Sánchez-Arias</span>, <span class="hlFld-ContribAuthor ">Agustina  Salicio</span>, <span class="hlFld-ContribAuthor ">Miriam  Belzunce</span>, <span class="hlFld-ContribAuthor ">Ana  Ugarte</span>, <span class="hlFld-ContribAuthor ">Haisul C. Y.  Chang</span>, <span class="hlFld-ContribAuthor ">Obdulia  Rabal</span>, <span class="hlFld-ContribAuthor ">Julen  Oyarzabal</span>, and <span class="hlFld-ContribAuthor ">José A.  Páramo</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Safety Profiling of a Potent Preclinical Candidate, (4-[4-[[(3R)-3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the Prevention and Treatment of Hemorrhage. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (7)
                                     , 2941-2957. <a href="https://doi.org/10.1021/jm501939z" title="DOI URL">https://doi.org/10.1021/jm501939z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501939z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501939z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BSafety%252BProfiling%252Bof%252Ba%252BPotent%252BPreclinical%252BCandidate%25252C%252B%2525284-%25255B4-%25255B%25255B%2525283R%252529-3-%252528Hydroxycarbamoyl%252529-8-azaspiro%25255B4.5%25255Ddecan-3-yl%25255Dsulfonyl%25255Dphenoxy%25255D-N-methylbenzamide%252529%252B%252528CM-352%252529%25252C%252Bfor%252Bthe%252BPrevention%252Band%252BTreatment%252Bof%252BHemorrhage%26aulast%3DOrbe%26aufirst%3DJosune%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D15122014%26date%3D25022015%26date%3D09042015%26date%3D16022015%26volume%3D58%26issue%3D7%26spage%3D2941%26epage%3D2957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manuel  Navarro-Oviedo</span>, <span class="hlFld-ContribAuthor ">Roberto  Muñoz-Arrondo</span>, <span class="hlFld-ContribAuthor ">Beatriz  Zandio</span>, <span class="hlFld-ContribAuthor ">Juan  Marta-Enguita</span>, <span class="hlFld-ContribAuthor ">Anna  Bonaterra-Pastra</span>, <span class="hlFld-ContribAuthor ">Jose Antonio  Rodríguez</span>, <span class="hlFld-ContribAuthor ">Carmen  Roncal</span>, <span class="hlFld-ContribAuthor ">Jose A.  Páramo</span>, <span class="hlFld-ContribAuthor ">Estefania  Toledo</span>, <span class="hlFld-ContribAuthor ">Joan  Montaner</span>, <span class="hlFld-ContribAuthor ">Mar  Hernández-Guillamon</span>, <span class="hlFld-ContribAuthor ">Josune  Orbe</span>. </span><span class="cited-content_cbyCitation_article-title">Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-67250-9" title="DOI URL">https://doi.org/10.1038/s41598-020-67250-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-67250-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-67250-9%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DCirculating%252BTIMP-1%252Bis%252Bassociated%252Bwith%252Bhematoma%252Bvolume%252Bin%252Bpatients%252Bwith%252Bspontaneous%252Bintracranial%252Bhemorrhage%26aulast%3DNavarro-Oviedo%26aufirst%3DManuel%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joe I.  Higham</span>, <span class="hlFld-ContribAuthor ">James A.  Bull</span>. </span><span class="cited-content_cbyCitation_article-title">Copper catalysed oxidative α-sulfonylation of branched aldehydes using the acid enhanced reactivity of manganese(
              iv
              ) oxide. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (33)
                                     , 4587-4590. <a href="https://doi.org/10.1039/D0CC01576H" title="DOI URL">https://doi.org/10.1039/D0CC01576H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CC01576H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CC01576H%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DCopper%252Bcatalysed%252Boxidative%252B%2525CE%2525B1-sulfonylation%252Bof%252Bbranched%252Baldehydes%252Busing%252Bthe%252Bacid%252Benhanced%252Breactivity%252Bof%252Bmanganese%252528%252Biv%252B%252529%252Boxide%26aulast%3DHigham%26aufirst%3DJoe%2BI.%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D33%26spage%3D4587%26epage%3D4590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yali  Sang</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fener  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>96 </em>, 103595. <a href="https://doi.org/10.1016/j.bioorg.2020.103595" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103595</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103595%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPharmacophore-fusing%252Bdesign%252Bof%252Bpyrimidine%252Bsulfonylacetanilides%252Bas%252Bpotent%252Bnon-nucleoside%252Binhibitors%252Bof%252BHIV-1%252Breverse%252Btranscriptase%26aulast%3DSang%26aufirst%3DYali%26date%3D2020%26volume%3D96%26spage%3D103595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Demin  Ren</span>, <span class="hlFld-ContribAuthor ">Ye  Tang</span>, <span class="hlFld-ContribAuthor ">Xianyong  Yu</span>, <span class="hlFld-ContribAuthor ">Yulin  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaofang  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of spiro[cyclopent-2/3-ene-1,2′-[1,3]thiazolo[3,2-a] pyrimidine] derivatives via 1,3-dipolar cycloaddition reaction of ethyl buta-2,3-dienoate. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Research</span><span> <strong>2018,</strong> <em>42 </em>
                                    (12)
                                     , 631-635. <a href="https://doi.org/10.3184/174751918X15426290490753" title="DOI URL">https://doi.org/10.3184/174751918X15426290490753</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3184/174751918X15426290490753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3184%2F174751918X15426290490753%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Research%26atitle%3DSynthesis%252Bof%252Bspiro%25255Bcyclopent-2%25252F3-ene-1%25252C2%2525E2%252580%2525B2-%25255B1%25252C3%25255Dthiazolo%25255B3%25252C2-a%25255D%252Bpyrimidine%25255D%252Bderivatives%252Bvia%252B1%25252C3-dipolar%252Bcycloaddition%252Breaction%252Bof%252Bethyl%252Bbuta-2%25252C3-dienoate%26aulast%3DRen%26aufirst%3DDemin%26date%3D2018%26date%3D2018%26volume%3D42%26issue%3D12%26spage%3D631%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renzhi  Liu</span>, <span class="hlFld-ContribAuthor ">Qihong  Mei</span>, <span class="hlFld-ContribAuthor ">Yan  Shen</span>, <span class="hlFld-ContribAuthor ">Yiqiang  Wu</span>, <span class="hlFld-ContribAuthor ">Wenlin  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Solvent-free Synthesis of Novel Spirocyclic Oxindole Derivatives via a Michael-Aldol Cascade by Grinding. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Research</span><span> <strong>2018,</strong> <em>42 </em>
                                    (5)
                                     , 244-246. <a href="https://doi.org/10.3184/174751918X15260499526233" title="DOI URL">https://doi.org/10.3184/174751918X15260499526233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3184/174751918X15260499526233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3184%2F174751918X15260499526233%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Research%26atitle%3DSolvent-free%252BSynthesis%252Bof%252BNovel%252BSpirocyclic%252BOxindole%252BDerivatives%252Bvia%252Ba%252BMichael-Aldol%252BCascade%252Bby%252BGrinding%26aulast%3DLiu%26aufirst%3DRenzhi%26date%3D2018%26date%3D2018%26volume%3D42%26issue%3D5%26spage%3D244%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Hydroxamates. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 435-480. <a href="https://doi.org/10.1002/9781118686263.ch12" title="DOI URL">https://doi.org/10.1002/9781118686263.ch12</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118686263.ch12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118686263.ch12%26sid%3Dliteratum%253Aachs%26atitle%3DHydroxamates%26date%3D2018%26date%3D2018%26spage%3D435%26epage%3D480%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPrivileged%252BStructures%252Bin%252BDrug%252BDiscovery%26aulast%3DYet%26aufirst%3DLarry%26date%3D2018%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">José A.  Rodríguez</span>, <span class="hlFld-ContribAuthor ">Tomás  Sobrino</span>, <span class="hlFld-ContribAuthor ">Esteban  López‐Arias</span>, <span class="hlFld-ContribAuthor ">Ana  Ugarte</span>, <span class="hlFld-ContribAuthor ">Juan A.  Sánchez‐Arias</span>, <span class="hlFld-ContribAuthor ">Alba  Vieites‐Prado</span>, <span class="hlFld-ContribAuthor ">Irene  de Miguel</span>, <span class="hlFld-ContribAuthor ">Julen  Oyarzabal</span>, <span class="hlFld-ContribAuthor ">José A.  Páramo</span>, <span class="hlFld-ContribAuthor ">Francisco  Campos</span>, <span class="hlFld-ContribAuthor ">Josune  Orbe</span>, <span class="hlFld-ContribAuthor ">José  Castillo</span>. </span><span class="cited-content_cbyCitation_article-title">CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Heart Association</span><span> <strong>2017,</strong> <em>6 </em>
                                    (6)
                                     <a href="https://doi.org/10.1161/JAHA.117.006042" title="DOI URL">https://doi.org/10.1161/JAHA.117.006042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1161/JAHA.117.006042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1161%2FJAHA.117.006042%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Heart%2520Association%26atitle%3DCM352%252BReduces%252BBrain%252BDamage%252Band%252BImproves%252BFunctional%252BRecovery%252Bin%252Ba%252BRat%252BModel%252Bof%252BIntracerebral%252BHemorrhage%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DJos%25C3%25A9%2BA.%26date%3D2017%26volume%3D6%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaowei  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaolian  Hu</span>, <span class="hlFld-ContribAuthor ">Hongwen  Tao</span>, <span class="hlFld-ContribAuthor ">Haochong  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaofang  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Novel Spiro(Indolizine-Pyrazole) Derivatives via 1,3-Dipolar Cycloaddition of Nitrilimine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Research</span><span> <strong>2017,</strong> <em>41 </em>
                                    (10)
                                     , 608-610. <a href="https://doi.org/10.3184/174751917X15064232103100" title="DOI URL">https://doi.org/10.3184/174751917X15064232103100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3184/174751917X15064232103100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3184%2F174751917X15064232103100%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Research%26atitle%3DSynthesis%252Bof%252BNovel%252BSpiro%252528Indolizine-Pyrazole%252529%252BDerivatives%252Bvia%252B1%25252C3-Dipolar%252BCycloaddition%252Bof%252BNitrilimine%26aulast%3DZhang%26aufirst%3DShaowei%26date%3D2017%26date%3D2017%26volume%3D41%26issue%3D10%26spage%3D608%26epage%3D610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charles M.  Marson</span>. </span><span class="cited-content_cbyCitation_article-title">Saturated Heterocycles with Applications in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 13-33. <a href="https://doi.org/10.1016/bs.aihch.2016.03.004" title="DOI URL">https://doi.org/10.1016/bs.aihch.2016.03.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2016.03.004%26sid%3Dliteratum%253Aachs%26atitle%3DSaturated%252BHeterocycles%252Bwith%252BApplications%252Bin%252BMedicinal%252BChemistry%26aulast%3DMarson%26aufirst%3DCharles%2BM.%26date%3D2017%26spage%3D13%26epage%3D33%26pub%3DElsevier%26atitle%3DHeterocyclic%252BChemistry%252Bin%252Bthe%252B21st%252BCentury%252B-%252BA%252BTribute%252Bto%252BAlan%252BKatritzky%26date%3D2017%26volume%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Zhao</span>, <span class="hlFld-ContribAuthor ">Jiang-Kun  Dai</span>, <span class="hlFld-ContribAuthor ">Dan  Liu</span>, <span class="hlFld-ContribAuthor ">Shi-Jun  Wang</span>, <span class="hlFld-ContribAuthor ">Jun-Ru  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Evaluation of Ester Derivatives of 10-Hydroxycanthin-6-one as Potential Antimicrobial Agents. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (3)
                                     , 390. <a href="https://doi.org/10.3390/molecules21030390" title="DOI URL">https://doi.org/10.3390/molecules21030390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21030390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21030390%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Band%252BEvaluation%252Bof%252BEster%252BDerivatives%252Bof%252B10-Hydroxycanthin-6-one%252Bas%252BPotential%252BAntimicrobial%252BAgents%26aulast%3DZhao%26aufirst%3DFei%26date%3D2016%26date%3D2016%26volume%3D21%26issue%3D3%26spage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Known Antifibrinolytics (<b>1</b>, <b>2</b> and <b>3</b>), MMP Inhibitors (<b>4</b>, <b>6</b>, <b>7</b>, <b>8</b>, <b>9</b>, and <b>10</b>), and Structure of a Novel Antihemorrhagic Agent CM-352 (<b>5</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0003.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Simplified scheme for the proposed cooperation between fibrinolytic and MMP systems in thrombus dissolution.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0004.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural information for MMP-13 and MMP-3 isoforms, in complex with ligands, guided the design of novel chemical series <b>5</b>′. (A) Complex of SC-78080 <b>6</b> with MMP-13 (PDB accession code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRY">3KRY</a>). (B) Complex of <b>10</b> with MMP-3 (PDB accession code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1D8F">1D8F</a>). The molecular surface is drawn to demonstrate the narrowness of the S1′ pocket. (C) Markush formula of novel α-spiropiperidine hydroxamates <b>5</b>′.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0005.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Anatomopathological images of mice treated with compounds <b>16</b> and <b>19d</b>. (A,B) Anatomopathological images of mice treated with <b>16</b> (10 mg/kg). (A) Hematoxylin and eosin staining of lung tissue vessels (magnification 400×) showing a microthrombus (arrows), (B) kidney with slight hypercellularity and small spheres of protein in the Bowman’s capsule (arrows) (magnification 600×). (C,D) Anatomopathological images of mice treated with <b>19d</b> (10 mg/kg). Hematoxylin and eosin staining of lung tissue vessels (magnification 100×) and kidney glomeruli and tubules (magnification 400×) with normal appearance and no thrombus formation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0006.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of compounds <b>23a</b> and <b>23b</b> obtained by X-ray crystallographic analysis. (A) <b>23a</b>, as previously reported;<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (B) <b>23b</b> together with its corresponding color-coded stick representation. Details for the X-ray crystallographic data of compound <b>23b</b> and its corresponding coordinates are reported in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>11</b>–<b>13</b>, <b>16</b>, <b>19a</b>–<b>c</b>, and <b>19f</b>–<b>i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) LDA, THF, −78 °C, 1 h, then 4-fluorobenzenesulfonyl fluoride, −78 °C, 1 h to RT overnight; (b) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (3:3:2), RT, 4 h; (c) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, RT, overnight; (d) NaOMe, overnight; (e) HCl/dioxane (2N), RT, 1 h; (f) corresponding aryl alcohol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80–90 °C, MW or conventional heating.</p></p></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of compounds <b>17</b>, <b>19m</b>, and <b>19o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) corresponding alcohol, NaH, RT, 30 min, then <b>27</b>, 80–90 °C, overnight; (b) HCl/dioxane (2N), RT, 1 h.</p></p></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>19d</b>, <b>19e</b>, <b>19j</b>, and <b>19l</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) corresponding alcohol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80–90 °C, overnight or DMA, 120 °C, MW, 2 h; (b) LiOH·H<sub>2</sub>O, THF/H<sub>2</sub>O (3:1 or 3:2) or THF/MeOH/H<sub>2</sub>O (3:3:2), RT, 4 h; (1c) EDC·HCl, HOBt, CH<sub>3</sub>NH·HCl or pyrrolidine, NMM, DMF, RT, overnight; (2c) Et<sub>3</sub>N, HATU, CH<sub>3</sub>NH·HCl, CH<sub>3</sub>CN, RT, overnight; (d) HCl/dioxane (2N), RT, 1–2 h.</p></p></figure><figure data-id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of compounds <b>14</b>, <b>15</b>, and <b>19p</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) LDA, THF, −78 °C, 1 h, then corresponding sulfonyl fluoride, −78 °C, 1 h and RT overnight; (1b) corresponding alcohol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80–100 °C, overnight; (2b) corresponding alcohol, Cs<sub>2</sub>CO<sub>3</sub>, CuI, <i>N</i>,<i>N</i>′-dimethylglycine, dioxane, reflux, overnight; (c) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (3:3:2), RT, 4 h; (d) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, RT, overnight; (e) HCl/dioxane (2N), RT, 2–3 h.</p></p></figure><figure data-id="sch5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>19k</b> and <b>19n</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, benzyl alcohol, THF, RT, 30 min, then <b>27</b>, 80 °C, overnight; (b) Pd/C, H<sub>2</sub> (1 atm), MeOH, RT, 1 h; (1c) ethyl 2-fluorobenzoate, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, overnight; (2c) methyl 4-(bromomethyl)benzoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 0 °C to RT, overnight; (d) LiOH·H<sub>2</sub>O, THF/H<sub>2</sub>O (3:1), RT, overnight; (e) EDC·HCl, HOBt, CH<sub>3</sub>NH·HCl, NMM, DMF, RT, overnight; (f) HCl/dioxane (2N), RT, 1 h.</p></p></figure><figure data-id="sch6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0012.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compound <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) [4-(trifluoromethoxy)phenyl]methanamine, 110 °C, overnight; (b) HCl/dioxane (2N), RT, 2 h.</p></p></figure><figure data-id="sch7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0013.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>20a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 4-methoxyphenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C, 2 h; (b) HCl/dioxane (4N), RT, 3 h; (c) MeI, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, RT, 30 min; (d) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (3:3:2), reflux, overnight; (e) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, RT, overnight; (f) HCl/dioxane (4N), RT, 3 h; (g) 3-bromo-1,1,1-trifluoropropane, K<sub>2</sub>CO<sub>3</sub>, DMF, RT, overnight; (h) pyridine, acetyl chloride, DMF, 0 °C, 5 min.</p></p></figure><figure data-id="sch8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/medium/jm-2014-01940y_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0014.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>21a</b>–<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-5/jm501940y/20150306/images/large/jm-2014-01940y_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501940y&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) corresponding acyl chloride, Et<sub>3</sub>N, DCM, RT, overnight; (b) HCl/dioxane (2N), RT, 1 h; (c) Pd/C, H<sub>2</sub> (1 atm), MeOH, RT, 1 h; (d) CH<sub>3</sub>NH·HCl, Et<sub>3</sub>N, HATU, CH<sub>3</sub>CN, RT, overnight.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i133">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 33 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Kauvar, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefering, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, C. E.</span><span> </span><span class="NLM_article-title">Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations</span> <span class="citation_source-journal">J. Trauma: Inj., Infect., Crit. Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">S3</span><span class="NLM_x">–</span> <span class="NLM_lpage">S11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2006&pages=S3-S11&author=D.+S.+Kauvarauthor=R.+Leferingauthor=C.+E.+Wade&title=Impact+of+hemorrhage+on+trauma+outcome%3A+an+overview+of+epidemiology%2C+clinical+presentations%2C+and+therapeutic+considerations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKauvar%26aufirst%3DD.%2BS.%26aulast%3DLefering%26aufirst%3DR.%26aulast%3DWade%26aufirst%3DC.%2BE.%26atitle%3DImpact%2520of%2520hemorrhage%2520on%2520trauma%2520outcome%253A%2520an%2520overview%2520of%2520epidemiology%252C%2520clinical%2520presentations%252C%2520and%2520therapeutic%2520considerations%26jtitle%3DJ.%2520Trauma%253A%2520Inj.%252C%2520Infect.%252C%2520Crit.%2520Care%26date%3D2006%26volume%3D60%26spage%3DS3%26epage%3DS11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis</span>.  <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span><span class="NLM_month">Mar</span><span class="NLM_day">26</span>,  <span class="NLM_volume">72</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span>)  <span class="NLM_fpage">585</span><span class="NLM_x">–</span> <span class="NLM_lpage">617</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=585-617&issue=5&author=P.+L.+McCormack&title=Tranexamic+acid%3A+a+review+of+its+use+in+the+treatment+of+hyperfibrinolysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DTranexamic%2520acid%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520treatment%2520of%2520hyperfibrinolysis%26jtitle%3DDrugs%26date%3D2012%26volume%3D72%26issue%3D5%26spage%3D585%26epage%3D617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Mannucci, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levi, M.</span><span> </span><span class="NLM_article-title">Prevention and treatment of major blood loss</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">2301</span><span class="NLM_x">–</span> <span class="NLM_lpage">2311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1056%2FNEJMra067742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=17538089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVKku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=2301-2311&author=P.+M.+Mannucciauthor=M.+Levi&title=Prevention+and+treatment+of+major+blood+loss"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention and treatment of major blood loss</span></div><div class="casAuthors">Mannucci, Pier Mannuccio; Levi, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2301-2311</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  In a medical setting, surgery is the most common cause of major blood loss, defined as a loss of 20% of total blood vol. or more.  In particular, cardiovascular procedures, liver transplantation and hepatic resections, and major orthopedic procedures including hip and knee replacement and spine surgery, are assocd. with severe bleeding.  The medications that have been most extensively evaluated as hemostatic agents include the antifibrinolytic lysine analogs aminocaproic acid and tranexamic acid; aprotinin, a bovine-derived protease inhibitor; and desmopressin, a synthetic analog of the antidiuretic hormone that raises the plasma levels of factor VIII and von Willebrand factor.  In addn., recombinant activated factor VII appears to be efficacious in an array of clin. situations assocd. with severe hemorrhage.  The authors review the therapeutic benefits of hemostatic drugs and consider the risk of adverse events.  In particular, the authors consider thrombotic complications, which constitute a major concern when agents that potentiate hemostasis are administered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGparywhZH_RD7Vg90H21EOLACvtfcHk0lhHdPsgjpDVQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVKku7Y%253D&md5=b8d5b6f843deb7a5ee51f4988fa35276</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMra067742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra067742%26sid%3Dliteratum%253Aachs%26aulast%3DMannucci%26aufirst%3DP.%2BM.%26aulast%3DLevi%26aufirst%3DM.%26atitle%3DPrevention%2520and%2520treatment%2520of%2520major%2520blood%2520loss%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D2301%26epage%3D2311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettersen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evertsson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pahlén, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonforsen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plowright, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boström, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fex, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thelin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilgendorf, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlund, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindberg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafsson, D.</span><span> </span><span class="NLM_article-title">Discovery of the Fibrinolysis Inhibitor AZD6564, Acting via Interference of a Protein–Protein Interaction</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">538</span><span class="NLM_x">–</span> <span class="NLM_lpage">543</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml400526d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=538-543&author=L.+Chengauthor=D.+Pettersenauthor=B.+Ohlssonauthor=P.+Schellauthor=M.+Karleauthor=E.+Evertssonauthor=S.+Pahl%C3%A9nauthor=M.+Jonforsenauthor=A.+T.+Plowrightauthor=J.+Bostr%C3%B6mauthor=T.+Fexauthor=A.+Thelinauthor=C.+Hilgendorfauthor=Y.+Xueauthor=G.+Wahlundauthor=W.+Lindbergauthor=L.+O.+Larssonauthor=D.+Gustafsson&title=Discovery+of+the+Fibrinolysis+Inhibitor+AZD6564%2C+Acting+via+Interference+of+a+Protein%E2%80%93Protein+Interaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fml400526d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400526d%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DPettersen%26aufirst%3DD.%26aulast%3DOhlsson%26aufirst%3DB.%26aulast%3DSchell%26aufirst%3DP.%26aulast%3DKarle%26aufirst%3DM.%26aulast%3DEvertsson%26aufirst%3DE.%26aulast%3DPahl%25C3%25A9n%26aufirst%3DS.%26aulast%3DJonforsen%26aufirst%3DM.%26aulast%3DPlowright%26aufirst%3DA.%2BT.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26aulast%3DFex%26aufirst%3DT.%26aulast%3DThelin%26aufirst%3DA.%26aulast%3DHilgendorf%26aufirst%3DC.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DWahlund%26aufirst%3DG.%26aulast%3DLindberg%26aufirst%3DW.%26aulast%3DLarsson%26aufirst%3DL.%2BO.%26aulast%3DGustafsson%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520the%2520Fibrinolysis%2520Inhibitor%2520AZD6564%252C%2520Acting%2520via%2520Interference%2520of%2520a%2520Protein%25E2%2580%2593Protein%2520Interaction%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D538%26epage%3D543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Hochschwender, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laursen, R. A.</span><span> </span><span class="NLM_article-title">The lysine binding sites of human plasminogen</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">256</span><span class="NLM_x">, </span> <span class="NLM_fpage">11172</span><span class="NLM_x">–</span> <span class="NLM_lpage">11176</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1981&pages=11172-11176&author=S.+M.+Hochschwenderauthor=R.+A.+Laursen&title=The+lysine+binding+sites+of+human+plasminogen"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHochschwender%26aufirst%3DS.%2BM.%26aulast%3DLaursen%26aufirst%3DR.%2BA.%26atitle%3DThe%2520lysine%2520binding%2520sites%2520of%2520human%2520plasminogen%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1981%26volume%3D256%26spage%3D11172%26epage%3D11176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Lecker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romaschin, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazer, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orser, B. A.</span><span> </span><span class="NLM_article-title">Tranexamic acid concentrations associated with human seizures inhibit glycine receptors</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">4654</span><span class="NLM_x">–</span> <span class="NLM_lpage">4666</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1172%2FJCI63375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=23187124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVakt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2012&pages=4654-4666&author=I.+Leckerauthor=D.+S.+Wangauthor=A.+D.+Romaschinauthor=M.+Petersonauthor=C.+D.+Mazerauthor=B.+A.+Orser&title=Tranexamic+acid+concentrations+associated+with+human+seizures+inhibit+glycine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tranexamic acid concentrations associated with human seizures inhibit glycine receptors</span></div><div class="casAuthors">Lecker, Irene; Wang, Dian-Shi; Romaschin, Alexander D.; Peterson, Mark; Mazer, C. David; Orser, Beverley A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4654-4666</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Antifibrinolytic drugs are widely used to reduce blood loss during surgery.  One serious adverse effect of these drugs is convulsive seizures; however, the mechanisms underlying such seizures remain poorly understood.  The antifibrinolytic drugs tranexamic acid (TXA) and ε-aminocaproic acid (EACA) are structurally similar to the inhibitory neurotransmitter glycine.  Since reduced function of glycine receptors causes seizures, we hypothesized that TXA and EACA inhibit the activity of glycine receptors.  Here we demonstrate that TXA and EACA are competitive antagonists of glycine receptors in mice.  We also showed that the general anesthetic isoflurane, and to a lesser extent propofol, reverses TXA inhibition of glycine receptor-mediated current, suggesting that these drugs could potentially be used to treat TXA-induced seizures.  Finally, we measured the concn. of TXA in the cerebrospinal fluid (CSF) of patients undergoing major cardiovascular surgery.  Surprisingly, peak TXA concn. in the CSF occurred after termination of drug infusion and in one patient coincided with the onset of seizures.  Collectively, these results show that concns. of TXA equiv. to those measured in the CSF of patients inhibited glycine receptors.  Furthermore, isoflurane or propofol may prevent or reverse TXA-induced seizures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog0xnAywntZ7Vg90H21EOLACvtfcHk0lgygzOlfFZtsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVakt7fJ&md5=a5308863d129437b3c32a618ac77fcaa</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1172%2FJCI63375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI63375%26sid%3Dliteratum%253Aachs%26aulast%3DLecker%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DD.%2BS.%26aulast%3DRomaschin%26aufirst%3DA.%2BD.%26aulast%3DPeterson%26aufirst%3DM.%26aulast%3DMazer%26aufirst%3DC.%2BD.%26aulast%3DOrser%26aufirst%3DB.%2BA.%26atitle%3DTranexamic%2520acid%2520concentrations%2520associated%2520with%2520human%2520seizures%2520inhibit%2520glycine%2520receptors%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D122%26spage%3D4654%26epage%3D4666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">McCormack, P. L.</span><span> </span><span class="NLM_article-title">Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">585</span><span class="NLM_x">–</span> <span class="NLM_lpage">617</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.2165%2F11209070-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=22397329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVOhsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=585-617&author=P.+L.+McCormack&title=Tranexamic+acid%3A+a+review+of+its+use+in+the+treatment+of+hyperfibrinolysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis</span></div><div class="casAuthors">McCormack, Paul L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">585-617</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Tranexamic acid, a synthetic deriv. of the amino acid lysine, is an antifibrinolytic agent that acts by binding to plasminogen and blocking the interaction of plasmin(ogen) with fibrin, thereby preventing dissoln. of the fibrin clot.  Tranexamic acid (Transamin) is indicated in Japan for use in certain conditions with abnormal bleeding or bleeding tendencies in which local or systemic hyperfibrinolysis is considered to be involved.  This article reviews the efficacy and tolerability of tranexamic acid in conditions amenable to antifibrinolytic therapy and briefly overviews the pharmacol. properties of the drug.  In large, randomized controlled trials, tranexamic acid generally significantly reduced perioperative blood loss compared with placebo in a variety of surgical procedures, including cardiac surgery with or without cardiopulmonary bypass, total hip and knee replacement and prostatectomy.  In many instances, tranexamic acid also reduced transfusion requirements assocd. with surgery.  It also reduced blood loss in gynaecol. bleeding disorders, such as heavy menstrual bleeding, postpartum hemorrhage and bleeding irregularities caused by contraceptive implants.  Tranexamic acid significantly reduced all-cause mortality and death due to bleeding in trauma patients with significant bleeding, particularly when administered early after injury.  It was also effective in traumatic hyphaema, gastrointestinal bleeding and hereditary angioneurotic edema.  While it reduces rebleeding in subarachnoid hemorrhage, it may increase ischemic complications.  Pharmacoeconomic analyses predicted that tranexamic acid use in surgery and trauma would be very cost effective and potentially life saving.  In direct comparisons with other marketed agents, tranexamic acid was at least as effective as ε-aminocaproic acid and more effective than desmopressin in surgical procedures.  It was more effective than desmopressin, etamsylate, flurbiprofen, mefenamic acid and norethisterone, but less effective than the levonorgestrel-releasing intra-uterine device in heavy menstrual bleeding and was as effective as prednisolone in traumatic hyphaema.  Tranexamic acid was generally well tolerated.  Most adverse events in clin. trials were of mild or moderate severity; severe or serious events were rare.  Therefore, while high-quality published evidence is limited for some approved indications, tranexamic acid is an effective and well tolerated antifibrinolytic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlJr4XyAhuZbVg90H21EOLACvtfcHk0lgygzOlfFZtsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVOhsbs%253D&md5=7ec7b17f913eea281e7be0be28495574</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2165%2F11209070-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11209070-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DP.%2BL.%26atitle%3DTranexamic%2520acid%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520treatment%2520of%2520hyperfibrinolysis%26jtitle%3DDrugs%26date%3D2012%26volume%3D72%26spage%3D585%26epage%3D617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shakur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bautista, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caballero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coats, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sayed, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gogichaishvili, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iribhogbe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izurieta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khamis, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komolafe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrero, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mejía-Mantilla, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miranda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olaomi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olldashi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramana, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravi, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yutthakasemsunt, S.</span><span> </span><span class="NLM_article-title">Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=23-32&author=H.+Shakurauthor=I.+Robertsauthor=R.+Bautistaauthor=J.+Caballeroauthor=T.+Coatsauthor=Y.+Dewanauthor=H.+El-Sayedauthor=T.+Gogichaishviliauthor=S.+Guptaauthor=J.+Herreraauthor=B.+Huntauthor=P.+Iribhogbeauthor=M.+Izurietaauthor=H.+Khamisauthor=E.+Komolafeauthor=M.+A.+Marreroauthor=J.+Mej%C3%ADa-Mantillaauthor=J.+Mirandaauthor=C.+Moralesauthor=O.+Olaomiauthor=F.+Olldashiauthor=P.+Perelauthor=R.+Petoauthor=P.+V.+Ramanaauthor=R.+R.+Raviauthor=S.+Yutthakasemsunt&title=Effects+of+tranexamic+acid+on+death%2C+vascular+occlusive+events%2C+and+blood+transfusion+in+trauma+patients+with+significant+haemorrhage+%28CRASH-2%29%3A+a+randomised%2C+placebo-controlled+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShakur%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DI.%26aulast%3DBautista%26aufirst%3DR.%26aulast%3DCaballero%26aufirst%3DJ.%26aulast%3DCoats%26aufirst%3DT.%26aulast%3DDewan%26aufirst%3DY.%26aulast%3DEl-Sayed%26aufirst%3DH.%26aulast%3DGogichaishvili%26aufirst%3DT.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DHerrera%26aufirst%3DJ.%26aulast%3DHunt%26aufirst%3DB.%26aulast%3DIribhogbe%26aufirst%3DP.%26aulast%3DIzurieta%26aufirst%3DM.%26aulast%3DKhamis%26aufirst%3DH.%26aulast%3DKomolafe%26aufirst%3DE.%26aulast%3DMarrero%26aufirst%3DM.%2BA.%26aulast%3DMej%25C3%25ADa-Mantilla%26aufirst%3DJ.%26aulast%3DMiranda%26aufirst%3DJ.%26aulast%3DMorales%26aufirst%3DC.%26aulast%3DOlaomi%26aufirst%3DO.%26aulast%3DOlldashi%26aufirst%3DF.%26aulast%3DPerel%26aufirst%3DP.%26aulast%3DPeto%26aufirst%3DR.%26aulast%3DRamana%26aufirst%3DP.%2BV.%26aulast%3DRavi%26aufirst%3DR.%2BR.%26aulast%3DYutthakasemsunt%26aufirst%3DS.%26atitle%3DEffects%2520of%2520tranexamic%2520acid%2520on%2520death%252C%2520vascular%2520occlusive%2520events%252C%2520and%2520blood%2520transfusion%2520in%2520trauma%2520patients%2520with%2520significant%2520haemorrhage%2520%2528CRASH-2%2529%253A%2520a%2520randomised%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D23%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Ker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, I.</span><span> </span><span class="NLM_article-title">Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis</span> <span class="citation_source-journal">BMJ [Br. Med. J.]</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">e3054</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2012&pages=e3054&author=K.+Kerauthor=P.+Edwardsauthor=P.+Perelauthor=H.+Shakurauthor=I.+Roberts&title=Effect+of+tranexamic+acid+on+surgical+bleeding%3A+systematic+review+and+cumulative+meta-analysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKer%26aufirst%3DK.%26aulast%3DEdwards%26aufirst%3DP.%26aulast%3DPerel%26aufirst%3DP.%26aulast%3DShakur%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DI.%26atitle%3DEffect%2520of%2520tranexamic%2520acid%2520on%2520surgical%2520bleeding%253A%2520systematic%2520review%2520and%2520cumulative%2520meta-analysis%26jtitle%3DBMJ%2520%255BBr.%2520Med.%2520J.%255D%26date%3D2012%26volume%3D344%26spage%3De3054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fergusson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hébert, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazer, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fremes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacAdams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murkin, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duke, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arellano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blajchman, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bussières, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martineau, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robblee, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clinch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pretorius, R.</span><span> </span><span class="NLM_article-title">BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery</span> <span class="citation_source-journal">N. Engl J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">2319</span><span class="NLM_x">–</span> <span class="NLM_lpage">2331</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1056%2FNEJMoa0802395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=18480196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVOhs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=2319-2331&author=D.+A.+Fergussonauthor=P.+C.+H%C3%A9bertauthor=C.+D.+Mazerauthor=S.+Fremesauthor=C.+MacAdamsauthor=J.+M.+Murkinauthor=K.+Teohauthor=P.+C.+Dukeauthor=R.+Arellanoauthor=M.+A.+Blajchmanauthor=J.+S.+Bussi%C3%A8resauthor=D.+C%C3%B4t%C3%A9author=J.+Karskiauthor=R.+Martineauauthor=J.+A.+Robbleeauthor=M.+Rodgerauthor=G.+Wellsauthor=J.+Clinchauthor=R.+Pretorius&title=BART+Investigators.+A+comparison+of+aprotinin+and+lysine+analogues+in+high-risk+cardiac+surgery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of aprotinin and lysine analogues in high-risk cardiac surgery</span></div><div class="casAuthors">Fergusson, Dean A.; Hebert, Paul C.; Mazer, C. David; Fremes, Stephen; MacAdams, Charles; Murkin, John M.; Teoh, Kevin; Duke, Peter C.; Arellano, Ramiro; Blajchman, Morris A.; Bussieres, Jean S.; Cote, Dany; Karski, Jacek; Martineau, Raymond; Robblee, James A.; Rodger, Marc; Wells, George; Clinch, Jennifer; Pretorius, Roanda</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2319-2331</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Antifibrinolytic agents are commonly used during cardiac surgery to minimize bleeding and to reduce exposure to blood products.  We sought to det. whether aprotinin was superior to either tranexamic acid or aminocaproic acid in decreasing massive postoperative bleeding and other clin. important consequences.  Methods: In this multicenter, blinded trial, we randomly assigned 2331 high-risk cardiac surgical patients to one of three groups: 781 received aprotinin, 770 received tranexamic acid, and 780 received aminocaproic acid.  The primary outcome was massive postoperative bleeding.  Secondary outcomes included death from any cause at 30 days.  Results: The trial was terminated early because of a higher rate of death in patients receiving aprotinin.  A total of 74 patients (9.5%) in the aprotinin group had massive bleeding, as compared with 93 (12.1%) in the tranexamic acid group and 94 (12.1%) in the aminocaproic acid group (relative risk in the aprotinin group for both comparisons, 0.79; 95% confidence interval [CI], 0.59 to 1.05).  At 30 days, the rate of death from any cause was 6.0% in the aprotinin group, as compared with 3.9% in the tranexamic acid group (relative risk, 1.55; 95% CI, 0.99 to 2.42) and 4.0% in the aminocaproic acid group (relative risk, 1.52; 95% CI, 0.98 to 2.36).  The relative risk of death in the aprotinin group, as compared with that in both groups receiving lysine analogs, was 1.53 (95% CI, 1.06 to 2.22).  Conclusions: Despite the possibility of a modest redn. in the risk of massive bleeding, the strong and consistent neg. mortality trend assocd. with aprotinin, as compared with the lysine analogs, precludes its use in high-risk cardiac surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobzx5n_vlwt7Vg90H21EOLACvtfcHk0lji3mu-Rj95_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVOhs74%253D&md5=8e2950a4ef6dd058bdc748eb2a3f27de</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0802395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0802395%26sid%3Dliteratum%253Aachs%26aulast%3DFergusson%26aufirst%3DD.%2BA.%26aulast%3DH%25C3%25A9bert%26aufirst%3DP.%2BC.%26aulast%3DMazer%26aufirst%3DC.%2BD.%26aulast%3DFremes%26aufirst%3DS.%26aulast%3DMacAdams%26aufirst%3DC.%26aulast%3DMurkin%26aufirst%3DJ.%2BM.%26aulast%3DTeoh%26aufirst%3DK.%26aulast%3DDuke%26aufirst%3DP.%2BC.%26aulast%3DArellano%26aufirst%3DR.%26aulast%3DBlajchman%26aufirst%3DM.%2BA.%26aulast%3DBussi%25C3%25A8res%26aufirst%3DJ.%2BS.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DD.%26aulast%3DKarski%26aufirst%3DJ.%26aulast%3DMartineau%26aufirst%3DR.%26aulast%3DRobblee%26aufirst%3DJ.%2BA.%26aulast%3DRodger%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DG.%26aulast%3DClinch%26aufirst%3DJ.%26aulast%3DPretorius%26aufirst%3DR.%26atitle%3DBART%2520Investigators.%2520A%2520comparison%2520of%2520aprotinin%2520and%2520lysine%2520analogues%2520in%2520high-risk%2520cardiac%2520surgery%26jtitle%3DN.%2520Engl%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D2319%26epage%3D2331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mangano, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudor, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietzel, C.</span><span> </span><span class="NLM_article-title">The risk associated with aprotinin in cardiac surgery</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">354</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1056%2FNEJMoa051379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=16436767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1yitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2006&pages=353-365&author=D.+T.+Manganoauthor=I.+C.+Tudorauthor=C.+Dietzel&title=The+risk+associated+with+aprotinin+in+cardiac+surgery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">The risk associated with aprotinin in cardiac surgery</span></div><div class="casAuthors">Mangano, Dennis T.; Tudor, Lulia C.; Dietzel, Cynthia</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-365</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The majority of patients undergoing surgical treatment for ST-elevation myocardial infarction receive antifibrinolytic therapy to limit blood loss.  This approach appears counterintuitive to the accepted medical treatment of the same condition - namely, fibrinolysis to limit thrombosis.  Despite this concern, no independent, large-scale safety assessment has been undertaken.  METHODS In this observational study involving 4374 patients undergoing revascularization, we prospectively assessed three agents (aprotinin [1295 patients], aminocaproic acid [883], and tranexamic acid [822]) as compared with no agent (1374 patients) with regard to serious outcomes by propensity and multivariable methods.  (Although aprotinin is a serine protease inhibitor, here we use the term antifibrinolytic therapy to include all three agents.) RESULTS In propensity-adjusted, multivariable logistic regression (C-index, 0.72), use of aprotinin was assocd. with a doubling in the risk of renal failure requiring dialysis among patients undergoing complex coronary-artery surgery (odds ratio, 2.59; 95 % confidence interval, 1.36 to 4.95) or primary surgery (odds ratio, 2.34; 95 % confidence interval, 1.27 to 4.31).  Similarly, use of aprotinin in the latter group was assocd. with a 55 % increase in the risk of myocardial infarction or heart failure (P < 0.001) and a 181 % increase in the risk of stroke or encephalopathy (P = 0.001).  Neither aminocaproic acid nor tranexamic acid was assocd. with an increased risk of renal, cardiac, or cerebral events.  Adjustment according to propensity score for the use of any one of the three agents as compared with no agent yielded nearly identical findings.  All the agents reduced blood loss.  CONCLUSIONS The assocn. between aprotinin and serious end-organ damage indicates that continued use is not prudent.  In contrast, the less expensive generic medications aminocaproic acid and tranexamic acid are safe alternatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk_HvNJKezFLVg90H21EOLACvtfcHk0ljnEo137nVgiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1yitw%253D%253D&md5=69529f9034301d12408aba2ab9dcb485</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa051379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa051379%26sid%3Dliteratum%253Aachs%26aulast%3DMangano%26aufirst%3DD.%2BT.%26aulast%3DTudor%26aufirst%3DI.%2BC.%26aulast%3DDietzel%26aufirst%3DC.%26atitle%3DThe%2520risk%2520associated%2520with%2520aprotinin%2520in%2520cardiac%2520surgery%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D354%26spage%3D353%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span>European Medicines Agency Recommends Lifting Suspension of Aprotinin; <span class="NLM_publisher-name">European Medicines Agency</span>, <span class="NLM_month">Feb</span><span class="NLM_day">17</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span><a href="http://www.ema.europa.eu/ema/pages/news_and_events/news/2012/02/news_detail_001447.jsp" class="extLink">http://www.ema.europa.eu/ema/pages/news_and_events/news/2012/02/news_detail_001447.jsp</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=European+Medicines+Agency+Recommends+Lifting+Suspension+of+Aprotinin%3B+European+Medicines+Agency%2C+Feb17%2C+2012%3B+http%3A%2F%2Fwww.ema.europa.eu%2Fema%2Fpages%2Fnews_and_events%2Fnews%2F2012%2F02%2Fnews_detail_001447.jsp."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Medicines%2520Agency%2520Recommends%2520Lifting%2520Suspension%2520of%2520Aprotinin%26pub%3DEuropean%2520Medicines%2520Agency%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Lijnen, H. R.</span><span> </span><span class="NLM_article-title">Matrix metalloproteinases and cellular fibrinolytic activity</span> <span class="citation_source-journal">Biochemistry (Moscow)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">92</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1023%2FA%3A1013908332232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=11841344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVSksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=92-98&author=H.+R.+Lijnen&title=Matrix+metalloproteinases+and+cellular+fibrinolytic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinases and cellular fibrinolytic activity</span></div><div class="casAuthors">Lijnen, H. R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry (Moscow, Russian Federation)(Translation of Biokhimiya (Moscow, Russian Federation))</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">92-98</span>CODEN:
                <span class="NLM_cas:coden">BIORAK</span>;
        ISSN:<span class="NLM_cas:issn">0006-2979</span>.
    
            (<span class="NLM_cas:orgname">MAIK Nauka/Interperiodica Publishing</span>)
        </div><div class="casAbstract">A review with 51 refs.  Several mol. interactions between the matrix metalloproteinase (MMP) and the plasminogen/plasmin (fibrinolytic) system may affect cellular fibrinolysis.  MMP-3 (stromelysin-1) specifically hydrolyzes urokinase (u-PA), yielding a 17-kDa N-terminal fragment contg. the functionally intact receptor (u-PAR)-binding sequence and a 32-kDa C-terminal fragment contg. the intact serine proteinase domain.  MMP-3 generates an angiostatin-like fragment (contg. kringles 1-4 with the cellular binding domains) from plasminogen.  Treatment with MMP-3 of monocytoid THP-1 cells satd. with bound plasminogen, results in a dose-dependent redn. of the amt. of u-PA-activatable plasminogen.  Treatment with MMP-3 of cell-bound u-PA, in contrast, does not alter cell-assocd. u-PA activity.  These data thus indicate that MMP-3 may down-regulate cell-assocd. plasmin activity by decreasing the amt. of activatible plasminogen, without affecting cell-bound u-PA activity.  MMP-3 also specifically interacts with the main inhibitors of the fibrinolytic system.  Thus, MMP-3 specifically hydrolyzes human α2-antiplasmin (α2-AP), the main physiol. plasmin inhibitor.  α2-AP cleaved by MMP-3 no longer forms a stable complex with plasmin and no longer interacts with plasminogen.  Cleavage and inactivation of α2-AP by MMP-3 may constitute a mechanism favoring local plasmin-mediated proteolysis.  Furthermore, MMP-3 specifically hydrolyzes and inactivates human plasminogen activator inhibitor-1 (PAI-1).  Stable PAI-1 bound to vitronectin is cleaved and inactivated by MMP-3 in a comparable manner as free PAI-1; the cleaved protein, however, does not bind to vitronectin.  Cleavage and inactivation of PAI-1 by MMP-3 may thus constitute a mechanism decreasing the antiproteolytic activity of PAI-1 and impairing the potential inhibitory effect of vitronectin-bound PAI-1 on cell adhesion and/or migration.  These mol. interactions of MMP-3 with enzymes, substrates and inhibitors of the fibrinolytic system may thus play a role in the regulation of (cellular) fibrinolysis.  Furthermore, the temporal and topog. expression pattern of MMP components, as well as studies in gene-deficient mice, suggest a functional role in neointima formation after vascular injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh4KTQowH26bVg90H21EOLACvtfcHk0ljnEo137nVgiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVSksL4%253D&md5=d69319d37b3c978edf8675270dfc0931</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1023%2FA%3A1013908332232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1013908332232%26sid%3Dliteratum%253Aachs%26aulast%3DLijnen%26aufirst%3DH.%2BR.%26atitle%3DMatrix%2520metalloproteinases%2520and%2520cellular%2520fibrinolytic%2520activity%26jtitle%3DBiochemistry%2520%2528Moscow%2529%26date%3D2002%26volume%3D67%26spage%3D92%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Orbe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrenetxe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivien, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orset, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parks, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birkland, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purroy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez de Lizarrondo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angles-Cano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Páramo, J. A.</span><span> </span><span class="NLM_article-title">Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">2909</span><span class="NLM_x">–</span> <span class="NLM_lpage">2919</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2011&pages=2909-2919&author=J.+Orbeauthor=J.+Barrenetxeauthor=J.+A.+Rodriguezauthor=D.+Vivienauthor=C.+Orsetauthor=W.+C.+Parksauthor=T.+P.+Birklandauthor=R.+Serranoauthor=A.+Purroyauthor=S.+Martinez+de+Lizarrondoauthor=E.+Angles-Canoauthor=J.+A.+P%C3%A1ramo&title=Matrix+metalloproteinase-10+effectively+reduces+infarct+size+in+experimental+stroke+by+enhancing+fibrinolysis+via+a+thrombin-activatable+fibrinolysis+inhibitor-mediated+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOrbe%26aufirst%3DJ.%26aulast%3DBarrenetxe%26aufirst%3DJ.%26aulast%3DRodriguez%26aufirst%3DJ.%2BA.%26aulast%3DVivien%26aufirst%3DD.%26aulast%3DOrset%26aufirst%3DC.%26aulast%3DParks%26aufirst%3DW.%2BC.%26aulast%3DBirkland%26aufirst%3DT.%2BP.%26aulast%3DSerrano%26aufirst%3DR.%26aulast%3DPurroy%26aufirst%3DA.%26aulast%3DMartinez%2Bde%2BLizarrondo%26aufirst%3DS.%26aulast%3DAngles-Cano%26aufirst%3DE.%26aulast%3DP%25C3%25A1ramo%26aufirst%3DJ.%2BA.%26atitle%3DMatrix%2520metalloproteinase-10%2520effectively%2520reduces%2520infarct%2520size%2520in%2520experimental%2520stroke%2520by%2520enhancing%2520fibrinolysis%2520via%2520a%2520thrombin-activatable%2520fibrinolysis%2520inhibitor-mediated%2520mechanism%26jtitle%3DCirculation%26date%3D2011%26volume%3D124%26spage%3D2909%26epage%3D2919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Xue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zygun, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demchuk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, V. W.</span><span> </span><span class="NLM_article-title">Contributions of multiple proteases to neurotoxicity in a mouse model of intracerebral haemorrhage</span> <span class="citation_source-journal">Brain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2009&pages=26-36&author=M.+Xueauthor=Y.+Fanauthor=S.+Liuauthor=D.+A.+Zygunauthor=A.+Demchukauthor=V.+W.+Yong&title=Contributions+of+multiple+proteases+to+neurotoxicity+in+a+mouse+model+of+intracerebral+haemorrhage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZygun%26aufirst%3DD.%2BA.%26aulast%3DDemchuk%26aufirst%3DA.%26aulast%3DYong%26aufirst%3DV.%2BW.%26atitle%3DContributions%2520of%2520multiple%2520proteases%2520to%2520neurotoxicity%2520in%2520a%2520mouse%2520model%2520of%2520intracerebral%2520haemorrhage%26jtitle%3DBrain%26date%3D2009%26volume%3D132%26spage%3D26%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Coussens, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fingleton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matrisian, L. M.</span><span> </span><span class="NLM_article-title">Matrix metalloproteinase inhibitors and cancer: trials and tribulations</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">2387</span><span class="NLM_x">–</span> <span class="NLM_lpage">2392</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1126%2Fscience.1067100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=11923519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BD38XisFSmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2002&pages=2387-2392&author=L.+M.+Coussensauthor=B.+Fingletonauthor=L.+M.+Matrisian&title=Matrix+metalloproteinase+inhibitors+and+cancer%3A+trials+and+tribulations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer therapy: matrix metalloproteinase inhibitors and cancer: trials and tribulations</span></div><div class="casAuthors">Coussens, Lisa M.; Fingleton, Barbara; Matrisian, Lynn M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">5564</span>),
    <span class="NLM_cas:pages">2387-2392</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  For at least 30 yr, matrix metalloproteinases (MMPs) have been heralded as promising targets for cancer therapy on the basis of their massive up-regulation in malignant tissues and their unique ability to degrade all components of the extracellular matrix.  Preclin. studies testing the efficacy of MMP suppression in tumor models were so compelling that synthetic metalloproteinase inhibitors (MPI) were rapidly developed and routed into human clin. trials.  The results of these trials have been disappointing.  Here we review the studies that brought MPI into clin. testing and discuss the design and outcome of the trials in light of new information about the cellular source, substrates, and mode of action of MMPs at different stages of tumor progression.  The important lessons learned from the MPI experience may be of great value for future studies of MPI and for cancer drug development in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquzqvwAiv5frVg90H21EOLACvtfcHk0ljnEo137nVgiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisFSmtb0%253D&md5=be0d4cfc46c6c451a2374e3545cb4ec6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscience.1067100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1067100%26sid%3Dliteratum%253Aachs%26aulast%3DCoussens%26aufirst%3DL.%2BM.%26aulast%3DFingleton%26aufirst%3DB.%26aulast%3DMatrisian%26aufirst%3DL.%2BM.%26atitle%3DMatrix%2520metalloproteinase%2520inhibitors%2520and%2520cancer%253A%2520trials%2520and%2520tribulations%26jtitle%3DScience%26date%3D2002%26volume%3D295%26spage%3D2387%26epage%3D2392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Krzeski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckland-Wright, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bálint, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cline, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beary, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aronstein, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spector, T. D.</span><span> </span><span class="NLM_article-title">Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">R109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=R109&author=P.+Krzeskiauthor=C.+Buckland-Wrightauthor=G.+B%C3%A1lintauthor=G.+A.+Clineauthor=K.+Stonerauthor=R.+Lyonauthor=J.+Bearyauthor=W.+S.+Aronsteinauthor=T.+D.+Spector&title=Development+of+musculoskeletal+toxicity+without+clear+benefit+after+administration+of+PG-116800%2C+a+matrix+metalloproteinase+inhibitor%2C+to+patients+with+knee+osteoarthritis%3A+a+randomized%2C+12-month%2C+double-blind%2C+placebo-controlled+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrzeski%26aufirst%3DP.%26aulast%3DBuckland-Wright%26aufirst%3DC.%26aulast%3DB%25C3%25A1lint%26aufirst%3DG.%26aulast%3DCline%26aufirst%3DG.%2BA.%26aulast%3DStoner%26aufirst%3DK.%26aulast%3DLyon%26aufirst%3DR.%26aulast%3DBeary%26aufirst%3DJ.%26aulast%3DAronstein%26aufirst%3DW.%2BS.%26aulast%3DSpector%26aufirst%3DT.%2BD.%26atitle%3DDevelopment%2520of%2520musculoskeletal%2520toxicity%2520without%2520clear%2520benefit%2520after%2520administration%2520of%2520PG-116800%252C%2520a%2520matrix%2520metalloproteinase%2520inhibitor%252C%2520to%2520patients%2520with%2520knee%2520osteoarthritis%253A%2520a%2520randomized%252C%252012-month%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2007%26volume%3D9%26spage%3DR109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Vandenbroucke, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Libert, C.</span><span> </span><span class="NLM_article-title">Is there new hope for therapeutic matrix metalloproteinase inhibition?</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">904</span><span class="NLM_x">–</span> <span class="NLM_lpage">927</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=904-927&author=R.+E.+Vandenbrouckeauthor=C.+Libert&title=Is+there+new+hope+for+therapeutic+matrix+metalloproteinase+inhibition%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVandenbroucke%26aufirst%3DR.%2BE.%26aulast%3DLibert%26aufirst%3DC.%26atitle%3DIs%2520there%2520new%2520hope%2520for%2520therapeutic%2520matrix%2520metalloproteinase%2520inhibition%253F%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D904%26epage%3D927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Orbe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez-Arias, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salicio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belzunce, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugarte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H. C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabal, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paramo, J. A.</span><span> </span><span class="NLM_article-title">Discovery and safety profiling of a potent pre-clinical candidate, (4-[4-[[(3<i>R</i>)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-<i>N</i>-methyl-benzamide) (CM-352), for the prevention and treatment of hemorrhage</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1021/jm501939z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501939z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=J.+Orbeauthor=J.+A.+Rodriguezauthor=J.+A.+Sanchez-Ariasauthor=A.+Salicioauthor=M.+Belzunceauthor=A.+Ugarteauthor=H.+C.+Y.+Changauthor=O.+Rabalauthor=J.+Oyarzabalauthor=J.+A.+Paramo&title=Discovery+and+safety+profiling+of+a+potent+pre-clinical+candidate%2C+%284-%5B4-%5B%5B%283R%29-3-%28hydroxycarbamoyl%29-8-azaspiro%5B4.5%5Ddecan-3-yl%5Dsulfonyl%5Dphenoxy%5D-N-methyl-benzamide%29+%28CM-352%29%2C+for+the+prevention+and+treatment+of+hemorrhage&doi=10.1021%2Fjm501939z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm501939z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501939z%26sid%3Dliteratum%253Aachs%26aulast%3DOrbe%26aufirst%3DJ.%26aulast%3DRodriguez%26aufirst%3DJ.%2BA.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DSalicio%26aufirst%3DA.%26aulast%3DBelzunce%26aufirst%3DM.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DH.%2BC.%2BY.%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DParamo%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520and%2520safety%2520profiling%2520of%2520a%2520potent%2520pre-clinical%2520candidate%252C%2520%25284-%255B4-%255B%255B%25283R%2529-3-%2528hydroxycarbamoyl%2529-8-azaspiro%255B4.5%255Ddecan-3-yl%255Dsulfonyl%255Dphenoxy%255D-N-methyl-benzamide%2529%2520%2528CM-352%2529%252C%2520for%2520the%2520prevention%2520and%2520treatment%2520of%2520hemorrhage%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26doi%3D10.1021%2Fjm501939z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Lund, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bugge, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frandsen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degen, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dano, K.</span><span> </span><span class="NLM_article-title">Functional overlap between two classes of matrix-degrading proteases in wound healing</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4645</span><span class="NLM_x">–</span> <span class="NLM_lpage">4656</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=4645-4656&author=L.+R.+Lundauthor=J.+Romerauthor=T.+H.+Buggeauthor=B.+L.+Nielsenauthor=T.+L.+Frandsenauthor=J.+L.+Degenauthor=R.+W.+Stephensauthor=K.+Dano&title=Functional+overlap+between+two+classes+of+matrix-degrading+proteases+in+wound+healing"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLund%26aufirst%3DL.%2BR.%26aulast%3DRomer%26aufirst%3DJ.%26aulast%3DBugge%26aufirst%3DT.%2BH.%26aulast%3DNielsen%26aufirst%3DB.%2BL.%26aulast%3DFrandsen%26aufirst%3DT.%2BL.%26aulast%3DDegen%26aufirst%3DJ.%2BL.%26aulast%3DStephens%26aufirst%3DR.%2BW.%26aulast%3DDano%26aufirst%3DK.%26atitle%3DFunctional%2520overlap%2520between%2520two%2520classes%2520of%2520matrix-degrading%2520proteases%2520in%2520wound%2520healing%26jtitle%3DEMBO%2520J.%26date%3D1999%26volume%3D18%26spage%3D4645%26epage%3D4656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Yadav, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, V. M.</span><span> </span><span class="NLM_article-title">Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1704</span><span class="NLM_x">–</span> <span class="NLM_lpage">1722</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.2174%2F092986711795471329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=21428880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslOiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1704-1722&author=R.+K.+Yadavauthor=S.+P.+Guptaauthor=P.+K.+Sharmaauthor=V.+M.+Patil&title=Recent+advances+in+studies+on+hydroxamates+as+matrix+metalloproteinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review</span></div><div class="casAuthors">Yadav, R. K.; Gupta, S. P.; Sharma, P. K.; Patil, V. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1704-1722</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Matrix metalloproteinases (MMPs) are a large family of calcium-dependent zinc- contg. endopeptidases, which are responsible for the tissue remodeling and degrdn. of the extracellular matrix (ECM), including collagens, elastins, gelatin, matrix glycoproteins, and proteoglycan.  The inappropriate expression of these MMPs constitutes part of the pathogenic mechanism in several diseases, therefore they are subject to inhibition.  They can be inhibited by endogenous proteinase inhibitors such as 2-macroglobulin or by the family of tissue inhibitors of metalloproteinases (TIMPs), which are glycoproteins of mol. wt. 21-30 kDa, consisting of 184-194 amino acid residues.  Recently, many different classes of synthetic inhibitors have been developed in which the hydroxamic acidbased class of compds. (hydroxamates) have been most widely studied, as their hydroxamic acid group (CONHOH) enables them to act as a bidentate ligand with the zinc ion present in MMPs, leading to much stronger interaction with the receptor as compared to any other class of inhibitors.  The present review describes in detail the recent development on this class of MMP inihibitors.  Compds. like 12,17e, f, g and h, 45j, 45k, 50f, 62a, 63a, and 63b have been reported to be highly promising for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_CdMJAf2dWbVg90H21EOLACvtfcHk0lhtS__YFWBv0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslOiu7c%253D&md5=a9a615faba9fca05433b6e2a452e2e56</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F092986711795471329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795471329%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DR.%2BK.%26aulast%3DGupta%26aufirst%3DS.%2BP.%26aulast%3DSharma%26aufirst%3DP.%2BK.%26aulast%3DPatil%26aufirst%3DV.%2BM.%26atitle%3DRecent%2520advances%2520in%2520studies%2520on%2520hydroxamates%2520as%2520matrix%2520metalloproteinase%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D1704%26epage%3D1722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Becker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villamil, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barta, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedell, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCrescenzo, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freskos, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getman, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heintz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carron, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munie, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swearingen, C. A.</span><span> </span><span class="NLM_article-title">Synthesis and Structure–Activity Relationships of β- and α-Piperidine Sulfone Hydroxamic Acid Matrix Metalloproteinase Inhibitors with Oral Antitumor Efficacy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6713</span><span class="NLM_x">–</span> <span class="NLM_lpage">6730</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0500875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6713-6730&author=D.+P.+Beckerauthor=C.+I.+Villamilauthor=T.+E.+Bartaauthor=L.+J.+Bedellauthor=T.+L.+Boehmauthor=G.+A.+DeCrescenzoauthor=J.+N.+Freskosauthor=D.+P.+Getmanauthor=S.+Hockermanauthor=R.+Heintzauthor=S.+C.+Howardauthor=M.+H.+Liauthor=J.+J.+McDonaldauthor=C.+P.+Carronauthor=C.+L.+Funckes-Shippyauthor=P.+P.+Mehtaauthor=G.+E.+Munieauthor=C.+A.+Swearingen&title=Synthesis+and+Structure%E2%80%93Activity+Relationships+of+%CE%B2-+and+%CE%B1-Piperidine+Sulfone+Hydroxamic+Acid+Matrix+Metalloproteinase+Inhibitors+with+Oral+Antitumor+Efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Fjm0500875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0500875%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DD.%2BP.%26aulast%3DVillamil%26aufirst%3DC.%2BI.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DBedell%26aufirst%3DL.%2BJ.%26aulast%3DBoehm%26aufirst%3DT.%2BL.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DFreskos%26aufirst%3DJ.%2BN.%26aulast%3DGetman%26aufirst%3DD.%2BP.%26aulast%3DHockerman%26aufirst%3DS.%26aulast%3DHeintz%26aufirst%3DR.%26aulast%3DHoward%26aufirst%3DS.%2BC.%26aulast%3DLi%26aufirst%3DM.%2BH.%26aulast%3DMcDonald%26aufirst%3DJ.%2BJ.%26aulast%3DCarron%26aufirst%3DC.%2BP.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DMehta%26aufirst%3DP.%2BP.%26aulast%3DMunie%26aufirst%3DG.%2BE.%26aulast%3DSwearingen%26aufirst%3DC.%2BA.%26atitle%3DSynthesis%2520and%2520Structure%25E2%2580%2593Activity%2520Relationships%2520of%2520%25CE%25B2-%2520and%2520%25CE%25B1-Piperidine%2520Sulfone%2520Hydroxamic%2520Acid%2520Matrix%2520Metalloproteinase%2520Inhibitors%2520with%2520Oral%2520Antitumor%2520Efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6713%26epage%3D6730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Becker, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barta, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedell, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bond, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carron, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCrescenzo, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easton, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freskos, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathis, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munie, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swearingen, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villamil, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welsch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, J.</span><span> </span><span class="NLM_article-title">Orally Active MMP-1 Sparing α-Tetrahydropyranyl and α-Piperidinyl Sulfone Matrix Metalloproteinase (MMP) Inhibitors with Efficacy in Cancer, Arthritis, and Cardiovascular Disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6653</span><span class="NLM_x">–</span> <span class="NLM_lpage">6680</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100669j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGjtbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6653-6680&author=D.+P.+Beckerauthor=T.+E.+Bartaauthor=L.+J.+Bedellauthor=T.+L.+Boehmauthor=B.+R.+Bondauthor=J.+Carrollauthor=C.+P.+Carronauthor=G.+A.+DeCrescenzoauthor=A.+M.+Eastonauthor=J.+N.+Freskosauthor=C.+L.+Funckes-Shippyauthor=M.+Heronauthor=S.+Hockermanauthor=C.+P.+Howardauthor=J.+R.+Kieferauthor=M.+H.+Liauthor=K.+J.+Mathisauthor=J.+J.+McDonaldauthor=P.+P.+Mehtaauthor=G.+E.+Munieauthor=T.+Sunyerauthor=C.+A.+Swearingenauthor=C.+I.+Villamilauthor=D.+Welschauthor=J.+M.+Williamsauthor=Y.+Yuauthor=J.+Yao&title=Orally+Active+MMP-1+Sparing+%CE%B1-Tetrahydropyranyl+and+%CE%B1-Piperidinyl+Sulfone+Matrix+Metalloproteinase+%28MMP%29+Inhibitors+with+Efficacy+in+Cancer%2C+Arthritis%2C+and+Cardiovascular+Disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Active MMP-1 Sparing α-Tetrahydropyranyl and α-Piperidinyl Sulfone Matrix Metalloproteinase (MMP) Inhibitors with Efficacy in Cancer, Arthritis, and Cardiovascular Disease</span></div><div class="casAuthors">Becker, Daniel P.; Barta, Thomas E.; Bedell, Louis J.; Boehm, Terri L.; Bond, Brian R.; Carroll, Jeffery; Carron, Chris P.; De Crescenzo, Gary A.; Easton, Alan M.; Freskos, John N.; Funckes-Shippy, Chris L.; Heron, Marcia; Hockerman, Susan; Howard, Carol Pearcy; Kiefer, James R.; Li, Madeleine H.; Mathis, Karl J.; McDonald, Joseph J.; Mehta, Pramod P.; Munie, Grace E.; Sunyer, Teresa; Swearingen, Craig A.; Villamil, Clara I.; Welsch, Dean; Williams, Jennifer M.; Yu, Ying; Yao, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6653-6680</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-hydroxy aryloxyarylsulfonyl pyrancarboxamides and piperidinecarboxamides such as I (R = MeOCH2CH2, cyclopropyl) are prepd. as selective matrix metalloproteinase (MMP) inhibitors avoiding nonselective MMP (in particular, MMP-1) inhibition for use as antitumor, antiarthritic, and cardiovascular agents.  The inhibition of MMPs 1, 2, 3, 7, 8, 9, 13, and 14 by N-hydroxy aryloxyarylsulfonyl pyrancarboxamides and piperidinecarboxamides is detd. as well as their calcd. lipophilicities; the pharmacokinetics, inhibition of human prostate, breast, and lung cancer cells, inhibition of cartilage degrdn., inhibition of ventricular dilation after myocardial infarction, and DSC calorimetric measurements for selected compds. are detd.  I (R = MeOCH2CH2) (SC-78080/SD-2590) was selected for development as an anticancer agent, while I (R = cyclopropyl) and an N-hydroxy trifluoromethylphenoxyphenylsulfonyl pyrancarboxamide were selected as backup compds.  The structure of I (R = MeOCH2CH2) bound to MMP-13 is detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY0b9GTt27EbVg90H21EOLACvtfcHk0linIUtcLyAYog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGjtbnJ&md5=0ee6c0fea7d5e86ff75095615dac8ec6</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fjm100669j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100669j%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DD.%2BP.%26aulast%3DBarta%26aufirst%3DT.%2BE.%26aulast%3DBedell%26aufirst%3DL.%2BJ.%26aulast%3DBoehm%26aufirst%3DT.%2BL.%26aulast%3DBond%26aufirst%3DB.%2BR.%26aulast%3DCarroll%26aufirst%3DJ.%26aulast%3DCarron%26aufirst%3DC.%2BP.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DEaston%26aufirst%3DA.%2BM.%26aulast%3DFreskos%26aufirst%3DJ.%2BN.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DHeron%26aufirst%3DM.%26aulast%3DHockerman%26aufirst%3DS.%26aulast%3DHoward%26aufirst%3DC.%2BP.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLi%26aufirst%3DM.%2BH.%26aulast%3DMathis%26aufirst%3DK.%2BJ.%26aulast%3DMcDonald%26aufirst%3DJ.%2BJ.%26aulast%3DMehta%26aufirst%3DP.%2BP.%26aulast%3DMunie%26aufirst%3DG.%2BE.%26aulast%3DSunyer%26aufirst%3DT.%26aulast%3DSwearingen%26aufirst%3DC.%2BA.%26aulast%3DVillamil%26aufirst%3DC.%2BI.%26aulast%3DWelsch%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DJ.%26atitle%3DOrally%2520Active%2520MMP-1%2520Sparing%2520%25CE%25B1-Tetrahydropyranyl%2520and%2520%25CE%25B1-Piperidinyl%2520Sulfone%2520Matrix%2520Metalloproteinase%2520%2528MMP%2529%2520Inhibitors%2520with%2520Efficacy%2520in%2520Cancer%252C%2520Arthritis%252C%2520and%2520Cardiovascular%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6653%26epage%3D6680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Lollini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eugui, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womble, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J.</span><span> </span><span class="NLM_article-title">Disease modification by RS-130830, a collagenase-3 selective inhibitor, in experimental osteoarthritis (OA)</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">S87</span><div class="note"><p class="first last">abstract 341</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=S87&issue=Suppl&author=L.+Lolliniauthor=J.+Hallerauthor=E.+M.+Euguiauthor=S.+W.+Wombleauthor=R.+Martinauthor=J.+Campbell&title=Disease+modification+by+RS-130830%2C+a+collagenase-3+selective+inhibitor%2C+in+experimental+osteoarthritis+%28OA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLollini%26aufirst%3DL.%26aulast%3DHaller%26aufirst%3DJ.%26aulast%3DEugui%26aufirst%3DE.%2BM.%26aulast%3DWomble%26aufirst%3DS.%2BW.%26aulast%3DMartin%26aufirst%3DR.%26aulast%3DCampbell%26aufirst%3DJ.%26atitle%3DDisease%2520modification%2520by%2520RS-130830%252C%2520a%2520collagenase-3%2520selective%2520inhibitor%252C%2520in%2520experimental%2520osteoarthritis%2520%2528OA%2529%26jtitle%3DArthritis%2520Rheum.%26date%3D1997%26volume%3D40%26issue%3DSuppl%26spage%3DS87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Aranapakam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosu, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingboe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandanayaka, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skotnicki, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiJoseph, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharr, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Killar, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowling, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tillett, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDevitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z. B.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2376</span><span class="NLM_x">–</span> <span class="NLM_lpage">2396</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0205550" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2376-2396&author=V.+Aranapakamauthor=J.+M.+Davisauthor=G.+T.+Grosuauthor=J.+Bakerauthor=J.+Ellingboeauthor=A.+Zaskauthor=J.+I.+Levinauthor=V.+P.+Sandanayakaauthor=M.+Duauthor=J.+S.+Skotnickiauthor=J.+F.+DiJosephauthor=A.+Sungauthor=M.+A.+Sharrauthor=L.+M.+Killarauthor=T.+Walterauthor=G.+Jinauthor=R.+Cowlingauthor=J.+Tillettauthor=W.+Zhaoauthor=J.+McDevittauthor=Z.+B.+Xu&title=Synthesis+and+structure-activity+relationship+of+N-substituted+4-arylsulfonylpiperidine-4-hydroxamic+acids+as+novel%2C+orally+active+matrix+metalloproteinase+inhibitors+for+the+treatment+of+osteoarthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm0205550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0205550%26sid%3Dliteratum%253Aachs%26aulast%3DAranapakam%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26aulast%3DGrosu%26aufirst%3DG.%2BT.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DEllingboe%26aufirst%3DJ.%26aulast%3DZask%26aufirst%3DA.%26aulast%3DLevin%26aufirst%3DJ.%2BI.%26aulast%3DSandanayaka%26aufirst%3DV.%2BP.%26aulast%3DDu%26aufirst%3DM.%26aulast%3DSkotnicki%26aufirst%3DJ.%2BS.%26aulast%3DDiJoseph%26aufirst%3DJ.%2BF.%26aulast%3DSung%26aufirst%3DA.%26aulast%3DSharr%26aufirst%3DM.%2BA.%26aulast%3DKillar%26aufirst%3DL.%2BM.%26aulast%3DWalter%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DG.%26aulast%3DCowling%26aufirst%3DR.%26aulast%3DTillett%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DMcDevitt%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%2BB.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520of%2520N-substituted%25204-arylsulfonylpiperidine-4-hydroxamic%2520acids%2520as%2520novel%252C%2520orally%2520active%2520matrix%2520metalloproteinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520osteoarthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2376%26epage%3D2396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zask, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandanayaka, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, J. I.</span><span> </span><span class="NLM_article-title">Synthesis and activity of quinolinylmethyl P1′ alpha-sulfone piperidine hydroxamate inhibitors of TACE</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3445</span><span class="NLM_x">–</span> <span class="NLM_lpage">3348</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3445-3348&author=C.+Zhangauthor=F.+Loveringauthor=M.+Behnkeauthor=A.+Zaskauthor=V.+Sandanayakaauthor=L.+Sunauthor=Y.+Zhuauthor=W.+Xuauthor=Y.+Zhangauthor=J.+I.+Levin&title=Synthesis+and+activity+of+quinolinylmethyl+P1%E2%80%B2+alpha-sulfone+piperidine+hydroxamate+inhibitors+of+TACE"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBehnke%26aufirst%3DM.%26aulast%3DZask%26aufirst%3DA.%26aulast%3DSandanayaka%26aufirst%3DV.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLevin%26aufirst%3DJ.%2BI.%26atitle%3DSynthesis%2520and%2520activity%2520of%2520quinolinylmethyl%2520P1%25E2%2580%25B2%2520alpha-sulfone%2520piperidine%2520hydroxamate%2520inhibitors%2520of%2520TACE%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D3445%26epage%3D3348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pikul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almstead, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natchus, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anastasio, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhail, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snider, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taiwo, Y. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunaway, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mieling, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janusz, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang-Weigand, S.</span><span> </span><span class="NLM_article-title">Design and synthesis of piperazine-based matrix metalloproteinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">380</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990366q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=369-380&author=M.+Chengauthor=B.+Deauthor=S.+Pikulauthor=N.+G.+Almsteadauthor=M.+G.+Natchusauthor=M.+V.+Anastasioauthor=S.+J.+McPhailauthor=C.+E.+Sniderauthor=Y.+O.+Taiwoauthor=L.+Chenauthor=C.+M.+Dunawayauthor=F.+Guauthor=M.+E.+Dowtyauthor=G.+E.+Mielingauthor=M.+J.+Januszauthor=S.+Wang-Weigand&title=Design+and+synthesis+of+piperazine-based+matrix+metalloproteinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm990366q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990366q%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDe%26aufirst%3DB.%26aulast%3DPikul%26aufirst%3DS.%26aulast%3DAlmstead%26aufirst%3DN.%2BG.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DAnastasio%26aufirst%3DM.%2BV.%26aulast%3DMcPhail%26aufirst%3DS.%2BJ.%26aulast%3DSnider%26aufirst%3DC.%2BE.%26aulast%3DTaiwo%26aufirst%3DY.%2BO.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDunaway%26aufirst%3DC.%2BM.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DMieling%26aufirst%3DG.%2BE.%26aulast%3DJanusz%26aufirst%3DM.%2BJ.%26aulast%3DWang-Weigand%26aufirst%3DS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520piperazine-based%2520matrix%2520metalloproteinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D369%26epage%3D380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span> <span class="citation_source-book">The Practice of Medicinal Chemistry</span>; <span class="NLM_contrib-group">Wermuth, C. G.</span>, Ed.; <span class="NLM_publisher-name">Elsevier Academic Press</span>: <span class="NLM_publisher-loc">San Diego</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=C.+G.+Wermuth&title=The+Practice+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThe%2520Practice%2520of%2520Medicinal%2520Chemistry%26aulast%3DWermuth%26aufirst%3DC.%2BG.%26pub%3DElsevier%2520Academic%2520Press%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Zheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tice, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S. B.</span><span> </span><span class="NLM_article-title">The use of spirocyclic scaffolds in drug discovery</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3673</span><span class="NLM_x">–</span> <span class="NLM_lpage">3682</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1016%2Fj.bmcl.2014.06.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=25052427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFykt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3673-3682&author=Y.+Zhengauthor=C.+M.+Ticeauthor=S.+B.+Singh&title=The+use+of+spirocyclic+scaffolds+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The use of spirocyclic scaffolds in drug discovery</span></div><div class="casAuthors">Zheng, Yajun; Tice, Colin M.; Singh, Suresh B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3673-3682</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Owing to their inherent three-dimensionality and structural novelty, spiro scaffolds have been increasingly utilized in drug discovery.  In this brief review, we highlight selected examples from the primary medicinal chem. literature during the last three years to demonstrate the versatility of spiro scaffolds.  With recent progress in synthetic methods providing access to spiro building blocks, spiro scaffolds are likely to be used more frequently in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqzTjJrsRkyLVg90H21EOLACvtfcHk0ljUTQNrPFiK_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFykt7bM&md5=9a2a644cf2b97edf7876b43b6457f6d5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.081%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DTice%26aufirst%3DC.%2BM.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DThe%2520use%2520of%2520spirocyclic%2520scaffolds%2520in%2520drug%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3673%26epage%3D3682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Kolodziej, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockerman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCrescenzo, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischke, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munie, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stehle, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swearingen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, D. P.</span><span> </span><span class="NLM_article-title">MMP-13 selective isonipecotamide alpha-sulfone hydroxamates</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">3561</span><span class="NLM_x">–</span> <span class="NLM_lpage">3564</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3561-3564&author=S.+A.+Kolodziejauthor=S.+L.+Hockermanauthor=G.+A.+DeCrescenzoauthor=J.+J.+McDonaldauthor=D.+A.+Mischkeauthor=G.+E.+Munieauthor=T.+R.+Fletcherauthor=N.+Stehleauthor=C.+Swearingenauthor=D.+P.+Becker&title=MMP-13+selective+isonipecotamide+alpha-sulfone+hydroxamates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKolodziej%26aufirst%3DS.%2BA.%26aulast%3DHockerman%26aufirst%3DS.%2BL.%26aulast%3DDeCrescenzo%26aufirst%3DG.%2BA.%26aulast%3DMcDonald%26aufirst%3DJ.%2BJ.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DMunie%26aufirst%3DG.%2BE.%26aulast%3DFletcher%26aufirst%3DT.%2BR.%26aulast%3DStehle%26aufirst%3DN.%26aulast%3DSwearingen%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DD.%2BP.%26atitle%3DMMP-13%2520selective%2520isonipecotamide%2520alpha-sulfone%2520hydroxamates%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3561%26epage%3D3564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zapico, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Sanmartín, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipiak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbajo, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schott, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pineda-Lucena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martínez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Santamaría, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pascual-Teresa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, A.</span><span> </span><span class="NLM_article-title">Potent “clicked” MMP2 inhibitors: synthesis, molecular modeling and biological exploration</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">4587</span><span class="NLM_x">–</span> <span class="NLM_lpage">4599</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=4587-4599&author=J.+M.+Zapicoauthor=P.+Serraauthor=J.+Garc%C3%ADa-Sanmart%C3%ADnauthor=K.+Filipiakauthor=R.+J.+Carbajoauthor=A.+K.+Schottauthor=A.+Pineda-Lucenaauthor=A.+Mart%C3%ADnezauthor=S.+Mart%C3%ADn-Santamar%C3%ADaauthor=B.+de+Pascual-Teresaauthor=A.+Ramos&title=Potent+%E2%80%9Cclicked%E2%80%9D+MMP2+inhibitors%3A+synthesis%2C+molecular+modeling+and+biological+exploration"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZapico%26aufirst%3DJ.%2BM.%26aulast%3DSerra%26aufirst%3DP.%26aulast%3DGarc%25C3%25ADa-Sanmart%25C3%25ADn%26aufirst%3DJ.%26aulast%3DFilipiak%26aufirst%3DK.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DSchott%26aufirst%3DA.%2BK.%26aulast%3DPineda-Lucena%26aufirst%3DA.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DMart%25C3%25ADn-Santamar%25C3%25ADa%26aufirst%3DS.%26aulast%3Dde%2BPascual-Teresa%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DA.%26atitle%3DPotent%2520%25E2%2580%259Cclicked%25E2%2580%259D%2520MMP2%2520inhibitors%253A%2520synthesis%252C%2520molecular%2520modeling%2520and%2520biological%2520exploration%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2011%26volume%3D9%26spage%3D4587%26epage%3D4599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fabre, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipiak, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zapico, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbajo, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schott, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martínez-Alcázar, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suárez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pineda-Lucena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pascual-Teresa, B.</span><span> </span><span class="NLM_article-title">Progress towards water-soluble triazole-based selective MMP-2 inhibitors</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">6623</span><span class="NLM_x">–</span> <span class="NLM_lpage">6641</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=6623-6641&author=B.+Fabreauthor=K.+Filipiakauthor=J.+M.+Zapicoauthor=N.+D%C3%ADazauthor=R.+J.+Carbajoauthor=A.+K.+Schottauthor=M.+P.+Mart%C3%ADnez-Alc%C3%A1zarauthor=D.+Su%C3%A1rezauthor=A.+Pineda-Lucenaauthor=A.+Ramosauthor=B.+de+Pascual-Teresa&title=Progress+towards+water-soluble+triazole-based+selective+MMP-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFabre%26aufirst%3DB.%26aulast%3DFilipiak%26aufirst%3DK.%26aulast%3DZapico%26aufirst%3DJ.%2BM.%26aulast%3DD%25C3%25ADaz%26aufirst%3DN.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DSchott%26aufirst%3DA.%2BK.%26aulast%3DMart%25C3%25ADnez-Alc%25C3%25A1zar%26aufirst%3DM.%2BP.%26aulast%3DSu%25C3%25A1rez%26aufirst%3DD.%26aulast%3DPineda-Lucena%26aufirst%3DA.%26aulast%3DRamos%26aufirst%3DA.%26aulast%3Dde%2BPascual-Teresa%26aufirst%3DB.%26atitle%3DProgress%2520towards%2520water-soluble%2520triazole-based%2520selective%2520MMP-2%2520inhibitors%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26spage%3D6623%26epage%3D6641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Orbe Lopategui, J.; Oyarzabal Santamarina, J.; Páramo Fernández, J. A.; Rodríguez García, J. A.</span><span> </span><span class="NLM_article-title">New antifibrinolytic compounds</span>. WO 2014012964 (A1), <span class="NLM_month">July</span><span class="NLM_day">17</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+Orbe+Lopategui&author=J.+Oyarzabal+Santamarina&author=J.+A.+P%C3%A1ramo+Fern%C3%A1ndez&author=J.+A.+Rodr%C3%ADguez+Garc%C3%ADa&title=New+antifibrinolytic+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DOrbe%2BLopategui%26aufirst%3DJ.%26atitle%3DNew%2520antifibrinolytic%2520compounds%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Bertini, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calderone, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fragai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luchinat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terni, B.</span><span> </span><span class="NLM_article-title">Crystal Structure of the Catalytic Domain of Human Matrix Metalloproteinase 10</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">336</span><span class="NLM_x">, </span> <span class="NLM_fpage">707</span><span class="NLM_x">–</span> <span class="NLM_lpage">716</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2004&pages=707-716&author=I.+Bertiniauthor=V.+Calderoneauthor=M.+Fragaiauthor=C.+Luchinatauthor=S.+Manganiauthor=B.+Terni&title=Crystal+Structure+of+the+Catalytic+Domain+of+Human+Matrix+Metalloproteinase+10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBertini%26aufirst%3DI.%26aulast%3DCalderone%26aufirst%3DV.%26aulast%3DFragai%26aufirst%3DM.%26aulast%3DLuchinat%26aufirst%3DC.%26aulast%3DMangani%26aufirst%3DS.%26aulast%3DTerni%26aufirst%3DB.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Catalytic%2520Domain%2520of%2520Human%2520Matrix%2520Metalloproteinase%252010%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D336%26spage%3D707%26epage%3D716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Schechter, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, A.</span><span> </span><span class="NLM_article-title">On the size of the active site in proteases. I. Papain</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1967</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm501940y&amp;key=10.1016%2FS0006-291X%2867%2980055-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm501940y&amp;key=6035483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADyaF2sXktVyhsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1967&pages=157-162&author=I.+Schechterauthor=A.+Berger&title=On+the+size+of+the+active+site+in+proteases.+I.+Papain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">On the size of the active site in proteases.  I.  Papain</span></div><div class="casAuthors">Schechter, Israel; Berger, Arieh</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-62</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">The action of papain on 40 diastereoisomeric peptides of alanine, ranging in length from Ala2 to Ala6, was studied to investigate the size of the active site.  The variations observed in the rates of hydrolysis lead to the conclusion that papain has a large active site which extends over ∼25 A. and can be divided into 7 "subsites," each accommodating 1 amino acid residue of the peptide substrate.  The subsites are located on both sides of the catalytic site, 4 on the one side and 3 on the other.  It is postulated that a long "groove" analogous to that found by x-ray analysis in lysozyme is present.  The substrate is believed to fit into the groove, binding to several subsites of specific geometry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_kZeRVAOVyrVg90H21EOLACvtfcHk0lhA9U-Z_KHrhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXktVyhsrg%253D&md5=a58ceccdbb5cc5c021af06912835f77c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2867%2980055-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252867%252980055-X%26sid%3Dliteratum%253Aachs%26aulast%3DSchechter%26aufirst%3DI.%26aulast%3DBerger%26aufirst%3DA.%26atitle%3DOn%2520the%2520size%2520of%2520the%2520active%2520site%2520in%2520proteases.%2520I.%2520Papain%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1967%26volume%3D27%26spage%3D157%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rabal, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span> </span><span class="NLM_article-title">Using novel descriptor accounting for ligand–receptor interactions to define and visually explore biologically relevant chemical space</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1086</span><span class="NLM_x">–</span> <span class="NLM_lpage">1102</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci200627v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1SmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=1086-1102&author=O.+Rabalauthor=J.+Oyarzabal&title=Using+novel+descriptor+accounting+for+ligand%E2%80%93receptor+interactions+to+define+and+visually+explore+biologically+relevant+chemical+space"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">Using Novel Descriptor Accounting for Ligand-Receptor Interactions To Define and Visually Explore Biologically Relevant Chemical Space</span></div><div class="casAuthors">Rabal, Obdulia; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1086-1102</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The definition and pragmatic implementation of biol. relevant chem. space is crit. in addressing navigation strategies in the overlapping regions where chem. and therapeutically relevant targets reside and, therefore, also key to performing an efficient drug discovery project.  Here, we describe the development and implementation of a simple and robust method for representing biol. relevant chem. space as a general ref. according to current knowledge, independently of any ref. space, and analyzing chem. structures accordingly.  Underlying our method is the generation of a novel descriptor (LiRIf) that converts structural information into a one-dimensional string accounting for the plausible ligand-receptor interactions as well as for topol. information.  Capitalizing on ligand-receptor interactions as a descriptor enables the clustering, profiling, and comparison of libraries of compds. from a chem. biol. and medicinal chem. perspective.  In addn., as a case study, R-groups anal. is performed to identify the most populated ligand-receptor interactions according to different target families (GPCR, kinases, etc.), as well as to evaluate the coverage of biol. relevant chem. space by structures annotated in different databases (ChEMBL, Glida, etc.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGropZIPrOWgqrVg90H21EOLACvtfcHk0lhA9U-Z_KHrhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1SmsLw%253D&md5=4530a7810f4b920b6cf1de72dea4cb39</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1021%2Fci200627v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200627v%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DOyarzabal%26aufirst%3DJ.%26atitle%3DUsing%2520novel%2520descriptor%2520accounting%2520for%2520ligand%25E2%2580%2593receptor%2520interactions%2520to%2520define%2520and%2520visually%2520explore%2520biologically%2520relevant%2520chemical%2520space%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D1086%26epage%3D1102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rabal, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span> </span><span class="NLM_article-title">Biologically relevant chemical space navigator: from patent and structure–activity relationship analysis to library acquisition and design</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3123</span><span class="NLM_x">–</span> <span class="NLM_lpage">3137</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci3004539" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Fjm501940y&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslWksbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=3123-3137&author=O.+Rabalauthor=J.+Oyarzabal&title=Biologically+relevant+chemical+space+navigator%3A+from+patent+and+structure%E2%80%93activity+relationship+analysis+to+library+acquisition+and+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Biologically Relevant Chemical Space Navigator: From Patent and Structure-Activity Relationship Analysis to Library Acquisition and Design</span></div><div class="casAuthors">Rabal, Obdulia; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3123-3137</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new and versatile visualization tool, based on a descriptor accounting for ligand-receptor interactions (LiRIf), is introduced for guiding medicinal chemists in analyzing the R-groups from a congeneric series.  Anal. is performed in a ref.-independent scenario where the whole biol. relevant chem. space (BRCS) is represented.  Using a real project-based data set, the authors show the impact of this tool on four key navigation strategies for the drug discovery process.  First, this navigator analyzes competitors' patents, including a comparison of patents coverage and the identification of the most frequent fragments.  Second, the tool analyzes the structure-activity relationship (SAR) leading to the representation of ref.-independent activity landscapes that enable the identification not only of crit. ligand-receptor interactions (LRI) and substructural features but also of activity cliffs.  Third, this navigator enables comparison of libraries, thus selecting com. available mols. that complement unexplored spaces or areas of interest.  Finally, this tool also enables the design of new analogs, which is based on reaction types and the exploration purpose (focused or diverse), selecting the most appropriate reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIldm-mo1cdrVg90H21EOLACvtfcHk0lhA9U-Z_KHrhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslWksbfP&md5=7ee9cb508b97b607067b519d580cab08</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1021%2Fci3004539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci3004539%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DOyarzabal%26aufirst%3DJ.%26atitle%3DBiologically%2520relevant%2520chemical%2520space%2520navigator%253A%2520from%2520patent%2520and%2520structure%25E2%2580%2593activity%2520relationship%2520analysis%2520to%2520library%2520acquisition%2520and%2520design%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D3123%26epage%3D3137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3KRY','PDB','3KRY'); return false;">PDB: 3KRY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1D8F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1D8F','PDB','1D8F'); return false;">PDB: 1D8F</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q3A" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1Q3A','PDB','1Q3A'); return false;">PDB: 1Q3A</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i129"><a href="/doi/suppl/10.1021/jm501940y">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_34141"></div></div></div></div></div><hr /></hr><p class="last">Details about purification methods, SFC methods, optical rotation, purities, and HPLC traces for final compounds, synthesis and crystallographic data for <b>23b</b>, and MMPs selectivity profiling. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm501940y/suppl_file/jm501940y_si_001.pdf">jm501940y_si_001.pdf (1.96 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm501940y&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-5%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm501940y" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm501940y" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c54549303c88","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
